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resumo O cancro é mundialmente uma das principais causas de morte, com cerca de 
14 milhões de novos casos diagnosticados por ano. Neste sentido, o 
desenvolvimento de métodos de diagnóstico mais eficientes em estágio inicial 
da doença é crucial para auxiliar o tratamento e aumentar a taxa de sobrevida 
dos pacientes, além de diminuir as despesas associadas aos tratamentos 
avançados. O antígeno específico da próstata (PSA) e a lactato desidrogenase 
(LDH) são proteínas comumente encontradas nos fluidos humanos (urina e 
soro) e têm sido alvo de atenção como biomarcadores do cancro e na 
monitorização do seu tratamento. No entanto, devido à sua baixa concentração 
e à complexidade das matrizes biológicas com uma grande quantidade de 
outros metabólitos presentes (proteínas, DNA, RNA), é geralmente aplicado 
um ou mais passos de pré-tratamento de amostras. Neste trabalho, foram 
estudadas técnicas alternativas de pré-tratamento baseadas em sistemas 
aquosos bifásicos (SAB) constituídos por líquidos iónicos (LIs) para extrair, 
concentrar e purificar proteínas que podem ser usadas como biomarcadores 
de cancro, como a PSA e LDH. Para este fim, foram realizados vários 
trabalhos preliminares para identificar os componentes e condições de 
formação mais promissores para criar SAB que possam ser utilizados para a 
extração de proteínas. Estes trabalhos contemplam a utilização de SAB para a 
extração de aminoácidos e proteínas modelo, assim como a utilização de SAB 
em matrizes mais complexas. Finalmente, os SAB foram aplicados para a 
extração e concentração de biomarcadores tumorais, nomeadamente PSA e 
LDH. Em suma, com este trabalho verificou-se que a versatilidade dos LIs 
permite adaptar a capacidade de extração e concentração, seletividade, e/ou 
precipitação induzida de biomarcadores de cancro a partir de fluidos humanos. 
Os sistemas aqui desenvolvidos são uma alternativa viável e eficiente para o 
pré-tratamento de amostras biológicas (soro e urina), contribuindo assim para 
o desenvolvimento de métodos de diagnóstico de cancro precoces. 
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abstract 
 
Cancer is worldwide a major cause of death, with ca. 14 million new diagnosed 
cases each year. Therefore, the search for more efficient early-stage diagnosis 
methods is crucial aiming at increasing the treatment rate and survival of 
patients, as well as to decrease the expenses associated to advanced 
treatment. Prostate specific antigen (PSA) and lactate dehydrogenase (LDH) 
are proteins commonly found in human fluids (urine and serum), and have 
been considered as cancer biomarkers and in the monitoring of cancer 
treatment. However, due to their low concentration and the complexity of 
biological matrices with a large amount of other metabolites present (proteins, 
DNA, RNA), the pretreatment of samples for their concentration and purification 
is usually applied. In this work, alternative pretreatment techniques based on 
aqueous biphasic systems (ABS)  composed of ionic liquids (ILs) have been 
studied to extract, concentrate and purify proteins that can be used as cancer 
biomarkers, such as PSA and LDH. To this end, several preliminary works 
were performed to identify the most promising phase-forming components and 
conditions to create ABS that could be used for the extraction of proteins. 
These works comprise studies on the extraction of amino acids and model 
proteins in ABS, followed by investigations on their use with more complex 
matrices. Finally, ABS were investigated for the extraction and concentration of 
tumor biomarkers, namely PSA and LDH. In summary, the versatility of ILs 
allows the tailoring of the ABS extraction and concentration capacity, 
selectivity, and/or induced precipitation of cancer biomarkers from human 
fluids. The systems here developed are a viable and efficient alternative for the 
pretreatment of biological samples (serum and urine), thus contributing to the 
development of early-stage methods of cancer diagnosis. 
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1.1. Cancer update overview 
Cancer is a major cause of death worldwide, with ca. 14 million new cases diagnosed each 
year1. According to the International Agency for Research on Cancer (IARC), in 2012, 32.6 million 
people lived with cancer and 8.2 million people died with this disease. The future trends disclose 
an even worst scenario, with over 20 million new cancer cases expected in 20252. Generally, the 
cancer incidence (excluding non-melanoma skin cancer) is higher for male individuals (205 per 
100,000) compared to females (165 per 100,000)2.  
In Portugal, the cancer incidence in 2012 was of 246.2 per 100,000 individuals,2 being the 
prostate, breast, colorectal, bladder and lung the types of cancer with higher incidence rates2. In 
Brazil, the cancer incidence in 2012 was 205.5 per 100,000 individuals,2 and the most prevalent 
cancers were prostate, breast and colorectal. According to the Brazilian National Cancer institute, 
600,000 news cases were estimated to occur in 20163. Although the cancer incidence is lower in 
Brazil, the cancer mortality is higher in this country (103.7 deaths per 100,000 individuals in Brazil 
versus 99.0 deaths per 100,000 individuals in Portugal). This relative higher mortality in Brazil is 
probably associated with differences in the implementation of early stage diagnosis programs 
between the two countries. In fact, cost-effective techniques for early stage diagnosis are 
extremely important in order to reduce the mortality and improve the prognosis associated with 
the most prevalent cancer types. Generally, the higher mortality rates are registered in countries 
where early stage diagnosis programs are not implemented. The worst scenario is found in low 
and middle income countries that register approximately 70% of cancer deaths4. Prostate, 
colorectal, breast and lung cancer cases in Latin America, Africa and South-West Asia are between 
2 to 5 times higher than in developed countries. Because several cancers have a high chance of 
cure if diagnosed early and treated adequately, it is possible to reduce the cancer burden through 
early detection.  
Currently, the most common techniques used in early stage diagnosis are based on 
immunoassays which demand extensive sample processing and highly sophisticated/expensive 
technical equipment. Thus, the development of low-cost and effective early-stage diagnosis and 
point of care prognosis methods are of great importance, particularly in developing countries. The 
development of cost-effective diagnosis techniques will allow to implement global and intensive 
public actions so that mortality rates associated with cancer might be reduced. This is particularly 
relevant because cancer constitutes one of the most important non-communicable diseases 
(NCDs), that it is expected to rise in the future due to the population ageing and the increased 
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exposure to cancer triggers, such as physical, chemical and biological carcinogens.  
Most cancers are the result of a combination of genetic predisposition, lifestyle factors 
(sedentary lifestyle, unhealthy diet and drugs consumption) and exposure to environmental 
agents (e.g. chemical, physical and biological carcinogens)1. In his initial research in 1953, Nordling 
et al.5 proposed that the cancer progression in organisms occurs by successive mutations and 
developed the multi-mutation theory of cancer. However, this initial hypothesis has been updated. 
Advances in DNA amplification and sequencing allowed to better understand some of the complex 
mechanisms of cancer cells and the dynamic changes in the genome6. The change of a normal cell 
into a neoplasic state involves the acquisition of several capabilities/traits that enables them to 
become tumorogenic and ultimately malignant. These distinctive and complementary capabilities 
that enables tumor growth and metastatic dissemination were compiled and conceptualized by 
Hanahan & Weinberg6,7 into the hallmarks of cancer. Figure 1.1. depicts the malignant cell 
development hallmarks that lead to cancer development6. 
 
.   
Figure 1.1. Illustration of cancer hallmarks according to Hanahan & Weinberg6. 
The hallmarks of cancer are constituted by six biological capabilities that emerge during the 
complex development of human tumors6. These hallmarks include sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis6. The cancer cells fundamental 
ability is to maintain chronic proliferation. In normal tissues, the production and release of 
growth-promoting signals (basic instructions that cells receive in their growth and-division cycle) 
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are controlled naturally6. In cancer cells, these signals are deregulated and start to be self-
sufficient; therefore, cancers cells can regulate their progression through the cell cycle as well as 
growth. This hallmark of sustaining proliferative signaling is complemented by the ability to evade 
growth suppressors. In fact, cancer cells are able to regulate the cell proliferation by inactivating 
tumor suppressor genes6. The most common tumor suppressor genes encode RB (retinoblastoma-
associated) and TP53 proteins. They regulate the biological function that covers the control of cell 
proliferation and senescence programs6. 
The hallmark of resisting to cell death is based on the ability of cancer cells to overcome 
apoptosis 8–10. In cancer treatments, the apoptotic program of cancer cells is activated by several 
physiologic stresses, including the DNA damage that can be associated with hyperproliferation. 
Nevertheless, cancer cells developed a variety of strategies to limit or to circumvent apoptosis, 
which is commonly considered as a barrier to cancer8,9. 
Another hallmark is the enabling of replicative mortality. Normal cells are limited to a 
number of successive cell growth-and-division cycles. In contrast, cancer cells possess an 
unlimited replicative potential (enabling replicative immortality) that promotes the growth of 
macroscopic tumors6. There are two major barriers to cell proliferation: senescence and crisis. 
Repeated cell growth-and-division cycles lead to a natural induction to a nonproliferative state 
(senescence). Then, the cells that successful pass through the first phase, enter into a crisis phase, 
that leads to the death of the majority of cells. The cancer cells replicative behavior (cell growth-
and-division cycles) is blocked in one of these barriers6. 
The induction of angiogenesis constitutes another important cancer hallmark. Since cancer 
tumors demand nutrients and oxygen to growth, and they release metabolic products and carbon 
dioxide11, they require blood vessels. The tumor angiogenesis process occurs by the development 
of vasculature through the creation of new or the spread of vessels. In tumor progression, the 
angiogenesis starts and remains continuously, in order to sustain the growth of neoplastic cells12. 
The angiogenesis is regulated by signaling proteins which act as stimulator or inhibitor on cell 
surface receptors5. 
The sixth hallmark is characterized by the active invasion and metastasis mechanisms, in 
which cancer cells promote morphological modifications which allow their attachment to other 
cells and to the extracellular matrix (ECM)5. The invasion and metastasis process was already 
characterized in a sequence entitled: "invasion-metastasis cascade"13,14. The process starts with 
successive biological changes in cells, allowing the invasion by cancer cells into blood and 
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lymphatic vessels, and finish with growth of micro metastatic lesions on macroscopic tumors 
(metastasis). 
The progress achieved in the last decade in cancer research allowed to identify novel 
potential hallmarks, namely the reprogramming of energy metabolism and evading immune 
destruction6. Genomic instability and mutability confer cancer cells the ability to modify or 
reprogram their cellular metabolism6. The succession of alterations in the genomes of neoplastic 
cells to promote mutant genotype confers a strategy to find subclones that can spread easily in 
the local tissue environment6. The role of the immune system in the resistance or eradication of 
cancer cells6 is currently considered an important aspect of the development of tumors. The 
immune system constantly tracks and eliminate cancer cells; however, at some point, solid 
tumors display the ability to avoid the immune system detection6. Thus, the tumor immunity 
ability plays an expressive role in tumor formation and progression in humans6. 
These six hallmarks, together with the two emerging ones, provide a solid foundation to 
understand the biology of cancer and thus can be applied to develop new approaches to detect  
and treat cancer6. The correct identification of cancer stages alongside with early stage diagnosis 
are critical aspects that, if properly addressed, may increase the patient life-span and treatment 
efficacy15. Traditionally, cancer screening is  based on the morphologic assessment of relevant 
cells collected through biopsy, however for many cancer types, including prostate, lung and ovary, 
this approach is not adequate to detect cancer in preliminary stages15. Recently, the increasing 
knowledge of the biology of cancer allowed to develop alternative possibilities to identify cancer 
at earlier stages. The connection between cancer tumors and blood vessels, for example, is 
responsible for the exchange of biomolecules between the tumors and the blood stream. Thus, 
the metabolic products associated with malignant cells can be found in human fluids. These 
biomolecules, which are usually expressed abnormally in the presence of cancer, may then be 
used as cancer biomarkers15.  
According to the National Cancer Institute, cancer biomarkers are molecules with biological 
activity or expression that are present in human fluids (saliva16,17, urine18–20, tears21,22 and serum23–
25), being their levels indicative of a pathologic condition26. Advances in genomics, proteomics and 
molecular biology allowed to identify several biomarkers that are now used as tools for early 
cancer detection27, for the evaluation of disease progression and response to treatment, disease 
relapse, and more recently for point of care diagnosis. Cancer biomarkers can also be applied to 
distinguish benign from malignant tumors, or one type of malignancy from another.28 Biochemical 
cancer biomarkers include DNA29–31, mRNA32,33, enzymes34,35, proteins36,37 and other 
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metabolites38,39. 
In the last decades, the importance of biomarkers in cancer detection research increased 
significantly40. A wide range of cancer biomarkers are currently used in clinical practice, and are 
approved by the Food and Drug Administration (FDA)41. Table 1.1. describes some of the cancer 
biomarkers used for diagnosis, stage definition, evaluation of response to treatment and prognosis 
of cancer.  
 
Table 1.1. Examples of cancer biomarkers identified by the National Cancer Institute42. 
Tumorous biomarker Biological fluids Cancer type [REF] 
Alpha-Fetoprotein (AFP) Blood 
Hepatocelular 
carcinoma (HCC) 
43
 
CA15-3/CA27.29 Blood Breast  
44 
CA19-9 Blood 
Pancreas and 
gallbladder 
45,46 
CA-125 Blood Ovaries 
47 
Calcitonin Blood Medullary thyroid 
48 
Carcinoembryonic antigen 
(CEA) 
Blood Colorectal and breast  49,50 
Chromogranin A (CgA) Blood 
Neuroendocrine 
tumors 
51 
Collagen, type I, alpha 1 
(COL1A1) 
Urine Prostate 52 
Cytokeratin fragments Blood Lung 53 
EGFR Blood Prostate 54 
Epidermal growth factor-
containing fibulin-like 
extracellular matrix protein 1 
(EFEMP1) 
Blood and urine Prostate 55 
Exosomes Urine Prostate 56 
HER2 Blood Prostate 54 
Lactate dehydrogenase (LDH) Blood Germ cell tumors 57,58 
MMP-9 Urine Prostate 59 
miRNA (miR-222-3p*miR-24-
3p/miR-30c-5p) 
Urine Prostate 60 
Oncosomes (CD9 and STEAP) Blood Prostate 61 
Prostate-specific antigen (PSA) Blood and urine Prostate 62 
Prostatic acid phosphatase 
(PAP) 
Blood Prostate 63 
Zinc-alpha 2-glycoprotein 
(AZGP1) 
Blood Prostate 64 
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1.2. Prostate cancer 
Prostate cancer (PCa) is the second most common type of cancer in men, representing 17% of 
the cancer-related diseases in males65. It is the fifth leading cause of cancer death worldwide with 
the highest mortality rates found in the Caribbean and Southern and Middle Africa65. Ethnicity and 
age are amongst the major risk factors with 97% of prostate cancer cases occurring in men over 50 
years old65. Considering that life expectancy is increasing in developed countries, an increase in 
PCa cases is therefore expected. The costs associated with the treatment of prostate cancer are 
high; in Europe alone, the total economic costs associated with the treatment of PCa exceeded 
€8.43 billion up to 201366. In order to decrease the burden associated with the increasing 
incidence of PCa, effective diagnosis and treatment monitoring is of utmost importance. Prostate 
cancer diagnosis is usually performed through digital rectal examination (DRE), transrectal 
ultrasound (TRUS) guided biopsy, and measurement of PCa biomarkers in blood. DRE is the most 
common procedure. However, DRE has poor reliability, particularly in small tumors that have not 
reached the prostatic capsule and therefore will not be identified67. Transrectal ultrasound guided 
biopsy is an invasive technique that allows the classical identification of cancer cells through 
biopsy. However, it has several and serious side effects, like febrile urinary tract infection (UTI), 
urosepsis, bleeding and hematuria. In addition, this procedure is also connected to 15%-20% of 
false negative results68. In addition to DRE and TRUS, several biomarkers have been identified and 
can be used in prostate cancer diagnosis (Table 1.2.). The prostate-specific antigen (PSA) blood 
test is still the most used diagnosis method due to its strong correlation with PCa69. 
 In recent years, due to the increase in the available treatments, the monitoring of treatment 
efficacy, disease relapse and prognosis are gaining importance. For that, new biomarkers have 
been studied and implemented in the clinical practice. These biomarkers allow to identify patients 
with a poor prognosis so that novel treatments can be initiated earlier70. In the past few years, 
several studies suggested that serum LDH levels in patients with solid tumors, including prostate 
cancer, are correlated with an adverse prognosis70. Therefore, the concomitant evaluation of both 
PSA and LDH in the same patient will allow to achieve better PCa diagnosis and prognosis, so that 
the most effective treatment may be selected at earlier stages.  
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Table 1.2. Examples of PCa biomarkers. 
Tumorous biomarker Biological fluids [REF] 
8-hydroxydeoxyguanosine Urine 
71
 
α-methylacyl coenzyme a 
racemase (amaCr) 
Urine 
72,73
  
annexin a3 Urine 
74
 
Collagen, type I, alpha 1 
(COL1A1) 
Urine 
52
 
E-cadherin Blood 
75–77
 
EGFR Blood 
54
 
Epidermal growth factor-
containing fibulin-like 
extracellular matrix protein 1 
(EFEMP1) 
Blood and urine 
55
 
Exosomes Urine 
56
 
Golgi membrane protein 1 
(Golm1 ) 
Urine 
78
 
GSTP1. Urine 
79–81
 
HER2 Blood 
54
 
Interleukin 6 (IL-6) and 
Interleukin 6 Receptor (IL-6R) 
Blood 
82,83
 
Kallikrein-4 (KLK-4) Blood 
84
 
Minichromosome 
maintenance 5 protein 
(Mcm5) 
Blood 
85
 
MMP-9 Urine 
59
 
miRNA (miR-222-3p*miR-24-
3p/miR-30c-5p) 
Urine 
60
 
Oncosomes (CD9 and STEAP) Blood 
61
 
PCA3 Blood and Urine 
86–88
 
Prostate-specific antigen (PSA) Blood and urine 
62
 
Prostatic acid phosphatase 
(PAP) 
Blood 
63
 
Steroid Receptor Co-Activator-
3 (Src-3) 
Blood 
89,90
 
TMPRSS2–ETS Urine 
91–93
 
Zinc-alpha 2-glycoprotein 
(AZGP1) 
Blood 
64
 
 
1.2.1. Prostate-specific antigen (PSA) 
Prostate-specific antigen (PSA) is a serine protease (human kallikrein gene family) (Figure 1.2.) 
with 33 KDa and an isoelectric point (pI) of 6.5–894,95, produced and secreted in prostatic 
epithelium glands. In 1988, the physiological function of PSA was revealed as a liquefying agent of 
seminal fluids, and this concept is the most commonly accepted until today96. PSA liquefies the 
seminal clot produced after ejaculation, facilitating the spermatozoa transport along the female 
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reproductive tract. The dissolution of the gel proteins from the seminal fluid (cleavage of 
semenogelin 1 and 2 (SEMG1, SEMG2), fibronectin, laminin and gelatin) occurs due to the  
chymotrypsin like endoproteolytic PSA activity96,97. In normal prostatic conditions, only a small 
portion of PSA escapes the prostatic gland and enters the circulatory system. The PSA diffuses into 
the circulatory system in its free form, where it interacts with protease inhibitors (primarily 
alpha1-antichymotrypsin, ACT) and forms a complex that can detected as a 80-90 KDa protein 
complex98. This complexed form manifests little or no catalytic activity in blood99. Increased levels 
of PSA in blood are believed to be a consequence of the disruption in the prostate architecture, 
including the basement membrane disordering, the loss of basal cell layer, alterations in the duct 
lumen architecture and epithelial cell polarity. Prostate tumors are characterized by such 
disruptions and thus by enabling the passage of PSA into circulation, elevating the basal PSA 
levels.  
 
 
Figure 1.2. Structure of Prostate-specific antigen (PSA) (PDB: 2zch). 
The quantification of total PSA (tPSA) and free PSA (fPSA) in human fluids has a significant 
role in the clinical management of PCa patients100. In 1979, Wang et al.101 reported the purification 
of PSA from prostate tissue. The authors showed that PSA was present in normal and benign 
hyperplastic prostate, as well as in malignant prostatic tissue and was undetected in any other 
human tissues101. After this study, PSA emerged as a potential prostate cancer biomarker. Catalona 
and co-workers102 latter proposed the serum PSA measurement as a first-line screening test for 
prostate cancer. Mostly based in Catalona102 seminal work, in 1994, the FDA approved PSA as a 
biomarker to be evaluated in screening methods to identify prostate cancer.  
A PSA value of > 4.0 ng.mL-1 has been defined in the literature103 as abnormal and it is 
frequently used as a cut-off, although for younger men a cut-off level of < 2.5 ng.mL-1 was recently 
proposed. For values between 4.0 and 10.0 ng.mL-1, the grey zone, there exists a 22% to 27% 
likelihood of cancer, whereas values above 10 ng.mL-1 yield up to a 67% chance of prostate 
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cancer104. Because PSA levels increase steadily with age, some urologists advocate the use of age-
related “normal” PSA cut-offs105, rather than using the limit of > 4 ng.mL-1 as universal. Oesterling 
et al.106 and Luboldt et al.107 concluded that the upper limit of the PSA cutoff, achieving 95% of 
specificity, would increase with age. Therefore, to maintain the equitable 95% specificity or an 
equivalent 5% false-positive rate across different ages, the PSA cutoff for recommending biopsy 
must necessarily increase with age. PSA test as a screening method for PCa is recommended to 
male individuals above 50 years old; however, in African American man the age decreases to 40 
years old, since ethnicity is a relevant factor for PCa incidence108.  
PSA is present in different biological fluids including blood, urine and semen. Hence, the 
quantification of PSA in any of these fluids could be used to identify PCa. The quantification of PSA 
levels in urine was firstly studied by Graves and co-workers109 in 1985. Since then, other authors 
reported the PSA quantification in urine110–112. In fact, urine PSA levels showed to be advantageous 
compared to serum PSA, being considered a non-invasive alternative for the early detection of PCa 
cancer. Although the exact mechanism by which urinary PSA levels are altered in PCa patients is 
not fully understood, some authors suggest that the disturbance of prostate architecture and the 
neovascularization alters the secretion of prostatic secretions (including PSA) in the prostatic 
urethra113. These changes lead to a decrease of PSA excretion through urine and to a consequent 
increase in PSA levels in the bloodstream. Thus, in prostate cancer patients the levels of PSA in 
blood are higher and the levels in urine are lower than the ones found in healthy patients113. The 
threshold value for PSA in urine was set at 150 ng.mL-1. This cutoff value for urinary PSA displays a 
sensitivity of 92.5%113 and it is recommended that patients with PSA levels <150 ng.mL-1 in urine 
should perform a prostatic biopsy113. Despite the many advantages of urine PSA testing, this 
technique is not yet used in the clinical practice, probably due to the lack of validated and cost-
effective detection and quantification methods.  
1.2.2. Lactate dehydrogenase (LDH) 
Lactate dehydrogenase (LDH), EC1.1.1.27 (Figure 1.3), is a NAD+-dependent enzyme 
(oxidoreductases family), with a molecular weight between 115 and 154 kDa114. LDH is responsible 
for the anaerobic conversion of pyruvate to lactate in the last step of lactic fermentation115. The 
oxidation reaction occurs in the LDH active site that presents hydrophilic and charged amino acids 
residues, such as glutamate, glutamine, aspartate, arginine and histidine116. LDH is usually present 
in the liver, cardiac muscle, kidneys, skeletal muscle and erythrocytes. It is composed of four 
polypeptide chains, each one encoded by a separated gene (M and H)115, resulting in five 
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combinations of polypeptide subunits and five molecular isoforms of LDH (M4, MH3, M2H2, M3H 
and H4), found in different quantities depending on the originating tissue
117 118.  
As previously mentioned, one of the hallmarks of cancer is the reprogramming of energy 
metabolism and neo-angiogenesis. Cancer cells energetic demands led these cells to produce high 
levels of pyruvate and lactate119. Several authors suggested that LDH ensures both an efficient 
anaerobic/glycolytic metabolism and a reduced dependence on oxygen under hypoxic conditions 
in tumor cells115. The relation between LDH levels and hypoxia is mediated by a tumor-driven 
angiogenesis pathway through the abnormal activation of the hypoxia inducible factor 1 (HIF-1)115. 
The biological activity of this hypoxia inducible factor is modulated by HIF-1α. This factor, in turn, 
upregulates several genes responsible for glycolytic energy metabolism, angiogenesis, 
erythropoiesis and cell survival. Because tumor hypoxia is enough to alter the gene expression of 
this factor, it will downregulate several other genes that encode for vascular endothelial growth 
factor, as an indirect marker of tumor hypoxia, neo-angiogenesis and worse prognosis, and 
therefore it is an useful cancer biomarker, particularly for prognosis evaluation115.  
 
Figure 1.3. Structure of Lactate dehydrogenase (LDH) (PDB: 1i10). 
LDH was already approved by the American Society of Clinical Oncology as a biomarker of 
germ cell tumors120. More recently, the LDH role in melanoma, lung cancer, prostate cancer, 
osteosarcoma and kidney cell carcinoma121–124 was highlighted in clinical trials. The normal levels 
of LDH in serum range between 100 and 300 U/L, and individuals with LDH levels (>225 U/L) have 
survival rates significantly reduced125. Individuals that display high levels of LDH (> 300 U/L) 
showed an average survival of 7 months, against the 12 months for patients with regular LDH 
levels125. The cutoff value corresponding to a high LDH is generally set at 250 U/L70, and LDH 
values have already been incorporated in prognostic scores for different types of cancer126. 
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However, the clinical significance of LDH levels in biological fluids is still under discussion127. 
Nishikawa et al.128 proposed that urine LDH isoenzymes levels might be a useful tool to evaluate 
urinary tract malignancy, especially in early stages. Notwithstanding, LDH-5 levels in body fluids 
can change with bacterial infections, particularly in urine 
127
. 
LDH isoenzymes are expressed in different levels in individuals that present PCa or benign 
prostatic hyperplasia (BPH)129. High LDH-5 levels and low LDH-1 levels occur in PCa cases, while in 
BPH cases the opposite behavior is observed130. In PCa early stage patients, LDH levels are barely 
abnormal. However, LDH levels display an added-value for assessment of prognosis, therapeutic 
efficacy and evaluation of symptoms131. LDH levels already shown to be an efficient prognostic 
indicator for PCa and breast cancer in patients with bone metastasis131,132. Moreover, LDH-5 
overexpression is sensitive to highly proliferating prostate carcinomas and can be useful to 
monitor the radiotherapy evolution133. LDH levels associated to circulating tumor cells counts 
(CTC) is an effective biomarker for castration-resistant prostate cancer (CRPC)134, and also an 
effective tool for discrimination between high-risk and low-risk patients with CRPC135. The results 
of two recent systematic reviews and meta-analysis70,124 further strengthened the usefulness of 
LDH as a prognosis biomarker in metastatic carcinomas. LDH levels quantified before treatment 
are considered as a simple and cost-effective prognostic factor that also has the potential to be a 
predictive biomarker that can be used to guide therapeutic decisions70.  
1.3. Cancer biomarkers detection methods 
Cancer biomarkers are of high relevance for early cancer detection. However, these 
biomarkers are usually present at low levels and present in complex matrices such as human 
fluids. Therefore, the major challenges in cancer detection through the 
identification/quantification of biomarkers are to avoid the interferences of other contaminant 
molecules and to concentrate cancer biomarkers up to levels above the equipment detection 
limits. 
Several techniques have been applied for cancer biomarkers detection and quantification136, 
such as polymerase chain reaction (PCR)137,138, enzyme-linked immunosorbent assay (ELISA)139,140, 
electrophoresis141,142, surface plasmon resonance (SPR)143,144, surface enhanced Raman 
spectroscopy (SERS)145–147, microcantilivers148,149, and colorimetric150,151, electrochemical152,153 and 
fluorescence assays154,155. The choice of these methods are obviously dependent on the type of 
biomarker to be quantified. For protein biomarkers, for example, the methods most commonly 
used include ELISA, and electrochemical, electrical and optical detection methods 139,140. More 
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recently, the identification and quantification of proteins as cancer biomarkers by mass 
spectrometry has also been applied136. In general, the quantification of protein biomarkers 
exhibits several difficulties associated with their intrinsic nature. Those difficulties include for 
example their sensitivity to changes in temperature, pH and ionic strength, their incapacity to 
replicate themselves contrarily to what happens with nucleic acid biomarkers that are easily 
“amplified”, and their concomitant occurrence with other proteins and biomolecules in biological 
fluids and tissues136. Such difficulties are, for some biomarkers and types of cancer, translated into 
a lack of accuracy, sensitivity and specificity of diagnostic methods.  
The identification and quantification of PSA is the most widely used assay to detect prostate 
cancer at earlier stages. Amongst the various identification and quantification techniques 
available for PSA, ELISA151,156, fluorescence microscopy157, surface plasmon resonance 
technology158, immunochromatography159,160, lateral flow immunoassay161, and 
immunochemiluminescence are the most employed. In the clinical practice, immunoassays are 
generally preferred and are approved by the FDA162. Even though some of these techniques have 
an adequate detection limit, most of them display significant drawbacks. ELISA is a powerful 
technique for antigen quantification, but requires highly skilled technical operators, laborious 
treatment steps, high cost specific antibodies, signal amplification using biochemical reactions,  
and specific and expensive equipment, and is thus time-consuming and expensive156,163–165. On the 
other hand, fluorescence and electrochemistry-based methods require the labelling of the target 
analyte for signal amplification. Furthermore, prolonged exposure of fluorescence dyes to 
excitation light source causes the photobleaching and quenching of signals that may lead to 
underestimated results136. 
Over the recent years, several authors have reported new PSA detection technologies using 
DNA microarrays and protein microarrays166 with promising results in terms of detection limits; 
however, such sophisticated technologies are far from being commercially available. Mass 
spectrometric methods with or without antibodies167 have also been proposed; yet, they require 
highly sophisticated and expensive equipment that is generally not available in clinical 
laboratories.  
Non-invasive methods for the PSA quantification in urine have been additionally 
developed113. However, the urine samples polishing is not an easy task. Several methods of 
extraction and pre-concentration of urine samples, such as dialysis and lyophilization168,169, 
filtration170, precipitation171 and SPE172 have been proposed. The major drawback in urine 
proteomic analysis is the fact that protein losses are high, not allowing accurate quantifications173, 
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thus requiring the development of a simple and efficient method to extract and concentrate PSA 
from human urine.  
LDH detection in biological samples is commonly performed using spectrophotometric 
assays174. This method is based on the LDH ability to catalyze lactates to pyruvates. During this 
reaction, NAD+ is reduced to NADH, which can be monitored at 340 nm. LDH also can be 
quantified by liquid chromatographic (LC)175,176 and electrochemical methods177. All of the 
aforementioned methods present however clinical diagnostic limitations (low accuracy, sensitivity 
and specificity) and some (particularly LC-based methods) are of high cost requiring expensive 
analytical equipment136. 
Generally, the quantification of LDH occurs in human serum, plasma and blood. Due to the 
high amount of protein in these biological fluids, a correct sample preparation is the most crucial 
step in the biomarkers quantification178. Serum is a human fluid that contains more than 10,000 
proteins179. The abundance of albumin in serum (35–50 mg/mL) is the most critical challenge in 
proteomic quantification180. High levels of proteins in serum promotes interferences with the 
identification and quantification of lower abundance proteins (lower than ng/mL in serum), such 
as  cancer biomarkers180. 
In general, all cancer biomarkers quantification methods in human fluids (serum, plasma, 
whole blood and urine) require samples’ pre-treatment in order to eliminate the high amount of 
other non-target proteins and metabolites to allow an accurate diagnosis. In this context, aqueous 
biphasic systems (ABS) can be seen as viable methods of extraction, concentration and purification 
of selected cancer biomarkers from human fluids, with significant advantages over conventional 
methods. The use of ABS to separate the target proteins from matrix interferences, such as other 
proteins and metabolites, will contribute to avoid false positives or negatives, one important 
limitation of the commercially available methods. 
1.4. Aqueous biphasic systems 
Aqueous biphasic systems (ABS) are used in liquid-liquid extraction methods that received a 
large attention for being mainly composed of water, promoting thus a biocompatible environment 
for bioactive molecules181. ABS are also considered environmental-friendly technologies since the 
use of volatile and hazardous organic solvents is avoided. They are usually constituted by two 
polymers, a polymer and a salt or two salts, that above a given concentration undergo separation 
into two coexisting phases182. 
Polymer-based ABS were demonstrated to be a promising technique for the extraction and 
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concentration of several biomolecules from human fluids, such as lactate dehydrogenase of 
Plasmodium (pLDH)183, DNA184, extracellular vesicles (SVE)185,186 and alkaline phosphatase187. 
Furthermore, polymer-polymer and polymer-salt ABS were already applied in human disease 
monitoring and diagnosis including bone diseases187 and cancer185,186. Raymond et al.187 
demonstrated that a system constituted by polyethylene glycol + dextran is capable to separate 
selectively alkaline phosphatase from its isoforms, valuable in the detection of bone diseases. The 
authors reported that the difference of the partition behavior of the alkaline phosphatase 
isoforms is based on the type of surfactants applied and specific anchoring interactions, which 
benefit the selective separation. In the cancer detection field, the system composed of 
polyethylene glycol + dextran was used to isolate extracellular vesicles from human serum185,186. 
These were isolated in one-step with purities between 70-75%. However, to increase their purity, a 
combined process with centrifugation and ABS allowed the removal of proteins from human 
serum increasing the purity of the extracellular vesicles up to 95%185. The behavior of PSA 
partition in presence of other human proteins (human serum albumin, human transferrin, and 
human gamma-globulin) was evaluated in ABS constituted by dextran-ficoll157, where low PSA 
partition coefficients were obtained (around 1.5). The authors reported that the PSA partition to 
the dextran-rich phase decreases in the presence of other proteins. Electrostatic forces induced by 
protein-protein interactions lead to the formation of PSA-protein complex which induce changes 
in the partition of PSA157. The effect was more pronounced in presence of high levels of proteins, 
showing that the PSA accurate quantification in human fluids is only possible by samples’ pre-
treatment and by the removal of contaminant proteins. 
Despite being widely exploited, conventional polymer-based ABS present some limitations in 
their phases polarities and a high viscosity, making difficult the phase separation and to tailor 
these systems selectivity. On the other hand, less traditional ABS composed of organic solvents + 
salts, ionic liquids (ILs) + salts and surfactants + salts present a higher polarity difference between 
the two phases, representing thus a more efficient and selective alternative to common polymer-
based ABS. These alternative ABS were applied to detect malaria183, cancer184 and endocrine 
disruptors188 in human fluids. In an attempt to produce an apparatus for malaria detection, lateral 
flow immunoassay (LFA) combined to surfactant-based ABS was established183. The authors 
developed a diagnostic strip paper that in contact with the ABS detects lactate dehydrogenase 
from Plasmodium (pLDH). In this work, ABS allowed to concentrate pLDH around 10 times and 
significantly decreased the time of diagnosis to around 8h183. The concentration of biomarkers 
using ABS constituted by surfactants + salts was also addressed by Mashayekhi et al.184 to improve 
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early cancer detection. DNA fragments were extracted mainly to the ABS top phase (salt-rich 
phase) and under the best conditions an increase of 9-fold of the DNA concentration was 
achieved. 
Recently IL-based ABS have been extensively investigated182. ILs are molten salts constituted 
by a large organic cation and an inorganic/organic anion with melting temperatures below 
100 °C189. Due to their ionic composition, most ILs present unique characteristics, such as 
negligible volatility at room temperature, non-flammability, high thermal and chemical stabilities, 
and a strong solvation capability for a wide range of compounds190,189. Some common chemical 
structures of ILs are displayed in Figure 1.4. 
 
Figure 1.4. Chemical structures of ILs. Cations: (i) N-(1-methylpyrrolidyl-4-butoxy-4-
oxoethyl)ammonium, (ii) tri(n-butyl)[4-butoxy-4-oxoethyl]ammonium, (iii) tetrabutylammonium, 
(iv) tri(n-butyl)[4-butoxy-4-oxoethyl] phosphonium, (v) Tetrabutylphosphonium. Anions: (i) 
bromide, (ii) chloride, (iii) lactate, (iv) dicyanamide, (v) pyruvate, (vi) salicylate. 
 
One of the most important advantages of ILs is the fact that their physicochemical properties 
Cations
i
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can be tailored by manipulating the chemical structure of their ions, and thus it is possible to 
synthesize ILs for a specific application. Due to this characteristic, the ILs solubility, solvation 
ability, biodegradability and toxicological features can be tailored for a given purpose. Their 
tailoring ability is extensible to IL-based ABS191, supporting the large interest devoted to this type 
of systems in the past years. IL-based ABS have been used in the separation of enzymes, proteins, 
amino acids, antibiotics, among many other solutes182,192,193. Albeit these studies can be used as 
guidelines for the application of IL-based ABS in the extraction of proteins, in most of these works, 
imidazolium-based ILs and inorganic salts were used as phase-forming components182,193. 
Regarding proteins, these IL-based ABS have been applied in the extraction of alcohol 
dehydrogenases194, aloe proteins195, azocasein196, BSA192,197–201, Cordyceps sinensis proteins202, 
cytochrome c203–205, hemoglobin198,199,206, Horseradish peroxidase207, immunoglobulin Y and G208, 
lipases209–213, myoglobin192,214, papain200,215, pepsin192, rubisco216, transferrin197 and Y-globulins203. 
Yet, to the best of our knowledge, works on the use of IL-based ABS and cancer biomarkers have 
not yet been reported. Most of the works in literature with IL-based ABS and proteins were carried 
out with imidazolium-based ILs193. Aiming at finding more biocompatible alternatives, the ABS 
studied in this thesis for the extraction of amino acids, proteins and cancer biomarkers are formed 
by ammonium- or phosphonium-based ILs. These tetraalkyl-based compounds also are less 
expensive and thermally more stable than the equivalent imidazolium counterparts217. 
 
1.5. Scope and objectives 
Cancer is a global epidemic with more than 14 million new cases diagnosed each year and 
with an estimated annual economic cost of approximately €1 trilion1. Thus, investments in cancer 
early-stage diagnosis methods are critically required to decrease mortality, to increase the 
patient’s lifespan and to decrease the associated economic and social burden of this disease. In 
the last decades, advances in scientific and medical research resulted in the ability to develop 
novel strategies to prevent and detect several diseases, including cancer. Nevertheless, the 
development of early detection methods for cancer is still at an initial stage, and a wide range of 
problems need to be solved until low-cost yet efficient methods become available worldwide. The 
quantification of cancer biomarkers in human fluids is a key method for cancer early-stage 
detection. The levels of prostate-specific antigen (PSA) and lactate dehydrogenase (LDH) in human 
fluids have been used as relevant diagnosis and prognosis biomarkers of prostate cancer. However, 
due to their low levels in human fluids and complexity of biological matrices, expensive and time-
consuming methods are necessary to purify and concentrate these cancer biomarkers before their 
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quantification. Based on this need, this thesis focus on the development of novel strategies for the 
pretreatment of human samples envisaging early-stage cancer detection according to the 
following steps: 
I) SCREENING of cost-effective ABS platforms for the separation and purification of amino 
acids and proteins to better understand the complexity and conditions required to deal with 
protein-based cancer biomarkers; 
II) DEVELOPMENT of IL-based ABS as effective tools of concentration and purification of 
cancer biomarkers from human fluids aiming their easier and more accurate 
detection/quantification. 
In order to visualize the thesis scope and structure, an illustrative representation of its layout 
is displayed in Figure 1.5. 
 
Figure 1.5. Present thesis layout. 
In order to better understand the partition behavior of cancer biomarkers in IL-based ABS, 
and since these biomarkers are proteins, ABS composed of glycine-betaine-based ILs and Na2SO4 
were initially studied (Chapter 2.1). Further to the ILs synthesis and characterization, the ABS 
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phase diagrams were determined and their ability to extract biomolecules was evaluated with two 
amino acids, namely tyrosine and tryptophan. The results obtained indicate that the amino acids 
preferentially partition to the IL-rich phase with remarkable extraction efficiencies. The acquired 
knowledge with the amino acids behavior in ABS represents a relevant basis to understand the 
interactions of more complex structures, such as proteins. In the following Chapter (Chapter 2.2), 
novel ABS composed of phosphonium- and ammonium-based ILs and a citrate-based salt were 
developed and used for the extraction of the protein Bovine Serum Albumin (BSA). These ILs, 
being more hydrophobic than the well-studied imidazolium-based, allow the use of lower 
amounts of phase-forming components to create ABS. Moreover, these ILs tend to be less toxic 
and more biodegradable than their imidazolium counterparts. It is shown that the extraction 
efficiencies of BSA to the IL-rich phase are of 100%, maintained up to high protein concentrations 
(at least up to 10 g.L-1). The recovery of the BSA from the IL-rich phase by dialysis was also 
demonstrated in addition to the IL recyclability and reusability. The protein stability in the IL-rich 
phase also was confirmed. In the following chapter, Chapter 2.3, the ability of ABS composed of 
polyethylene glycols of different molecular weights (PEG 400, 600 and 1000 g.mol-1) and a citrate-
based salt to selectively extract ovalbumin (OVA) from complex protein mixtures (directly from 
egg white) was investigated. These ABS do not require the use of ILs and make use of a more 
biocompatible and biodegradable salt. In almost all ABS it was observed a preferential partition of 
ovalbumin to the polymer-rich phase, with extraction efficiencies higher than 90%. The best ABS 
were then applied to the purification of ovalbumin from egg white allowing to gather novel 
knowledge on the behavior of several proteins and on dealing with complex matrices. Successful 
results were obtained since pure OVA was isolated and recovered from the complex matrix. In 
Chapter 2.4 the recovery of Major Royal Jelly Proteins (MRJPs) from honey (biological complex 
mixture) was investigated using ABS composed of phosphonium-based ILs and carbohydrates. In 
all systems, MRJPs almost completely precipitate at the ABS interface. The obtained recovery yield 
of MRJPs range between 83.8 and 97.3%, with MRJP1 obtained with a purity level ranging from 
80% to 90%. This work demonstrates the use of ABS as depletion methods, relevant as 
pretreatment strategies of biological samples. 
All the works developed in Chapter 2 provide new knowledge towards the understanding of 
the behavior of amino acids and proteins in IL-ABS, i.e. which conditions favor their selective 
extraction or precipitation. This type of knowledge is relevant to identify the most promising ABS 
to be used in the concentration and purification of cancer biomarkers. Amino acids were 
investigated since they correspond to the structural units of proteins. OVA and BSA were chosen 
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as model proteins because they correspond to albumins extensively studied in a wide variety of 
fields, and have a similar amino acids sequence with HSA, the most abundant protein in human 
serum. The last work, carried out with honey and MRJPs, was performed to address the use of ABS 
in highly complex matrices.   
Based on the previous knowledge and on the requirement of finding more biocompatible IL-
based ABS for the pretreatment of human fluids, Chapter 3.1 addresses the synthesis of glycine-
betaine-based-ILs and their study as phase-forming components of ABS for the depletion of 
Human Serum Albumin (HSA) and Immunoglobulin G (IgG) from human serum. The obtained 
results reveal that most of the systems investigated allow the complete depletion of HSA and IgG 
from serum to the ABS interphase, in a single-step. The depletion of these highly abundant 
proteins allow the identification of low abundance proteins in serum, such as transferrin. In 
Chapter 3.2, IL-based ABS were applied to extract and concentrate cancer biomarkers, namely 
PSA, present in human urine. The complete extraction of PSA to the IL-rich phase was achieved, 
with its simultaneous concentration up to 250-fold in the IL-rich phase. Finally, in Chapter 3.3, the 
selectivity of the investigated IL-based ABS for LDH in presence of contaminant proteins typically 
found in human serum was ascertained. The IL-based ABS developed allowed the one-step 
extraction of LDH from human serum, while leading to the precipitation of the remaining proteins 
present in serum, representing thus a depletion method. 
The final section of this thesis (Chapter 4) provides a global view of the developed work, with 
some final remarks and future perspectives.  
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2.1. Extraction of amino acids using aqueous biphasic systems formed by glycine-
betaine ionic liquid analogues   
This chapter is based on an unpublished work with the following authors involved: 
Matheus M. Pereira, Joana Gomes, João A. P. Coutinho, Aminou Mohamadou and Mara G. Freire 
2.1.1. Abstract 
Given the biotechnology advances observed in recent years in terms of upstream, the 
development of effective and biocompatible downstream processes becomes mandatory to 
decrease the costs of biotechnological products. Although a large interest has been devoted to 
ionic-liquid-based aqueous biphasic systems (IL-based ABS) as tailored separation platforms, 
imidazolium-based ILs have been the preferred choice as phase-forming agents. To overcome the 
toxicity and biodegradability issues associated to imidazolium-based ILs, in this work, ABS 
composed of IL analogues of glycine-betaine (AGB-ILs) were investigated. Six AGB-ILs were 
synthesized, characterized in terms of ecotoxicity, and applied towards the development of novel 
bio-based ABS. Then, the respective ABS ternary phase diagrams, as well as the tie-lines and tie-
line lengths, were determined at 25°C. Finally, their performance as extraction platforms was 
evaluated with two amino acids (L-tryptophan and L-tyrosine). In all studied systems, amino acids 
migrate preferentially to the IL-rich phase, with maximum extraction efficiencies of 97% and 100% 
for L- tyrosine and L-Tryptophan, respectively, achieved in a single-step. In summary, this work 
demonstrates that novel bio-based ABS composed of AGB-ILs are improved platforms for the 
extraction of biomolecules, and thus can be envisaged as promising separation strategies for 
other value-added compounds of biotechnological interest. 
2.1.2. Introduction 
Advances in biotechnology have enhanced the production of a wide variety of value-added 
biocompounds1. Nevertheless, the major drawback is still their recovery and purification from the 
original complex media by cost-effective techniques, while keeping their biological activity. 
Therefore, the development of more benign and effective separation techniques has been a hot 
topic of research in the past few years2. 
Aqueous biphasic systems (ABS) fit within the liquid-liquid extraction/purification techniques. 
These are formed by two compounds (two salts, two polymers or a polymer and a salt), that when 
dissolved above given concentrations in aqueous media result in the formation of two immiscible 
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aqueous liquid phases, each enriched in one of the phase-forming components3,4. Due to the large 
amount of water in their composition, ABS could be seen as more biocompatible extraction 
platforms when compared to liquid-liquid extraction systems employing volatile organic 
compounds. Although widely studied in the past decades2,5, conventional polymer-based ABS 
have coexisting phases of high viscosity turning the phases separation step difficult to occur in a 
short time and without energetic/centrifugation inputs. Furthermore, the coexisting phases in 
these more conventional polymer-based ABS display a restricted polarity difference, which 
hampers enhanced extraction efficiencies and high selectivity to be achieved in a single-step6. In 
fact, several attempts can be found in the literature to improve the performance of polymer-
based ABS, either by introducing additives or by the functionalization of polymers. However, after 
the introduction of ionic-liquid-based ABS by Gutowski et al.7, a shift in the ABS research field was 
noticed. These systems have shown remarkable extraction efficiencies and high selectivity’s, 
observed for a wide variety of biocompounds and matrices5. 
Ionic liquids (ILs) are salts, with melting temperatures below 100°C8. Due to their ionic 
nature, most ILs present notable properties, such as a negligible volatility at atmospheric 
conditions, non-flammability, high thermal and chemical stabilities, and a strong solvation ability 
for a wide range of compounds8,9. Besides these features, they have been labelled as “designer 
solvents” due to the ability of combining a large number of ions with significantly different 
chemical structures, allowing the design of improved ILs for particular applications. This 
characteristic is also reflected in IL-based ABS5, and is one of the main reasons behind the 
outstanding performance of these more recent systems over the conventional polymer-based 
ones. IL-based ABS have been successfully applied in the separation of antioxidants10, 
alkaloids11,12, amino acids13, proteins/enzymes14,15,16, among others. The largest fraction of IL-
based ABS investigated hitherto are based on imidazolium-based ILs and inorganic salts as phase-
forming components5. However, imidazolium-based ILs display high toxicity and may compromise 
the biological activity of several molecules, thus motivating the research on more benign ILs to be 
applied in ABS. Although some reports have appeared in the past few years with this issue in 
mind, these studies were mainly carried out with cholinium-based ILs, either combined with salts 
or with polymers to create ABS17–23. However, nowadays, there are other ILs derived from natural 
sources that could be explored in the creation of ABS. Among these, analogues of glycine-betaine-
(AGB)24 can be seen as a promising alternative. These organic osmolytes accumulate in a variety of 
plant species in response to environmental stress25,26. Both compounds have positive effects on 
enzyme and membrane integrity along with adaptative roles in mediating osmotic adjustment in 
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plants growing under stress conditions. Hydrophobic ILs based on AGB have been applied in the 
extraction of pesticides27 and metal ions28–30. However, based on their natural-derived source, and 
if coupled with anions that turn them miscible with water, these ILs can be used in the creation of 
more biocompatible ABS aiming at the separation and recovery of biologically active compounds. 
Taking into account this possibility and advantages connected to AGB-ILs, this work is focused on 
the development of more biocompatible IL-based ABS and on the evaluation of their performance 
to extract amino acids. To this end, six AGB-ILs have been synthesized, and their ability to create 
ABS with Na2SO4 addressed. The respective ternary phase diagrams were determined at 25°C to 
infer the mixture compositions required to form two-phase system, followed by the evaluation of 
their performance to extract amino acids. Their ecotoxicity towards the marine bacterium Vibrio 
fischeri will also be discussed. 
2.1.3. Experimental procedures 
Materials. The AGB-ILs were synthesized by us according to previously reported protocols24. 
The ILs triethyl[2-ethoxy-2-oxoethyl]ammonium bromide ([Et3NC2]Br), tri(n-propyl)[2-ethoxy-2-
oxoethyl]ammonium bromide, ([Pr3NC2]Br), tri(n-butyl)[2-ethoxy-2-oxoethyl]ammonium bromide 
([Bu3NC2]Br), tri(n-butyl)[2-ethoxy-2-oxoethyl]phosphonium bromide ([Bu3PC2]Br), and n-(1-
methylpyrrolidyl-2-ethoxy-2-oxoethyl)ammonium bromide ([MepyrNC2]Br) were synthesized by 
the reaction of ethyl 2-bromoacetate and triethylamine, tri(n-propyl)-amine, tri(n-butyl)amine, 
tri(n-butyl)phosphine or n-methylpyrrolidine, respectively. The synthesis pathway for the AGB-
based ILs is depicted in Appendix A. Tri(n-butyl)[2-butoxy-2-oxoethyl]phosphonium bromide 
([Bu3PC4]Br) was synthesized in this work for the first time by the reaction of tri(n-butyl)phosphine 
(83.8 mL, 65.2 g, 0.35 mol) in ethyl acetate (150 mL) and 4-bromobutyric acid ethyl ester (29.6 mL, 
37.5 g, 0.22 mol) in 50 mL of ethyl acetate. The mixture was refluxed under constant stirring for 2 
days at 40°C, and then stirred at room temperature for one day. The brownish oil produced was 
recovered and washed three times with ethyl acetate (250 mL) and kept at 60 °C. The white 
product obtained with a yield of 85%, which crystallized after 48 h, was washed with ethyl acetate 
(250 mL) and diethyl ether (250 mL) and then dried in vacuum. After this procedure, the purity of 
each IL was further checked by 1H nuclear magnetic resonance (NMR) (cf. Appendix A). The purity 
of the synthesized ILs is > 98%. All ILs synthesized in this study were solid at room temperature. 
The chemical structures of the ILs synthesized are depicted in Figure 2.1.1. 
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Figure 2.1.1. Chemical structure of the synthesized ILs: (i) [MepyrNC2]Br; (ii) [Et3NC2]Br; (iii) 
[Pr3NC2]Br; (iv) [Bu3NC2]Br; (v) [Bu3PC2]Br; and (vi) [Bu3PC4]Br. 
 
All tertiary amines and the 2-bromoacetic acid ethyl ester were acquired from Sigma-Aldrich. 
NaSO4 (anhydrous, 100 wt% pure) was from Prolabo. L-Tryptophan (purity > 99.0 wt%) and L- 
tyrosine (purity 99.0 wt%) were acquired from Sigma–Aldrich and Fluka, respectively.  
 
Microtox® toxicity tests. The Microtox® test was used to evaluate the ecotoxicity of the ILs 
synthesized towards the marine bacterium Vibrio fischeri, through the determination of its 
luminescence inhibition in presence of aqueous solutions of ILs. The bacterium was exposed to a 
series of aqueous diluted solutions of each IL, ranging from 0 to 81.9 wt%, being 100% the 
concentration of the stock solution. After 5, 15 and 30 min of exposure of the bacterium to each IL 
aqueous solutions, the light output of the bacterium was assessed and compared with the light 
output of the blank control (an aqueous solution without the presence of any AGB-ILs), enabling 
the calculation of the EC50 values at 5, 15 and 30 min through the Microtox® Omni™ Software 
version31. 
2. Screening of aqueous biphasic systems as alternative extraction and purification platforms for proteins 
35 
Phase diagrams and tie-lines. Aqueous solutions of each synthesized IL ([MepyrNC2]Br, 
[Et3NC2]Br, [Pr3NC2]Br, [Bu3NC2]Br, [Bu3PC2]Br, [Bu3PC4]Br), at concentrations between 50 and 70 
wt%, and aqueous solutions of Na2SO4 at 17 wt%, were initially prepared and used for the 
determination of the binodal curves. The phase diagrams were determined through the cloud 
point titration method at 25°C and atmospheric pressure. Further details are given elsewhere32. 
The system compositions were determined by the weight quantification of all components added 
within   10-4 g. The tie-lines (TLs) were determined by a gravimetric method proposed by 
Merchuk33. Different mixture points at the biphasic region (total weight of 3 g) were prepared in 
small glass ampoules (ca. 5 mL), vigorously stirred, centrifuged for 10 min and allowed to reach 
equilibrium by the separation of the phases for at least 10 min at 25°C. After separation of the 
two phases, both the top and bottom phases were weighted. Each individual TL was determined 
by application of the lever-arm rule to the relationship between the top phase composition and 
the overall system composition. The experimental binodal curves were correlated using Equation 
(2.1.1): 
[𝐼𝐿] = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]0.5) − (𝐶[𝑠𝑎𝑙𝑡]3)] (2.1.1) 
where [𝐼𝐿] and [𝑠𝑎𝑙𝑡] are the IL and the salt weight fraction percentages, respectively, and 𝐴, 𝐵, 
and 𝐶 are constants obtained by the regression of the experimental data (see Appendix A).  
The determination of the TLs was accomplished through the solution of the following system 
of four equations (Equations (2.1.2) to (2.1.5)) aiming at determining four unknown 
values  ([𝐼𝐿]IL, [𝐼𝐿]salt, [𝑠𝑎𝑙𝑡]IL and [𝑠𝑎𝑙𝑡]salt): 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝐼𝐿
0.5) − (𝐶[𝑠𝑎𝑙𝑡]𝐼𝐿
3 )] (2.1.2) 
 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
0.5 ) − (𝐶[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
3 )] (2.1.3) 
 
[𝐼𝐿]𝐼𝐿 =
[𝐼𝐿]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝐼𝐿]𝑠𝑎𝑙𝑡 (2.1.4) 
 
[𝑠𝑎𝑙𝑡]𝐼𝐿 =
[𝑠𝑎𝑙𝑡]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡 (2.1.5) 
where the subscripts "IL", "salt" and "M" represent the top and the bottom phases and the 
mixture composition, respectively. The parameter α is the ratio between the weight of the top 
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phase and the weight of the overall mixture. For the calculation of each tie-line length (TLL), 
Equation (2.1.6) was employed: 
𝑇𝐿𝐿 = √([𝑠𝑎𝑙𝑡]𝐼𝐿 − [𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡)2 + ([𝐼𝐿]𝐼𝐿 − [𝐼𝐿]𝑠𝑎𝑙𝑡)2 (2.1.6) 
pH measurements. The pH of the IL- and Na2SO4-rich aqueous phases was measured at 25°C 
using a Mettler Toledo S47 SevenMulti™ dual meter pH/conductivity equipment within ±0.02. The 
calibration of the pH meter was carried out with two buffers (pH values of 4.00 and 7.00, acquired 
from Metrohm). 
Extraction of amino acids. The ternary mixtures compositions used in the partitioning 
experiments were chosen based on the phase diagrams determined in this work, i.e. at 
compositions which lead to the formation of two phase systems. Aqueous solutions of amino 
acids were prepared at a concentration of 0.83 g.L-1 for L-tryptophan and 0.44 g.L-1 for L-Tyrosine, 
and used as the aqueous solution in each ABS preparation. Each mixture was vigorously stirred, 
centrifuged for 10 min, and left to equilibrate for more 10 min at 25°C to reach the amino acids 
complete partitioning between the coexisting phases. After, a careful separation of the phases 
was performed and the amount of each amino acid in each phase was quantified by UV-
spectroscopy, using a BioTeck Synergy HT microplate reader, at a wavelength of 280 nm, and 
using calibration curves previously established (cf. Appendix A). At least three independent ABS 
were prepared and 3 samples of each phase quantified. The percentage extraction efficiency of L-
tryptophan (𝑬𝑬𝑻𝑹𝒀%) and L-tyrosine (𝑬𝑬𝑻𝒀𝑹%), is the percentage ratio between the amount of 
each amino acid in the IL-rich phase to that in the total mixture, defined according to Equation 
(2.1.7): 
𝐸𝐸AA% =
𝑤𝐴𝐴
𝐼𝐿
𝑤𝐴𝐴
𝐼𝐿 + 𝑤𝐴𝐴
𝑆𝑎𝑙𝑡   100 (2.1.7) 
where 𝑤𝐴𝐴
𝐼𝐿  and 𝑤𝐴𝐴
𝑆𝑎𝑙𝑡 are the total weight of amino acids in the IL-rich and in the salt-rich 
aqueous phases, respectively. In all systems the top phase corresponds to the IL-rich phase 
whereas the bottom phase is mainly constituted by the Na2SO4 salt and water. 
2.1.4. Results and discussion 
Ecotoxicity of AGB-ILs. The evaluation of the AGB-ILs toxicity was determined by exposing 
the marine bacterium Vibrio fischeri to several aqueous solutions of each IL, at different 
concentrations, for which the EC50 values were determined after 5, 15 and 30 min of exposure. 
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The EC50 data at 30 min are presented in Table 2.1.1. The corresponding EC50 values for 5 and 15 
min are presented in the Appendix A. According to the EC50 values at 30 min (maximum exposure 
time), the toxicity of the synthesized AGB-ILs increases according to the rank: [Et₃NC₂]Br < 
[Bu₃PC₂]Br < [MepyrNC₂]Br ≈ [Pr₃NC₂]Br < [Bu₃NC₂]Br < [Bu₃PC₄]Br. All ILs investigated share the 
common bromide anion; however, they comprise cations with different central atoms (N vs. P), 
with different alkyl side chains length, and with cyclic vs. non-cyclic cationic structures. The results 
obtained reveal that an increase in the alkyl side chain length increases the IL ecotoxic nature (as 
observed by the ranks:  [Et₃NC₂]Br < [Pr₃NC₂]Br < [Bu₃NC₂]Br and [Bu₃PC₂]Br < [Bu₃PC₄]Br). Longer 
aliphatic moieties strongly interact with (or better penetrate) the phospholipid bilayer of 
membranes cells, as reflected by the stronger inhibition of the bacterium luminescence. ILs with 
longer alkyl side chains are more ecotoxic, in good agreement with the literature34,35. Taking into 
account the cation central atom, the EC50 values decrease considerably from [Bu₃PC₂]Br (2141.9 
mg. L-1) to [Bu₃NC₂]Br (340.0 mg.L-1), meaning that the phosphonium-based IL is less toxic than its 
ammonium-based counterpart. This trend is the opposite to what has been found in the 
literature, for which the EC50 values are higher in ammonium-based ILs compared to their 
phosphonium counterparts36. This result indicates that the presence of an alkoxy group may 
change the ILs ecotoxicity. Since the [MepyrNC₂]Br presents a cyclic cation structure, it is expected 
to be more toxic than the linear-based counterparts36–39. In fact, this IL is more toxic than 
[Et₃NC₂]Br, in spite of having a lower total number of carbons in the aliphatic chains connected to 
the N central atom. 
Table 2.1.1. EC50 values (mg.dm
−3) with the respective 95% confidence limits (within brackets) of 
AGB-ILs after 30 minutes of exposure of the marine bacterium Vibrio fischeri. 
AGB-IL EC50 (mgˑdm
−3) at 30 min (lower limit; upper limit) 
[Bu3PC4]Br 191.3 182.07; 200.57 
[Bu3PC2]Br 2141.9 1519.93; 2763.84 
[Bu3NC2]Br 340.0 299.20; 380.83 
[Pr3NC2]Br 1589.8 673.78; 2505.87 
[Et3NC2]Br 4634.8 3823.66; 5502.15 
[MepyrNC2]Br 1590.0 1165.35; 2014.71 
 
Phase diagrams and tie-lines. Novel ternary phase diagrams for several ILs ([MepyrNC2]Br, 
[Et3NC2]Br, [Pr3NC2]Br, [Bu3NC2]Br, [Bu3PC2]Br, [Bu3PC4]Br) + Na2SO4 + water were determined at 
25°C and atmospheric pressure. The respective phase diagrams are displayed in Figure 2.1.2. In all 
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ABS, the top phase corresponds to the IL-rich phase while the bottom phase is mainly constituted 
by Na2SO4 and water.  
In all phase diagrams shown in Figure 2.1.2, the monophasic and the biphasic areas are 
localized below and above the solubility curves, respectively. AGB-ILs with phase diagrams with a 
larger area above the solubility curve present a higher ability to form two phases, i.e. require a 
lower amount of salt to create two-phase systems. Overall, the ability of AGB-ILs to form ABS at 
25°C follows the rank: [Bu3PC4]Br > [Bu3PC2]Br > [Bu3NC2]Br > [Pr3NC2]Br > [Et3NC2]Br > 
[MepyrNC2]Br. It was previously shown that tetraalkylammonium- and tetraalkylphosphonium-
based ILs present a higher ability to create ABS with a given salt, i.e. require a lower amount of 
salt or IL to undergo liquid-liquid demixing, than imidazolium-based ILs40. This trend was also 
observed in this work with AGB-ILs (cf. the Appendix A). This feature is a major advantage since 
lower amounts of IL or salt are required to create ABS, meaning that a higher amount of water will 
be present, an advantage when envisioning their use as separation techniques of biologically 
active compounds.  
In Figures 2.1.2a and 2.1.2b are represented the phases diagrams for the systems composed 
of [Bu3PC2]Br and [Bu3PC4]Br, and of [Bu3NC2]Br, [Pr3NC2]Br, [Et3NC2]Br and [MepyrNC2]Br, 
allowing to address the effect of the IL cation alkyl chain length on the ABS formation ability. In 
general, ILs with longer alkyl side chains are more hydrophobic and more easily salted-out by the 
salt from aqueous media. Accordingly, [Bu3PC2]Br requires a larger amount of Na2SO4 to form ABS 
than [Bu3PC4]Br. In the same line, the longer the alkyl side chain in the [Et3-Bu3NC2]Br series of ILs, 
the lower the amount of salt or IL required to form two-phase systems. These trends are in 
accordance with the literature41, in which an increase in the IL cation alkyl side chain leads to a 
higher ability to create ABS. Finally, [MepyrNC2]Br is the IL with the lowest ability to create ABS. 
Although this IL comprises a cyclic ring contrarily to the remaining ILs, it presents a higher affinity 
for water due to the lower number of methylene groups in its structure, and thus requires higher 
amounts of salt to be salted-out from aqueous media.  
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Figure 2.1.2. Phase diagrams for the systems composed of IL + Na2SO4 + H2O at 25 °C: (a) [Bu3PC2]Br (); 
[Bu3PC4]Br (); (b) [MepyrNC2]Br (); [Et3NC2]Br (); [Pr3NC2]Br (); [Bu3NC2]Br (); (c) [Bu3PC2]Br (); 
[Bu3NC2]Br (). 
The phase diagrams for the systems constituted by [Bu3PC4]Br and [Bu3NC4]Br are depicted in 
Figure 2.1.2c. Although with a similar cation chemical structure, [Bu3PC4]Br presents a better 
phase separation in presence of aqueous solutions of Na2SO4. The higher ability of phosphonium-
based ILs to create ABS when compared with their ammonium-based counterparts was already 
demonstrated with other salts40,42,43. In general, phosphonium-based ILs are more hydrophobic 
than ammonium-based ones as a result of the cation central atom charge distribution44. 
All experimental data corresponding to the binodal curves were fitted using Equation (2.1.1), 
as presented in Figure 2.1.2. The regression parameters estimated by least-squares regression, 
standard deviations (σ), and correlation coefficients (R2) are displayed in Table 2.1.2. Equation 
(2.1.1) adequately describes the experimental binodal curves, confirmed by the good correlation 
coefficients obtained.  
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Table 2.1.2. Correlation parameters of Equation 2.1.1 used to describe the experimental binodal 
data at 25°C. 
IL A ± σ B ± σ 105 (C ± σ) R2 
IL + Na2SO4 + water 
[Bu3PC4]Br 88.82 ± 0.97 -0.518 ± 0.007 61.38 ± 1.89 0.9997 
[Bu3PC2]Br 98.20 ± 7.33 -0.556 ± 0.036 34.09 ± 5.29 0.9984 
[Bu3NC2]Br 80.07 ± 1.74 -0.418 ± 0.011 15.71 ± 1.38 0.9986 
[Pr3NC2]Br 77.60 ± 0.73 -0.395 ± 0.005 3.75 ± 0.91 0.9995 
[Et3NC2]Br 83.40 ± 0.59 -0.345 ± 0.004 1.86 ± 0.941 0.9998 
[MepyrNC2]Br 82.24 ± 1.33 -0.328 ± 0.008 1.50 ± 1.97 0.9994 
 
The experimental TLs determined for each ABS, along with their respective length (TLL), as 
well as the compositions of each phase for the mixtures corresponding to the extraction studies, 
are reported in Table 2.1.3. The graphical representation of the TLs for all the systems 
investigated is presented in Appendix A. 
Table 2.1.3. Experimental TLs and TLLs of the ABS composed of IL + Na2SO4+ H2O at 25°C. 
Weight fraction composition / (wt %) 
IL + Na2SO4+ water 
IL [IL]IL [salt]IL [IL]M [salt]M [IL]salt [salt]salt TLL 
[Bu3PC4]Br 
67.80 0.27 39.78 7.45 0.31 17.79 69.73 
62.54 0.46 23.33 9.92 1.35 15.23 62.95 
[Bu3PC2]Br 
62.77 0.64 39.98 7.43 0.81 19.08 64.65 
65.39 0.53 37.28 10.20 0.10 22.99 69.03 
[Bu3NC2]Br 
43.84 2.06 24.75 9.96 5.52 17.91 41.46 
52.28 0.86 29.79 9.85 4.16 19.25 53.38 
55.03 0.80 40.39 7.47 0.69 25.58 59.72 
61.71 0.38 38.27 10.78 0.32 27.61 67.15 
[Pr3NC2]Br 
51.44 1.08 40.00 7.65 4.03 28.31 54.67 
57.31 0.58 41.09 10.13 2.037 33.12 64.13 
[Et3NC2]Br 
41.09 4.20 36.71 6.60 15.25 20.14 30.36 
44.97 3.20 38.19 7.38 12.57 23.19 38.07 
[MepyrNC2]Br 
43.94 4.20 39.16 7.54 12.03 26.50 38.92 
46.10 3.63 37.32 9.82 10.30 28.86 43.80 
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Extraction of amino acids. The extraction efficiency of the investigated systems for two 
amino acids, namely L-tryptophan and L-tyrosine, was determined at a common mixture 
composition (≈40 wt% of IL, ≈7.5 wt% of Na2SO4 and ≈52.5 wt% of an aqueous solution containing 
L-tryptophan or L-tyrosine) in order to address the potential of the investigated systems to act as 
separation platforms. The results obtained at 25°C are displayed in Figure 2.1.3. The chemical 
structures of the two amino acids are also provided as an inset. In all systems, L-tryptophan and L-
tyrosine preferentially migrate to the most hydrophobic phase, i.e. the IL-rich phase, with 
extraction efficiencies higher than 70%, and up to 100%, achieved in a single-step. In general, 
higher extraction efficiencies are obtained for L-tryptophan. Furthermore, the extraction 
efficiency of the studied ABS for L-tryptophan (to the IL-rich phase) follows the rank: [Bu3NC2]Br > 
[MepyrNC2]Br ≈ [Et3NC2]Br ≈ [Pr3NC2]Br  > [Bu3PC2]Br > [Bu3PC4]Br, while the behavior observed 
for L-tyrosine is according to: [MepyrNC2]Br ≈ [Et3NC2]Br > [Pr3NC2]Br > [Bu3NC2]Br > [Bu3PC2]Br > 
[Bu3PC4]Br. With the exception of the IL [Bu3NC2]Br, the ILs rank in terms of extraction 
performance is similar for both amino acids. The trend on the extraction efficiencies closely 
depends on the IL hydrophobicity; the higher the IL hydrophobicity, as discussed according to 
their phase diagrams, the lower the extraction efficiencies. 
 
Figure 2.1.3. Extraction efficiency (EE%) of tryptophan (blue bars) and tyrosine (orange bars) in ABS 
composed of 40 wt% of IL + 7.5 wt% of Na2SO4 at 25°C. 
In general, the amino acids partition in IL-based ABS is ruled by different driving forces, 
including the ability of ILs to establish specific interactions with amino acids and the salting-out 
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strength of the salt used to create ABS. In IL-based ABS constituted by imidazolium-based ILs, it 
was already reported that electrostatic, π∙∙∙π and H-bonding interactions play a pivotal 
role32,41,45,46. Nevertheless, salting-out effects appear to be dominant, especially when employing 
high-charge density salts, e.g. K3C6H5O7 or K3PO4 
32,41,45,46. In the same line, the amino acids (L-
tryptophan, L-phenylalanine, L-tyrosine, L-leucine, and L-valine) partitioning in pH-controlled IL-
based ABS (constituted by [C4mim]Br and K3C6H5O7/C6H8O7) allowed to conclude that hydrophobic 
interactions are the main driving force; however, electrostatic interactions and salting-out effects 
have also a strong contribution46. 
Depending on the system pH, different chemical species of amino acids are predominantly 
present due to their functional groups ionization/protonation (-COOH and -NH2 groups). According 
to the pH measurements of the IL- and Na2SO4- rich phase, which range between 3.1 and 6.2, as 
shown in the Appendix A, both amino acids (L-tryptophan and L-tyrosine) are predominately 
positively charged in the investigated ABS (protonation constants of L-tryptophan: pKa = 2.38; 
9.39); and of L-tyrosine: pKa = 2.20; 9.11; 10.7)47. Even so, they partition to the phase with a lower 
ionic strength further supporting the influence of the salting-out effect exerted by the salt.  
In summary, the systems investigated display a good performance to extract amino acids 
from aqueous media, with the additional advantage of using lower amounts of salt in the ABS 
composition (compared to previously published data)48 and through the use of more 
environmentally-friendly and biocompatible ILs. 
2.1.5. Conclusions  
In order to develop more benign and biocompatible ABS, in this work, a series of AGB-ILs 
(based on glycine-betaine analogues) were synthesized, characterized in terms of ecotoxicity, 
applied in the creation of novel ABS, and used to extract amino acids, namely L-tryptophan  and L-
tyrosine. The systems investigated demonstrated to be remarkable separation routes, with 
maximum extraction efficiencies for L-tryptophan and L-tyrosine of 100% and 97%, respectively, 
achieved in a single-step. Besides the low ecotoxicity of AGB-ILs, the extraction efficiencies are 
considerably higher than those reported with conventional polymer-based ABS. Thus, the systems 
here investigated improve the biocompatibility and sustainability of ABS and still act as 
remarkable extraction platforms. According to the reported results, the application of these novel 
ABS could be extended to other added-value compounds. 
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2.2. Enhanced extraction of bovine serum albumin with aqueous biphasic 
systems of phosphonium- and ammonium-based ionic liquids  
This chapter is based on the published manuscript  
Matheus M. Pereira, Sónia N. Pedro, Maria V. Quental, Álvaro S. Lima, João A. P. Coutinho and 
Mara G. Freire 
Journal of Biotechnology. 206 (2015) 17-25. 
2.2.1. Abstract 
Novel aqueous biphasic systems (ABS) composed of phosphonium- or ammonium-based ionic 
liquids (ILs), combined with a buffered aqueous solution of potassium citrate/citric acid (pH=7.0), 
were investigated for the extraction of proteins. For that purpose, the phase diagrams, tie-lines 
and tie-line lengths were determined at 25°C, and the performance of these ABS for the 
extraction of bovine serum albumin (BSA) was then evaluated. The obtained results reveal that, 
with the exception of the more hydrophobic ILs, most of the systems investigated allow the 
complete extraction of BSA to the IL-rich phase in a single-step. These remarkable extraction 
efficiencies are far superior to those afforded by more conventional extraction systems previously 
reported. The composition of the biphasic systems, i.e. the amount of phase-forming 
components, was also investigated aiming at reducing the overall costs of the process without 
losing efficiency on the protein extraction. It is shown that the extraction efficiencies of BSA are 
maintained at 100% up to high protein concentrations (at least up to 10 g.L-1). The recovery of the 
BSA from the IL-rich phase by dialysis is also shown in addition to the demonstration of the IL 
recyclability and reusability, at least for 3 times. In the sequential three-step extractions (BSA 
recovery/IL reusability), the extraction efficiencies of BSA for the IL-rich phase were maintained at 
100%.  For the improved ABS, the preservation of the protein native conformation was confirmed 
by Size Exclusion High-Performance Liquid Chromatography (used also as the quantification 
method) and by Fourier Transform Infra-Red spectroscopy. According to the results herein 
reported, ABS composed of phosphonium- or ammonium-based ILs and a biodegradable organic 
salt represent an alternative and remarkable platform for the extraction of BSA and may be 
extended to other proteins of interest. 
2.2.2. Introduction 
Proteins are biomolecules formed by a sequence of amino acids and which perform a wide 
array of functions within living organisms1. However, the proteins specific functions are 
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dependent on the stability of their native structure2. Most proteins have low structural stability 
and may be denatured in presence of some chemical compounds, namely polymers, salts or 
organic solvents3–6, high temperature and pressure conditions7,8 or through pH changes9. 
Therefore, when foreseeing the extraction and/or purification of proteins, those parameters must 
be addressed aiming at maintaining the proteins structure - a major challenge in the 
biotechnology field. 
Serum albumins are the major soluble protein constituents in body fluids and have many 
relevant physiological functions. Amongst several valuable characteristics, one of the most 
important relays on their function as carriers of various compounds within the circulatory 
system10. BSA (bovine serum albumin), a protein with some common features to other serum 
albumins, such as ESA (equine serum albumin), LSA (leporine serum albumin) and HSA (human 
serum albumin)11, has been extensively studied as a model protein in a wide variety of fields. 
Some examples include studies on the interaction of serum albumins with chlorophylls12 and with 
ionic surfactants13 due to the particular similarity (in 76% of the amino acid sequence) between 
BSA and HSA14,15. For these investigations, pure proteins are required. The extraction and 
purification of BSA was already investigated using various methodologies, such as reversed 
micelle approaches16–18, ultrafiltration19 or tangential flow filtration20, precipitation21,22 and by 
liquid-liquid approaches23,24. 
Amongst the several extraction and purification methods commonly applied to proteins, the 
use of aqueous biphasic systems (ABS) received a remarkable attention since they are mainly 
composed of water and thus are of high biocompatibility - favorable environment for the 
purification of biologically active biomolecules25,26. ABS fit within the liquid-liquid 
extraction/purification techniques and are environmentally-friendly since the use of volatile and 
hazardous organic solvents is avoided. ABS are typically composed of non-volatile pairs dissolved 
in aqueous media, such as two polymers, a polymer and a salt or two salts, which above given 
concentrations undergo liquid-liquid demixing. The selective partitioning of a target molecule, e.g. 
a protein, depends upon its affinity for each aqueous-rich phase, as well as on other parameters, 
such as pH, temperature and system composition. ABS have gained relevant attention since 
several early-stage processing steps, namely clarification, concentration and purification can be 
carried out in a single-stage. Moreover, the application of ABS at a large-scale has already been 
demonstrated26. Typical polymer-based ABS display, however, a high viscosity, which hinders the 
mass transfer and also lead to a slower phase separation. In the past decade, ionic-liquid-based 
ABS were proposed by Gutowski et al.27 as alternatives to polymer-based systems. Ionic liquids 
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(ILs) belong to the molten salts group (with melting temperatures below 100°C) and are usually 
constituted by a large organic cation and an inorganic/organic anion. Due to their ionic character, 
most ILs present a negligible volatility at atmospheric conditions, non-flammability, high thermal 
and chemical stabilities, and a strong solvation capability for a large variety of compounds28,29. 
Nevertheless, one of the most important features of ILs arises from their tailoring ability resulting 
from cation-anion combinations – a property that is further extended to IL-based ABS30. Due to 
the large amount of water and non-volatile nature of ILs, the respective ABS also appear as viable 
media for biocompatible extractions. IL-based ABS have been used in the separation of enzymes, 
proteins, amino acids and antibiotics31,32. Albeit these studies can be used as guidelines for the 
application of IL-based ABS in the extraction of proteins, in most of these works, imidazolium-
based ILs and inorganic salts were used as phase-forming components32. In particular, these IL-
based ABS have been applied in the extraction of bovine serum albumin, lysozyme, trypsin, 
myoglobin, peroxidase, cytochrome c, globulins, hemoglobin and ovalbumin32–36. Mainly ILs with 
anions with a strong alkaline or acidic character were investigated, and phosphate buffered 
solutions were employed to maintain the pH of the aqueous medium while avoiding the 
denaturation of proteins34,37,38. Nonetheless, phosphate ions can bind to metal ions, such as 
calcium, zinc or magnesium, which are essential to maintain the integrity of some 
proteins/enzymes39. These high-charge density phosphate-based salts can be adequately 
substituted by more biocompatible and biodegradable organic salts, such as citrate-based salts 
that combined with citric acid afford a wide buffered pH region. On the other hand, few studies 
have considered phosphonium- and ammonium-based ILs as phase-forming constituents of ABS 
for the extraction of proteins38,40,41. Kragl and co-workers42 studied ABS constituted by Ammoeng 
110 to purify two alcohol dehydrogenases. The authors42 concluded that this IL stabilizes the 
enzymes and increases the solubility of hydrophobic species. More recently, Desai et al.43 studied 
ABS formed by an ammonium- or phosphonium-based IL and a phosphate-buffered solution to 
extract rubisco – a vegetable protein. These tetraalkyl-based compounds are less expensive and 
thermally more stable than the equivalent imidazolium-based counterparts, are available on a 
multi-ton scale, and have already been used in industrial processes44. Still, to decrease the cost of 
IL-based processes, studies on the recovery and reusability of ILs are of outstanding importance 
when envisaging their scale-up and industrial implementation. For instance, imidazolium-based 
ILs employed in the extraction of gallic acid by ABS were recovered and reused by back-extraction 
approaches45. 
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This work aims at investigating the extraction capacity of ABS formed by phosphonium- and 
ammonium-based ILs and a citrate-based salt for BSA, and to further evaluate the protein stability 
in the IL-rich phase, as well as the protein recovery and recyclability/reusability of ILs. 
 
2.2.3. Experimental procedures 
Materials. The ABS studied in this work are composed of a buffer aqueous solution 
constituted by potassium citrate, K3C6H5O7·H2O, ≥ 99 wt% pure from Sigma–Aldrich, and citric 
acid, C6H8O7∙H2O, 100 wt% pure from Fisher Scientific. The ionic liquids studied were the 
following: tetrabutylammonium chloride ([N4444]Cl), > 97% pure, tetrabutylphosphonium bromide 
([P4444]Br), > 96% pure, tetrabutylphosphonium chloride ([P4444]Cl), > 95% pure, 
tri(isobutyl)methylphosphonium tosylate ([Pi(444)1][Tos]), > 95% pure, and 
tri(butyl)methylphosphonium methylsulfate ([P4441][MeSO4]), > 99% pure. All phosphonium-based 
ILs were generously offered by Cytec Ind., while the ammonium-based compound was acquired 
from Sigma-Aldrich. The chemical structures of the ILs studied are depicted in Figure 2.2.1. Bovine 
Serum Albumin (BSA), fraction V, pH 7.0, fat acid free, was purchased from Acros. 
 
Figure 2.2.1. Chemical structure of the studied ILs: [P4444]Br (I); [P4444]Cl (II); [Pi(444)1][Tos] (III); 
[P4441][MeSO4] (IV); and [N4444]Cl (V). 
 
 
(I) (II)
(III) (IV)
(V)
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Phase diagrams and tie-lines. Aqueous solutions of each IL ([P4444]Br, [P4444]Cl, [Pi(444)1][Tos], 
[P4441][MeSO4] and [N4444]Cl ) at circa 90 wt% and aqueous solutions of the mixture 
K3C6H5O7/C6H8O7 (as a buffer solution at pH = 7.0, mole ratio of ≈ 15:1) at ≈ 50 wt% were prepared 
and used for the determination of the binodal curves. The phase diagrams were determined 
through the cloud point titration method46 at 25°C and atmospheric pressure. The system 
compositions were determined by the weight quantification of all components added within  10-
4 g. The tie-lines (TLs) were determined by a gravimetric method originally proposed by Merchuk 
et al. 47. Different mixture points at the biphasic region were prepared in small glass ampoules (ca. 
5 mL) especially designed for the purpose, vigorously stirred and allowed to reach equilibrium by 
the separation of the phases for at least 10 min at 25°C. After separation of the two phases, both 
the top and bottom phases were weighted. Each individual TL was determined by application of 
the lever-arm rule to the relationship between the top weight phase composition and the overall 
system composition. The experimental binodal curves were correlated using Equation (2.1.1): 
[𝐼𝐿] = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]0.5) − (𝐶[𝑠𝑎𝑙𝑡]3)] (2.2.1) 
where [𝐼𝐿] and [𝑠𝑎𝑙𝑡] are the IL and the salt weight fraction percentages, respectively, and 𝐴, 𝐵, 
and 𝐶 are constants obtained by the regression of the experimental data (see Appendix B).  
The determination of the TLs was accomplished through the solution of the following system 
of four equations (Equations (2.1.2) to (2.1.5)) aiming at determining four unknown 
values  ([𝐼𝐿]IL, [𝐼𝐿]salt, [𝑠𝑎𝑙𝑡]IL and [𝑠𝑎𝑙𝑡]salt): 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝐼𝐿
0.5) − (𝐶[𝑠𝑎𝑙𝑡]𝐼𝐿
3 )] (2.2.2) 
 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
0.5 ) − (𝐶[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
3 )] (2.2.3) 
 
[𝐼𝐿]𝐼𝐿 =
[𝐼𝐿]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝐼𝐿]𝑠𝑎𝑙𝑡 (2.2.4) 
 
[𝑠𝑎𝑙𝑡]𝐼𝐿 =
[𝑠𝑎𝑙𝑡]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡 (2.2.5) 
where the subscripts "IL", "salt" and "M" represent the top and the bottom phases and the 
mixture composition, respectively. The parameter α is the ratio between the weight of the top 
phase and the weight of the overall mixture. For the calculation of each tie-line length (TLL), 
Equation (2.1.6) was employed: 
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𝑇𝐿𝐿 = √([𝑠𝑎𝑙𝑡]𝐼𝐿 − [𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡)2 + ([𝐼𝐿]𝐼𝐿 − [𝐼𝐿]𝑠𝑎𝑙𝑡)2 (2.2.6) 
Extraction of bovine serum albumin (BSA). The ternary mixtures compositions used in the 
partitioning experiments were chosen based on the phase diagrams determined in this work for 
each IL-salt-water system. Different mixture compositions were studied to evaluate the effect of 
the concentration of the phase-forming components through the extraction of BSA. BSA at 
concentrations of circa 0.5, 1.0, 5.0 and 10.0 g.L-1 were also used as the aqueous solution. Each 
mixture was vigorously stirred, centrifuged for 10 min, and left to equilibrate for 10 min at 25°C to 
reach the BSA complete partitioning between the coexisting phases. After, a careful separation of 
the phases was performed and the amount of BSA in each phase was quantified by SE-HPLC (Size 
Exclusion High-Performance Liquid Chromatography). Each phase was diluted at a 1:10 (v:v) ratio 
in a phosphate buffer solution before injection. A Chromaster HPLC (VWR, Hitachi) coupled to an 
UV detector was used. SE-HPLC was performed with an analytical column (25 cm x 2 mm i.d., 25 
µm), Lichrospher 100 RP-18, from Merck. A 100 mM phosphate buffer in MiliQ water (mobile 
phase) was run isocratically with a flow rate of 1 mL·min-1. The temperature of the column and 
auto-sampler was kept constant at 25°C. The injection volume was of 25 µL. The wavelength was 
set at 280 nm whereas the retention time of BSA was found to be circa 16 min within an analysis 
time of 40 min. The quantification of BSA in each phase was carried out by an external standard 
calibration method (R2=0.9997) - cf. Appendix B with the established calibration curve and 
associated standard deviations. The limit of detection of BSA was found to be 0.011 g.L-1. At least 
three independent ABS were prepared and 3 samples of each phase were quantified. The 
percentage extraction efficiency of BSA, 𝑬𝑬𝑩𝑺𝑨%, is the percentage ratio between the amount of 
protein in the IL-rich aqueous phase to that in the total mixture, and is defined according to 
Equation (2.2.7): 
𝐸𝐸BSA% =
𝑤𝐵𝑆𝐴
𝐼𝐿
𝑤𝐵𝑆𝐴
𝐼𝐿 + 𝑤𝐵𝑆𝐴
𝑆𝑎𝑙𝑡   100 (2.2.7) 
where 𝑤𝐵𝑆𝐴
𝐼𝐿  and 𝑤𝐵𝑆𝐴
𝑆𝑎𝑙𝑡 are the total weight of protein in the IL-rich and in the salt-rich aqueous 
phases, respectively. In all systems the top phase corresponds to the IL-rich phase whereas the 
bottom phase is mainly constituted by the citrate-based salt and water.  
Recovery of bovine serum albumin (BSA) from the IL-rich phase and reusability of the ILs. In 
order to guarantee the recovery of BSA after the extraction to the IL-rich phase and the ILs 
recyclability, a three-step recovery/extraction process was here attempted. In this approach, the 
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system composed of 30 wt% [Pi(444)1][Tos] + 30 wt% of K3C6H5O7/C6H8O7 + 40 wt% of an aqueous 
solution of BSA at 0.5 g.L-1 was chosen. After the initial extraction of BSA as described before, 
which occurs for the IL-rich phase, the protein was recovered by dialysis. The IL-rich phase 
containing BSA was dialyzed against 100 mL of ultra-pure water, for 12h at room temperature and 
under moderate agitation, using a dialysis tubing cellulose membrane (average flat width 10 mm 
(0.4 in.), molecular weight cut-off = 14,000) from Sigma. The dialysate solution containing BSA was 
recovered, and the aqueous phase containing the IL was dried under vacuum at 60°C up to a 
constant weight, and then reused to form a new ABS with K3C6H5O7/C6H8O7 and an aqueous 
solution of BSA at 0.5 g.L-1 in order to perform a subsequent extraction of the protein. This step 
was repeated one more time to ascertain on the recyclability and reusability of the IL employed 
and its efficiency when employed as a phase-forming component of a given ABS for the extraction 
of proteins. 
Fourier transform infrared spectroscopy (FT-IR). FT-IR spectra were recorded using a Perkin 
Elmer Spectrum Bx spectrophotometer with a resolution of 4 cm−1. Several aqueous solutions 
containing BSA (1.0 g.L−1) and ILs at different concentrations were used to perform the FT-IR 
analysis. The spectra were obtained in the wavelength range from 1700 to 1500 cm−1. 
2.2.4. Results and discussion 
Phase diagrams and tie-lines. Novel phase diagrams for the various systems consisting of IL + 
water + K3C6H5O7/C6H8O7 buffer (pH = 7.0) at 25°C and atmospheric pressure were determined in 
this work. The respective phase diagrams are depicted in Figure 2.2.2 and Figure 2.2.3. The 
corresponding data are provided in Appendix B. All the calculations considering the weight 
fraction of the phase-forming components were carried out discounting the complexed water in 
the commercial citrate-based salt. 
Figure2.2.2 depicts the phase diagrams for the systems constituted by phosphonium-based 
ILs and allows the evaluation of the ILs ability to form ABS. In all phase diagrams, the two-phase 
region is positioned above the solubility curve while the monophasic region is localized below. 
Diagrams with the largest area above the binodal curve have therefore a higher ability to form 
two phases, i.e. the IL is more easily salted-out by the salt. Therefore, the capacity of 
phosphonium-based ILs to form ABS (or ILs more easily salted-out) follows the order: [P4444]Br > 
[P4441][MeSO4] > [P4444]Cl > [Pi(444)1][Tos]. Since not all the cations and anions are common there is 
a balanced effect of both ions to be hydrated and to form ABS. Nevertheless, the results obtained 
here are in close agreement with the trend previously described in the literature for ABS 
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composed of phosphonium-based ILs + K3PO4 + water
48. In general, phosphonium-based ILs have a 
higher ability to undergo phase separation in ABS when compared with their imidazolium-based 
counterparts48 – a major advantage when considering the amount of phase-forming compounds 
required to form liquid-liquid systems. 
  
Figure 2.2.2. Phase diagrams for the systems composed of IL + K3C6H5O7/C6H8O7 + H2O at 25°C and 
pH 7.0: [P4444]Br (); [P4441][MeSO4] (); [P4444]Cl (); [Pi(444)1][Tos] (); and adjusted binodal data 
through Equation 2.2.1 (__). 
Since several ILs with different lengths at the cation alkyl chains were investigated, a direct 
comparison can only be made between [P4444]Br and [P4444]Cl, whereas the first is more able to 
undergo a phase separation. The Cl- anion presents a higher aptitude to be hydrated or to form 
hydration complexes, and thus more salt is required to induce the salting-out when compared 
with bromide-based ILs49. Bromide has a weaker ability to hydrogen-bond with water or to form 
hydration complexes, and less salt is required for phase separation in ABS. In addition, when 
comparing the performance of [P4441][MeSO4] and [Pi(444)1][Tos], the [Tos]-based IL requires a 
higher amount of salt to undergo liquid-liquid demixing. 
The phase diagrams for the systems composed of [N4444]Cl and [P4444]Cl are presented in 
Figure 2.2.3. Although similar, the [P4444]-based IL presents a slightly higher ability to form ABS. 
The higher hydrophobicity of phosphonium-based ILs (when compared to the ammonium-based 
counterparts) was shown by Carvalho et al. 50 and is reflected in the phase behavior of ternary 
systems composed of similar ILs, water and other salts46. It is well-accepted that the water-IL 
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miscibility derives essentially from hydrogen-bonding interactions mainly occurring with the 
anion51. Nevertheless, the anion is similar in both cases, and the small deviations in the phase 
diagram are a result of the charge distribution at the central atom of the IL cation. Even so, both 
tetrabutyl-based cations are known for their high capacity to form ABS mainly due to the 
presence of heteroatoms surrounded by four alkyl chains and no aromatic character, and 
therefore with a low affinity for water. 
 
Figure 2.2.3. Phase diagrams for the systems composed of IL + K3C6H5O7/C6H8O7 + H2O at 25°C and 
pH 7.0: [P4444]Cl ();[N4444]Cl (); and adjusted binodal data through Equation (2.2.1) (
__). 
 
Table 2.2.1. Correlation parameters of Equation (2.2.1) used to describe the experimental binodal 
data at 25°C. 
IL A ± σ B ± σ 105 (C ± σ) R2 
IL + K3C6H5O7/C6H8O7 + water 
[P4444]Br 66.13 ± 0.98 -0.527 ± 0.013 0.21 ± 0.24 0.9988 
[P4444]Cl 116.40 ± 2.65 -0.399 ± 0.009 3.05 ± 0.20 0.9849 
[N4444]Cl 69.16 ± 1.22 -0.222 ± 0.007 2.78 ± 0.12 0.9978 
[Pi(444)1][Tos] 149.90 ± 2.39 -0.318 ± 0.006 2.83 ± 0.10 0.9953 
[P4441][MeSO4] 85.89 ± 1.30 -0.356 ± 0.007 5.40 ± 0.29 0.9971 
The experimental data corresponding to the binodal curves were fitted using Equation (2.2.1) 
as shown in Figure 2.2.2 and Figure 2.2.3. The regression parameters estimated by least-squares 
regression, standard deviations (σ) and correlation coefficients (R2) are displayed in Table 2.2.1. 
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Equation (2.2.1) adequately describes the experimental binodal curves as confirmed by the good 
correlation coefficients obtained.  
 
Figure 2.2.4. Phase diagrams for the systems composed of [Pi(444)1][Tos]+ K3C6H5O7/C6H8O7 + H2O 
at 25°C and pH 7.0: binodal curve data (); TL data (); and adjusted binodal data through 
Equation (2.2.1) (__). 
 
Table 2.2.2. Experimental TLs and TLLs of the ABS composed of IL + K3C6H5O7/C6H8O7 + H2O at 25°C. 
Weight fraction composition / (wt %) 
IL + K3C6H5O7/C6H8O7 + water 
IL [IL]IL [salt]IL [IL]M [salt]M [IL]salt [salt]salt TLL 
[P4444]Br 
58.75 0.05 29.17 29.38 0.02 58.30 82.72 
52.02 0.21 19.99 20.30 1.74 31.75 59.35 
[P4444]Cl 
80.98 0.83 28.82 29.10 0.56 44.43 91.48 
75.06 1.20 27.08 27.09 1.08 41.11 84.05 
[N4444]Cl 
60.80 0.34 30.25 30.68 0.02 60.71 85.67 
58.51 0.57 24.21 24.68 3.05 39.56 67.79 
[Pi(444)1][Tos] 
80.78 3.90 29.51 29.83 1.74 43.87 85.57 
78.90 4.21 29.86 27.57 3.28 40.23 83.76 
68.25 6.25 29.89 25.09 5.20 37.20 70.23 
37.62 16.32 30.19 20.80 7.52 34.48 35.15 
[P4441][MeSO4] 
58.35 1.18 29.10 28.93 3.38E-04 56.55 80.44 
41.87 4.03 19.61 19.88 1.72 32.62 49.29 
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The experimental TLs in each ABS, along with their respective length, and at the compositions 
for which the extraction studies of BSA were conducted, are reported in Table 2.2.2. An example 
of the TLs obtained for the [Pi(444)1][Tos]-based system is depicted in Figure 2.2.4. The graphical 
representation of the TLs for the remaining systems are presented in Appendix B.  
 Extraction of bovine serum albumin (BSA). The extraction efficiencies of BSA in each IL-based 
ABS, and which allow the evaluation of the IL for such a purpose, were determined for a common 
mixture composition (30 wt% of IL, 30 wt% of K3C6H5O7/C6H8O7 and 40 wt% of an aqueous solution 
containing BSA at 0.5 g..L-1). The results obtained are reported in Table 2.2.3. In all systems, the 
top phase corresponds to the IL-rich phase while the bottom phase is majorly composed of the 
citrate-based salt and water. 
Table 2.2.3. Extraction efficiency of BSA (EEBSA%) at 25°C and pH 7.0 in the ABS composed of ILs 
and K3C6H5O7/C6H8O7. 
IL 
Weight fraction composition / (wt %) 
EEBSA% 
IL Salt 
[P4444]Br 29.98 ± 0.11 30.01 ± 0.93 - 
[P4444]Cl 30.40 ± 0.80 30.48 ± 0.38 100 
[N4444]Cl 31.30 ± 0.73 30.97 ± 1.30 100 
[Pi(444)1][Tos] 29.92 ± 0.27 30.39 ± 0.32 100 
[P4441][MeSO4] 31.30 ± 0.72 30.97 ± 1.30 100 
 
With the exception of the ABS composed of [P4444]Br, for which a complete precipitation of 
the protein was observed (no protein was detected at the coexisting phases as determined by SE-
HPLC), all the other ABS are able to completely extract BSA to the IL-rich phase – with extraction 
efficiencies of 100% attained in a single-step. For these systems, the SE-HPLC chromatograms 
used for the BSA quantification confirm the presence of BSA only at the IL-rich phase, as well as 
the absence of BSA aggregates or the protein fragmentation – Figure 2.2.5. Moreover, for these 
systems, no losses of protein by precipitation where observed. 
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Figure 2.2.5. Size exclusion chromatography results of a BSA standard solution (---); BSA in the salt 
rich-phase (∙∙∙∙); and BSA in the IL rich-phase (──) corresponding to the ABS composed of 
[Pi(444)1][Tos] (20 wt%) + K3C6H5O7/C6H8O7 (30 wt%). 
[P4444]Br is the most hydrophobic IL investigated (from the ILs trend shown in Figure 2.2.2) 
and leads to the complete precipitation and/or denaturation of BSA, being therefore not 
adequate for this type of extractions. When comparing the TL data presented in Table 2.2.2. for 
the similar mixture composition, it can be inferred that neither the IL content or water content at 
the IL-rich phase seem to be responsible for the protein precipitation. The composition of water in 
the [P4444]Br-rich phase is around 40 wt% and similar to that found in the [P4441][MeSO4]-rich 
phase. Therefore, these data indicate that the changes in the protein structure may result from 
specific interactions occurring between the protein and the IL. Hydrophobic interactions 
responsible for proteins precipitation have been reported with polymers (PEG and PPG), organic 
solvents (acetone, ethanol, methanol and dimethyl sulfoxide) and salts52–54. For instance, the 
precipitation of rubisco was also observed with the molecular weight increase of the polymers 
used as phase-forming components of ABS, and that was related with a decrease in the free 
volume available as well as with the hydrophobicity increase in such a phase43. 
In general, and with the exception of the [P4444]Br-based ABS, BSA still preferentially 
partitions to the most hydrophobic phase, i.e., the IL-rich phase. This trend is similar to that 
observed in ABS formed by polyethylene glycol (PEG) and potassium citrate, where BSA 
preferentially partitions for the more hydrophobic PEG-rich phase18. Lu et al.18 also reported that 
either an increase on the salt or polymer concentration, i.e. increase of the TLL, leads to a 
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preferential partitioning of BSA to the polymer-rich phase. This behavior was explained based on 
the salting-out effect afforded by an increased concentration of salt in the system, leading thus to 
a preferential exclusion of the protein to the opposite phase18. The isoelectric point of BSA is 4.755. 
Hence, BSA is negatively charged at pH 7 and in all the studied ABS. Based on the overall results 
shown in Table 2.2.3., the partitioning of BSA to the IL-rich phase seems to be driven by a 
combined effect of favorable dispersive interactions, salting-out effect exerted by the citrate-
based salt, and electrostatic interactions between the positively charged IL cations and the 
negatively charged amino acid residues at the surface of the protein. 
Overall, the extraction efficiencies achieved in this work are significantly higher than those 
observed in polymer-based ABS previously reported56–58. Saravanan et al.58 studied PEG4000-
magnesium sulfate ABS to purify BSA with a maximum yield of 82.68%. In ABS composed of PEG 
and sodium citrate, Perumalsamy and Batcha59 reported extraction efficiencies lower than 50%. 
Thus, IL-based ABS seem to be more effective in the extraction of proteins from aqueous media 
than polymer-based systems. Lin et al.60 compared the effects of eight imidazolium-based ILs and 
identified the optimal conditions for the extraction of four proteins. Under the optimum 
conditions, the average recovery of BSA was 90.5%. Ding et al.61 also investigated the use of a 
series of functionalized alkylguanidinium ILs as phase-forming components of ABS, while applying 
single factor experiments to optimize the extraction performance, with a maximum extraction 
efficiency of BSA of 97%. Even in dye-affinity systems (containing the Reactive Red-120 dye) and 
after the optimization of the pH of the aqueous phase, temperature, and composition of the ABS, 
the maximum extraction efficiencies achieved of BSA for the IL-rich phase are below 100%62. 
Therefore, remarkable extraction efficiencies of BSA were obtained in this work with ABS 
composed of more stable and less expensive phosphonium- or ammonium-based ILs and a 
biodegradable organic salt. The ABS studied in this work seem to have an enhanced potential for 
the extraction of proteins, and their application to the purification and concentration of added-
value proteins is a main topic of further work at our laboratory. 
Influence of the IL, salt and bovine serum albumin (BSA) concentrations. Aiming at reducing 
the amount of salt and IL required to form ABS, while keeping the complete extraction ability for 
BSA, a series of ABS containing variable concentrations of [Pi(444)1][Tos] (20-30 wt%) and salt (20-30 
wt%) was prepared. [Pi(444)1][Tos] was selected since it is the only IL that is liquid at room 
temperature (from the set of ILs investigated) and therefore easier to handle and to prepare the 
target mixture compositions. The results obtained for the IL concentration effect are depicted in 
Table 2.2.4. In all systems, the complete extraction of BSA was attained. Therefore, the 
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concentration of IL can be decreased down to 20 wt% without losing the ABS complete extraction 
performance.  
Table 2.2.4. Effect of the IL, salt and protein concentration in the extraction efficiencies of BSA 
(EEBSA%) for the system composed of [Pi(444)1][Tos] (from 20 to 30 wt%) + K3C6H5O7/C6H8O7 (from 20 
to 30 wt%) at 25°C and pH 7.0. 
[BSA] / (g.L-1) 
Weight fraction composition / (wt %) 
EEBSA% 
IL  Salt 
0.5 
30.22 ± 0.21 25.74 ± 0.04 100 
31.56 ± 0.93 20.77 ± 0.03 100  
26.22 ± 0.36 30.48 ± 0.36 100  
20.41 ± 0.37 30.64 ± 0.09 100 
1.0 20.13 ± 0.07 30.41 ± 0.12 100 
5.0 20.21 ± 0.06 30.32 ± 0.17 100 
10.0 20.43 ± 0.15 30.47 ± 0.38 100 
The effect of the salt concentration through the extraction efficiency of BSA is also shown in 
Table 2.2.4.. All compositions allow the complete extraction of BSA, in a single-step, and without 
precipitation and/or denaturation of the protein. The variation of the salt amount has been 
reported to drive the migration of proteins to the top phase due to a decrease in the difference of 
the electrostatic potential between the coexisting phases in PEG-salt systems63. Even so, in IL-salt-
based ABS, the extraction efficiencies are kept at 100% within the salt concentration range 
evaluated. In fact, the mixture compositions (20 wt% of salt + 30 wt% of IL) and (30 wt% of salt + 
20 wt% of IL) are very close to the binodal curve and correspond to minimum concentrations 
required to form ABS with [Pi(444)1][Tos]. 
The results presented in Table 2.2.4. show the extraction efficiencies of BSA, in a given ABS 
and composition, as a function of the protein concentration at the aqueous phase. It is shown that 
the investigated [Pi(444)1][Tos]-based ABS can be used to completely extract BSA from aqueous 
solutions with a concentration up to 10 g·L-1 (without the saturation of the IL-rich phase and with 
no precipitation and/or denaturation effects observed).  
Recovery of bovine serum albumin (BSA) from the IL-rich phase and reusability of the ILs. To 
guarantee the development of a sustainable and low-cost extraction procedure, we additionally 
evaluated the recovery of BSA from the IL-rich phase and further use of the IL to create a new ABS 
and to conduct subsequent extractions with new aqueous solutions containing BSA. In this step, 
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the ABS composed of 30 wt% of [Pi(444)1][Tos], 30 wt% of K3C6H5O7/C6H8O7 and 40 wt% of an 
aqueous solution containing BSA at 0.5 g..L-1 was investigated. After the first extraction, the top 
phase was separated, and the BSA recovered by dialysis. After the separation of BSA, the IL-rich 
phase was dried under vacuum at 60°C. Then, the non-volatile components at the IL-rich phase, 
namely the IL and salt, were used to create a new ABS by the addition of a fresh aqueous solution 
containing BSA at 0.5 g..L-1, as well as more citrate-based salt to achieve the initial mixture 
composition. After the formation of the ABS and the conditions mentioned before for achieving 
the equilibrium, the phases were separated and the amount of BSA in each phase was again 
quantified. This overall procedure was repeated one more time. In all experiments of BSA 
recovery/IL reusability, the complete extraction of BSA (extraction efficiency of 100%) to the IL 
rich-phase was verified, meaning that ILs can be reused in ABS without a decrease on the systems 
extraction efficiency. However, it should be highlighted that unless cyclic, closed, and more 
complex systems are used, inevitable losses of IL will occur by the simple transference of the fluid 
into different vials. Moreover, and from the TLs data shown in Table 2.2.2, there is also the loss of 
1.74 wt% of [Pi(444)1][Tos] per extraction, which corresponds to the IL present in the salt-rich phase. 
For the three consecutive extractions investigated, a total loss of 9.96 wt% of [Pi(444)1][Tos] occurs. 
Bovine serum albumin (BSA) stability in ionic liquid solutions. Proteins are complex 
macromolecules which retain their structural and functional stability in their native environment; 
yet, small variations in their environment, such as temperature, pressure, pH and presence of 
some solutes can alter their native structure. Most works reported in the literature focused on the 
extraction ability of IL-based ABS for proteins64–66, and few studies41,60,67 have investigated the 
protein stability after being extracted into the IL-rich phase. However, if proteins are being 
extracted to a given phase, the protein stability is a prerequisite that cannot be discarded. The SE-
HPLC chromatograms used for the BSA quantification, with one example being displayed in 
Fig.2.2.5, allow to endorse that there is no significant fragmentation or formation of aggregates of 
BSA under the studied conditions. In addition, the native structure of BSA at the IL-rich phase, in 
the systems investigated, was always confirmed by the size-exclusion chromatograms. The 
absence of BSA at the salt-rich phase also confirms the complete extraction of the protein for the 
IL-rich phase in the studied systems. Recently, Desai et al.43 demonstrated that other proteins, 
such as IgG and Rubisco, due to their higher molecular weight, tend to cluster into aggregates in 
presence of phosphonium-based ILs. Baker and Heller68 also reported the aggregation of HSA in 
an aqueous solution with 50 wt% of an imidazolium-based IL. However, BSA remained stable in all 
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the IL-based ABS tested (with exception of the [P4444]Br-based system) supporting the viability of 
these systems to deal with the extraction/purification of proteins. 
  
Figure 2.2.6. FT-IR spectra of a BSA standard solution (0.5 g.L-1) (──); BSA in a 12.5 wt% 
[Pi(444)1][Tos] aqueous solution (-----); BSA in a 25 wt% [Pi(444)1][Tos] aqueous solution (──); and BSA 
in a 50 wt% [Pi(444)1][Tos] aqueous solution (∙∙∙∙∙∙∙). 
FT-IR spectra provides information for identifying the structure of proteins based on energy 
absorption bands of specific functional groups or chemical bonds. The most widely used 
absorption bands as structure probes for proteins are the amide I vibrations69, which fall between 
1690 and 1600 cm-1. Fig. 2.2.5. depicts the FT-IR spectra of BSA in a buffered aqueous solution and 
BSA in an aqueous solution of [Pi(444)1][Tos] at different concentrations (up to 50 wt%). These 
results corroborate that there are no significant changes of the protein absorbance peaks 
suggesting that the protein may maintain its spatial structure in aqueous solutions of [Pi(444)1][Tos]. 
2.2.5. Conclusions  
In this work, the ability of less studied classes of IL-based ABS, composed of phosphonium- or 
ammonium-based ILs, was evaluated in what concerns their performance for the extraction of 
proteins, namely BSA. For that purpose, the respective phase diagrams, tie-lines and tie-line 
lengths were also ascertained. For almost all the studied systems, and at all the conditions 
analyzed, BSA preferentially migrates to the IL-rich phase, with the exception of the more 
hydrophobic IL investigated ([P4444]Br) that induced the precipitation of the protein. However, the 
remaining phosphonium- and ammonium-based ABS were able to completely extract BSA top the 
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IL-rich phase. Remarkable extraction efficiencies of 100% were obtained in a single-step, without 
evidence of protein denaturation in concentrations up to 10 g.L-1 of BSA. Moreover, the recovery 
of the protein by dialysis and the IL reusability were also investigated in three-step consecutive 
extractions, and where it was demonstrated that IL-based ABS can be adequately reused without 
losses on their extraction performance. ABS composed of phosphonium- or ammonium-based ILs 
and a biodegradable organic salt are improved systems for the extraction of BSA when compared 
with the more traditional polymer-based or other IL-based ABS. Furthermore, 
tetralkylphosphonium- and tetralkylammonium-based ILs are less expensive, and thermally and 
chemically more stable, than the widely studied imidazolium-based counterparts. According to 
the reported results, these new ABS can be foreseen as alternative and cost-effective platforms 
for the separation and purification of other proteins of interest. 
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2.3. Single-Step Purification of Ovalbumin from Egg White Using Aqueous 
Biphasic Systems  
This chapter is based on the published manuscript  
Matheus M. Pereira, Rafaela A. P. Cruz, Mafalda R. Almeida, Álvaro S. Lima, João A. P. Coutinho 
and Mara G. Freire 
Process Biochemistry. 51(2016) 781-791. 
2.3.1. Abstract 
The ability of aqueous biphasic systems (ABS) composed of polyethylene glycols of different 
molecular weights (PEG 400, 600 and 1000 g.mol-1) and buffered aqueous solutions of potassium 
citrate/citric acid (pH = 5.0 - 8.0) to selectively extract ovalbumin from egg white was here 
investigated. Phase diagrams, tie-lines and tie-line lengths were determined at 25°C and the 
partitioning of ovalbumin in these systems was then evaluated. Aiming at optimizing the selective 
extraction of ovalbumin in the studied ABS, factors such as pH, PEG molecular weight and amount 
of the phase-forming components were initially investigated with pure commercial ovalbumin. In 
almost all ABS, it was observed a preferential partitioning of ovalbumin to the polymer-rich phase, 
with extraction efficiencies higher than 90%. The best ABS were then applied in the purification of 
ovalbumin from real egg white samples. In order to ascertain on the ovalbumin purity and yield, 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion high 
performance liquid chromatography (SE-HPLC) analyses were conducted, confirming that the 
isolation/purification of ovalbumin from egg white was completely achieved in a single-step with 
a recovery yield of 65%. The results obtained show that polymer-salt-based ABS allow the 
selective extraction of ovalbumin from egg white with a simpler approach and better performance 
than previously reported. Finally, it is shown that ovalbumin can be completely recovered from 
the PEG-rich phase by an induced precipitation using an inexpensive and sustainable separation 
platform which can be easily applied on an industrial scale. 
2.3.2. Introduction 
Egg white is an aqueous-rich medium mainly composed of proteins, circa 10-12%, such as 
ovalbumin, ovotransferrin, lysozyme and ovomucin1. In addition to their nutritional importance, 
egg white proteins display multiple functional properties, such as foaming, emulsification and 
heat-setting. As a result, egg white plays a major role in the food industry2. Furthermore, new 
applications involving egg white proteins are increasingly being found due to their antimicrobial 
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and antioxidant properties3, which have contributed for the production of health- and 
pharmaceutical-related products. Ovalbumin is the main protein of egg white, being responsible 
for most of its functional properties, and represents about 54% of the total protein content4. 
Ovalbumin is a glycoprotein consisting of 385 amino acids (45 kDa) with an isoelectric point of 
4.55. Because of the remarkable applications involving egg white proteins of high purity level6–9, 
the development of novel cost-effective purification techniques is in great demand. 
Ovalbumin was one of the first proteins isolated from egg white10. For that purpose, 
Hopkins10 developed a method using high amounts of ammonium sulfate for ovalbumin 
precipitation. Nevertheless, the high amount of salt used can lead to the proteins irreversible 
unfolding. Nowadays, proteins from egg white are typically separated by  electrophoresis, ion-
exchange chromatography, size exclusion liquid chromatography, ultrafiltration, adsorption, 
among others11–18. However, some of these methods, currently employed, are multi-stage and 
with high equipment and operating costs. In the context of the development of alternative 
processes for the purification of proteins, a large interest has been devoted to aqueous biphasic 
systems (ABS) in the past decades13. ABS are a liquid-liquid extraction/purification technique 
which provides a highly biocompatible media since they are mainly composed of water19. 
Nevertheless, the extraction and purification of proteins from a complex matrix, such as egg 
white, is a difficult task due to some similarities between the proteins present in the raw material.  
Most works in the literature have been focused on the evaluation of the extraction and 
recovery ability of ABS employing commercial and pure egg white proteins. For instance, Saravan 
et al.20 studied the partitioning behavior of ovalbumin in poly(ethyleneglycol) (PEG)–poly(acrylic 
acid) ABS, achieving an extraction yield of 87.4%. Nerli et al.21 investigated the thermodynamic 
forces involved in the partitioning of ovalbumin in various aqueous two-phase polymer systems 
(constituted by PEGs of different molecular weights and dextran). The authors21 demonstrated 
that the ovalbumin transfer to the top phase is exothermic, which suggests electrostatic 
interactions between the hydroxyl groups of PEG and the hydrophilic side chain of the protein. 
Dallora et al.22 investigated the partition coefficients of trypsin and lysozyme, and demonstrated 
that they can range between 1.0 and 2.4 for trypsin and from 2.3 to 9.0 for lysozyme, depending 
on the polymer chain size and on the tie-line length. The analysis of the separation factor, defined 
as the ratio of partition coefficients of two proteins, shows that high degrees of separation could 
be achieved22. In addition to these studies employing pure proteins, Coen et al.23 investigated the 
purification of egg white proteins using ammonium-sulfate precipitation and found some 
difficulties in the separation of lysozyme and ovalbumin. The extraction of lysozyme from egg 
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white was also attempted using an ABS composed of PEG 600 and a sulfate-based salt at 25°C and 
pH = 1024. The authors reported an extraction of 70% of lysozyme from egg white with no loss in 
the enzymatic activity. Yang and co-workers25 demonstrated the application of PEG 
4000/potassium citrate ABS to extract lysozyme from egg white. Diederich et al.26 showed the 
selective separation of avidin from the remaining proteins from egg white using an ABS composed 
of PEG 600 + potassium phosphate + 3 wt% NaCl, with a purity level higher than 60% and recovery  
yields > 90% (for avidin). In an attempt to reach higher purification levels, multi-stage ABS 
separations, by means of liquid-liquid chromatography, have been also investigated. Shibusawa et 
al.27,28 fractionated chicken egg white proteins by high-speed counter-current chromatography 
(HSCCC) using an ABS composed of PEG 1000 and potassium phosphate salts at different pH 
values. After the optimization of several operational conditions, the authors27,28 demonstrated to 
be able to purify the proteins present in the crude sample solution prepared from fresh egg white 
using CCC. Zhi et al.29 also employed ABS coupled to HSCCC aiming at purifying the major protein 
components in hen egg white, including ovaltransferrin, ovalbumin and lysozyme. Ovalbumin was 
successfully purified (up to 95%) from the hen egg white sample with a PEG 1000 + potassium 
phosphate ABS29. Other approaches have been described for the purification of egg white 
proteins, namely by the use of ion exchange columns followed by precipitations steps30,31. It 
should be however highlighted that most works reporting higher purification levels of egg white 
proteins comprise several stages of equilibrium and require specialized equipment, such as those 
using HSCCC27–29. 
This work is focused on the development of an one-step extraction/purification process of 
ovalbumin from egg white using ABS constituted by polyethylene glycol of different molecular 
weights (PEG 400, PEG 600 and PEG 1000) and a citrate-buffered medium (pH = 5, 6, 7 and 8 
according to different K3C6H5O7:C6H8O7 mole fraction ratios). Initially, the phase diagrams of each 
ternary system, i.e. the description of the binodal curves which separate the monophasic from the 
biphasic regimes, were determined at 25°C. The respective tie-lines and tie-line lengths were also 
determined. These biphasic systems were then optimized regarding their extraction performance 
for commercial ovalbumin and finally employed to separate ovalbumin from egg white. 
2.3.3. Experimental procedures 
Materials. The ABS studied in this work are composed of a buffer aqueous solution 
constituted by potassium citrate monohydrate, K3C6H5O7·H2O, ≥ 99 wt% pure from Sigma–Aldrich, 
and citric acid monohydrate, C6H8O7·H2O, 100 wt% pure from Fisher Scientific. Polyethylene glycol 
of different molecular weights, namely 400 g.mol-1 (PEG 400), 600 g.mol-1 (PEG 600), and 1000 
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g.mol-1 (PEG 1000), and ovalbumin from hen egg white, were acquired from Fluka. All compounds 
were used as received. Fresh eggs were bought in a local supermarket. 
Phase diagrams and tie-lines. Aqueous solutions of polyethylene glycol (PEG 400, PEG 600 
and PEG 1000) at 90 wt% and aqueous solutions of the buffer K3C6H5O7/C6H8O7 (pH = 5, 6, 7 and 8 
according to different K3C6H5O7:C6H8O7 mole fraction ratios) at ≈ 50 wt% were prepared and used 
for the determination of the binodal curves. The phase diagrams were determined through the 
cloud point titration method32,33 at 25°C and atmospheric pressure. The system compositions 
were determined by the weight quantification of all components added within   10-4 g. The tie-
lines (TLs) were determined by a gravimetric method originally proposed by Merchuk et al.34. A 
mixture point in the biphasic region of the phase diagram was prepared using small ampules (ca. 
10 mL) especially designed for the purpose, vigorously stirred, and allowed to reach equilibrium 
by the separation of the phases for at least 12 h at (25 ± 1)°C. After separation of the two phases, 
both the top and bottom phases were weighted. Each individual TL was determined by application 
of the lever-arm rule to the relationship between the top phase weight and the overall system 
composition. The experimental binodal curves were correlated using Equation (2.3.1): 
[𝑃𝐸𝐺] = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]0.5) − (𝐶[𝑠𝑎𝑙𝑡]3)] (2.3.1) 
where [𝑃𝐸𝐺] and [𝑠𝑎𝑙𝑡] are the polymer and the salt weight fraction percentages, respectively, 
and 𝐴, 𝐵, and 𝐶 are constants obtained by the regression of the experimental data (see Appendix 
C).  
The determination of the TLs was accomplished through the solution of the following system 
of four equations (Equations (2.3.2) to (2.3.5)) aiming at determining four unknown 
values  ([𝑃𝐸𝐺]PEG, [𝑃𝐸𝐺]salt, [𝑠𝑎𝑙𝑡]PEG and [𝑠𝑎𝑙𝑡]salt): 
[𝑃𝐸𝐺]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑃𝐸𝐺
0.5 ) − (𝐶[𝑠𝑎𝑙𝑡]𝑃𝐸𝐺
3 )] (2.3.2) 
 
[𝑃𝐸𝐺]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
0.5 ) − (𝐶[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
3 )] (2.3.3) 
 
[𝑃𝐸𝐺]𝑃𝐸𝐺 =
[𝑃𝐸𝐺]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝑃𝐸𝐺]𝑠𝑎𝑙𝑡 (2.3.4) 
 
[𝑠𝑎𝑙𝑡]𝑃𝐸𝐺 =
[𝑠𝑎𝑙𝑡]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡 (2.3.5) 
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where the subscripts "PEG", "salt" and "M" represent the polymer (top) and the salt (bottom) rich 
phases and the mixture composition, respectively. The parameter α is the ratio between the 
weight of the top phase and the weight of the total mixture. The tie-line lengths (TLLs) were 
determined according Equation (2.3.6): 
𝑇𝐿𝐿 = √([𝑠𝑎𝑙𝑡]𝑃𝐸𝐺 − [𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡)2 + ([𝑃𝐸𝐺]𝑃𝐸𝐺 − [𝑃𝐸𝐺]𝑠𝑎𝑙𝑡)2 (2.3.6) 
Partitioning of commercial ovalbumin in PEG-salt ABS. Fixed mixture compositions in 
several ABS were selected and used to evaluate their performance for the extraction of 
ovalbumin. Initial optimization tests were carried out with pure commercial ovalbumin. Then, the 
best ABS was employed in the separation of ovalbumin from egg white. Commercial ovalbumin 
was diluted in water at a concentration of circa 0.5 g.L-1 while egg white was diluted in water at 
1:10 (v:v). These aqueous solutions were then used in the formation of each ABS (plus PEG and 
K3C6H5O7/C6H8O7) at given concentrations. Each mixture was vigorously stirred and left to 
equilibrate for 12 h at (25 ± 1)°C. Finally, the two liquid phases were separated and weighted 
followed by the determination of the concentration of ovalbumin in each phase. The protein 
amount was quantified through UV-spectroscopy, using a SHIMADZU UV-1700, Pharma-Spec 
Spectrometer, at a wavelength of 280 nm, and using a calibration curve previously established. 
The partition coefficient of ovalbumin, KOva, was determined according to Equation (2.3.7): 
𝐾OVA% =
[𝑂𝑣𝑎]𝑃𝐸𝐺
[𝑂𝑣𝑎]𝑠𝑎𝑙𝑡
  (2.3.7) 
where [𝑂𝑣𝑎]𝑃𝐸𝐺  and [𝑂𝑣𝑎]𝑠𝑎𝑙𝑡  are the concentration of protein in the PEG-rich and in the salt-
rich aqueous phases, respectively.  
The percentage extraction efficiencies of ovalbumin, 𝑬𝑬𝑶𝒗𝒂%, are defined as the percentage 
ratio between the amount (total weight) of ovalbumin in the PEG-rich aqueous phase and that in 
the total mixture, according to Equation (2.3.8):  
𝐸𝐸Ova% =
𝑤𝑂𝑣𝑎
𝑃𝐸𝐺
𝑤𝑂𝑣𝑎
𝑃𝐸𝐺 + 𝑤𝑂𝑣𝑎
𝑆𝑎𝑙𝑡  𝒙100  (2.3.8) 
where 𝑤𝑂𝑣𝑎
𝑃𝐸𝐺 and 𝑤𝑂𝑣𝑎
𝑆𝑎𝑙𝑡 are the total weight of protein in the PEG-rich and in the salt-rich aqueous 
phases, respectively. Control or “blank” solutions at the same mixture compositions used in the 
extraction/separation studies (with no protein added) were always used to reduce possible 
interferences of the phase-forming components through the ovalbumin quantification.  
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Partitioning of ovalbumin directly extracted from egg white in PEG-salt ABS. After the initial 
optimization tests carried out with commercial ovalbumin, a fixed mixture composition (25 wt% of 
PEG + 25 wt% of K3C6H5O7/C6H8O7 (pH 7) + 50 wt% of an aqueous solution containing egg white at 
1:10 (v:v)) was used to evaluate the performance of the studied ABS for the extraction and further 
purification of ovalbumin from egg white. Each mixture was vigorously stirred and left to 
equilibrate for 12 h at (25 ± 1)°C. The two liquid phases were separated and weighted followed by 
the determination of the concentration of ovalbumin and total proteins in each phase. The total 
protein amount was quantified through UV-spectroscopy, using a SHIMADZU UV-1700, Pharma-
Spec Spectrometer, at a wavelength of 280 nm, and using a calibration curve previously 
established. The quantification of ovalbumin, purification efficiency and identification of all 
proteins in each phase were carried out by SDS-PAGE and SE-HPLC. At least three independent 
ABS were prepared and 3 samples of each phase were quantified. 
The percentage recovery yield of ovalbumin, 𝑹𝒀𝑶𝒗𝒂%, is the percentage ratio between the 
amount of protein in the PEG-rich aqueous phase to that in the initial egg white solution, and is 
defined according to Equation (2.3.9):  
𝑅𝑌Ova% =
𝑤𝑂𝑣𝑎
𝑃𝐸𝐺
𝑤𝑂𝑣𝑎
𝐸𝑔𝑔 𝑤ℎ𝑖𝑡𝑒
 𝒙100  (2.3.9) 
where 𝑤𝑂𝑣𝑎
𝐸𝑔𝑔 𝑤ℎ𝑖𝑡𝑒
 and 𝑤𝑂𝑣𝑎
𝑃𝐸𝐺 are the total weight of ovalbumin in the egg white solution and in 
the PEG-rich phase, respectively.  
The purification efficiency was calculated dividing the HPLC peak area corresponding to 
ovalbumin by the total area of the peaks corresponding to all proteins in the PEG-rich phase 
(taking into account all the dilution factors applied to each solution) according to Equation 
(2.3.10): 
𝑃𝑢𝑟𝑖𝑡𝑦Ova% =
𝐴𝑂𝑣𝑎
𝑃𝐸𝐺
𝐴𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑠
𝑃𝐸𝐺  𝒙100  (2.3.10) 
where 𝐴𝑂𝑣𝑎
𝑃𝐸𝐺  and 𝐴𝑇𝑜𝑡𝑎𝑙 𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠
𝑃𝐸𝐺  are the peak areas corresponding to ovalbumin and the total area 
of the peaks corresponding to all proteins present in the PEG-rich phase, respectively. 
Recovery of ovalbumin from the PEG-rich phase. After the optimization of the 
extraction/purification conditions using ABS, the isolation of ovalbumin from the PEG-rich phase 
was carried out. For this purpose the following ABS was used as a proof of concept: 25 wt% of PEG 
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400 + 25 wt% of K3C6H5O7/C6H8O7 (pH = 7) + 50 wt% of an aqueous solution containing egg white 
at 1:10 (v:v). The PEG-rich phase containing ovalbumin from egg white was separated and further 
centrifuged at (4.0 ± 0.5)°C during 20 min at 5000 rpm. This procedure was adapted from the 
literature 35 and allows the precipitation of proteins as a result of their low solubility in PEG 
aqueous solutions at low temperatures. The pellet obtained was then resuspended in a phosphate 
buffer solution (50 mM and pH 7.4). This solution containing ovalbumin was further evaluated by 
FT-IR and SE-HPLC. After the induced precipitation step, the PEG-rich phase was also analyzed by 
SE-HPLC in order to ensure that all proteins were precipitated. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Taking into 
account the UV-spectroscopy quantification of the total amount of proteins in each phase, all 
samples were diluted so that the amount of total protein in each gel lane in the SDS-PAGE was 
circa 0.5 µg. Samples of the aqueous phases of each ABS containing ovalbumin were diluted at 2:1 
(v:v) in a dissociation buffer consisting of 2.5 mL of 0.5 M Tris-HCl pH 6.8, 4.0 mL of 10 % (w/v) SDS 
solution, 2.0 mL of glycerol, 2.0 mg of bromophenol blue and 310 mg of dithiothreitol (DTT). This 
overall solution was heated at 95°C for 5 min to denature the proteins by reducing disulfide 
linkages, and thus overcoming some forms of the tertiary protein folding and breaking up the 
quaternary protein structure. Electrophoresis was run on polyacrylamide gels (stacking: 4 % and 
resolving: 20 %) with a running buffer constituted by 250 mM Tris-HCl, 1.92 M glycine, and 1 % 
SDS. The proteins were stained with Coomassie Brilliant Blue G-250 0.1 % (w/v), methanol 50 % 
(v/v), acetic acid 7 % (v/v) and water 42.9 % (v/v). All gels were placed in an orbital shaker at a 
moderate speed during 2-3 h at room temperature. The gels were further distained in a solution 
containing acetic acid at 7 % (v/v), methanol at 20 % (v/v) and water at 73 % (v/v) in an orbital 
shaker at a moderate speed during 3-4 h at room temperature. SDS-PAGE Molecular Weight 
Standards, namely marker molecular weight full-range from VWR, were used as protein 
standards. All gels were analyzed using the Image Lab 3.0 (BIO-RAD) analysis tool. 
Size Exclusion High-Performance Liquid Chromatography (SE-HPLC). A mixture composed of 
25 wt% of PEG 400 + 25 wt% of K3C6H5O7/C6H8O7 (pH = 7) + 50 wt% of an aqueous solution 
containing egg white at 1:10 (v:v) was studied to evaluate the yield and purity of ovalbumin. After 
12h at 25°C to attain the equilibrium, a careful separation of the phases was performed and the 
amount of ovalbumin and remaining proteins in each phase was quantified by SE-HPLC (Size 
Exclusion High-Performance Liquid Chromatography). The phases were diluted at a 1:10 (v:v) ratio 
in a phosphate buffer saline solution before injection. A Chromaster HPLC (VWR, Hitachi) coupled 
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to a DAD detector was used. SE-HPLC was performed with an analytical column (25 cm  2 mm 
i.d., 25 m), Lichrospher 100 RP-18, from Merck. A 100 mM phosphate buffer in MiliQ water 
(mobile phase) was run isocratically with a flow rate of 1 mL·min-1. The temperature of the 
column and auto-sampler was kept constant at 25°C. The injection volume was of 25 µL. The 
wavelength was set at 280 nm whereas the retention time of ovalbumin was found to be circa 18 
min within an analysis time of 30 min. The quantification of ovalbumin in each phase was carried 
out by an external standard calibration method in the range of 0.01 to 1.0 g.L-1 of protein.  
 Fourier transform infrared spectroscopy (FT-IR). FT-IR spectra were recorded using a Perkin 
Elmer Spectrum Bx spectrophotometer with a resolution of 4 cm−1. Several aqueous solutions 
containing ovalbumin at a fixed concentration (1.0 g.L−1) and PEGs at different concentrations 
were used to perform the FT-IR analysis. The spectra were obtained in the wavelength range from 
1800 to 1400 cm−1. 
2.3.4. Results and discussion 
Phase diagrams and tie-lines. All phase diagrams (PEG + water + K3C6H5O7/C6H8O7) were 
determined at 25°C and at atmospheric pressure. The binodal curves depicted in Figure 2.3.1. 
illustrate the impact of pH (pH = 5, 6, 7 and 8) on the behavior of PEG-400-based phase diagrams. 
The effect of the molecular weight of the polymer (PEG 400, PEG 600 and PEG 1000) is shown in 
Figure 2.3.2. The detailed experimental weight fraction data are reported in Appendix C. In all 
studied ABS, the top phase corresponds to the PEG-rich aqueous phase while the bottom phase is 
mainly composed of the K3C6H5O7/C6H8O7 aqueous buffer. In all calculations, the water amount in 
the original salt was considered in the total amount of water.  
Figure 2.3.1 shows the binodal curves for ABS composed of PEG 400 at different pH values 
achieved by the use of different K3C6H5O7/C6H8O7 mole fractions. In general, the higher the pH of 
the aqueous solution the larger is the biphasic region, i.e. lower amounts of salt are required to 
form an ABS at a given concentration of PEG. In ABS composed of polymers and salts, the latter 
tends to be preferentially hydrated (Gibbs free energy of hydration of C6H5O7
3- (ΔhydG) = −2765 
kJ.mol−1)36, and to induce the salting-out of the more hydrophobic substance (PEG). Therefore, the 
variations on the binodal curves observed with the pH values are a direct consequence of the 
K3C6H5O7/C6H8O7 ratio and further speciation and relative abundance of the trivalent, divalent and 
monovalent citrate anions. Larger amounts of the trivalent citrate anion (C6H5O7
3-) exist at higher 
pH values, a stronger salting-out species when compared with C6H6O7
2- and C6H7O7
- (according to 
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the Hofmeister series37), and thus, lower amounts of the phase-forming components are required 
to undergo liquid-liquid demixing. 
  
Figure 2.3.1. Phase diagrams for the systems composed of PEG 400 + K3C6H5O7/C6H8O7 + H2O at 
25°C: pH 5 (); pH 6 (); pH 7 (); pH 8 (). Adjusted binodal data using Equation (2.3.1) (__). 
Figure 2.3.2 depicts the phase diagrams for ABS formed by PEGs of different molecular 
weights and the citrate-based salt at a fixed pH value (pH = 7). PEG-based ABS reveal different 
abilities for phase separation induced by the length of their polymeric chains. The capacity for 
forming ABS according to the polymer molecular weight follows the order: PEG 1000 > PEG 600 > 
PEG 400. This effect was also observed with polymer/ionic liquid, polymer/salt and 
polymer/polymer combinations38–40. The increase of the polymer molecular weight leads to an 
increased hydrophobicity of these molecules, reducing their affinity for water. Therefore, the 
formation of ABS by a salting-out phenomenon induced by the citrate-based salt is more 
favorable for polymers of higher molecular weight.  
The experimental data corresponding to the binodal curves were fitted using Equation 
(2.3.1). The regression parameters estimated by least-squares regression, standard deviations (σ) 
and correlation coefficients (R2) are displayed in Table 2.3.1. Equation (2.3.1) is able to correlate 
the experimental binodal curves with high accuracy, as shown by the correlation coefficients 
obtained (R2 > 0.9961). 
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Figure 2.3.2. Phase diagrams for the systems composed of PEG + K3C6H5O7/C6H8O7 + H2O at 25°C 
and pH 7.0: PEG 400 (); PEG 600 (); PEG 1000 (). Adjusted binodal data using Equation 
(2.3.1) (__). 
 
Table 2.3.1. Correlation parameters used to describe the experimental binodal data by Equation 
(2.3.1). 
PEG pH A ± σ B ± σ 105 (C ± σ) R2 
PEG + K3C6H5O7/C6H8O7 + water 
400 
5.0 160.0 ± 7.4 -0.302 ± 0.010 0.54 ± 0.04 0.9998 
6.0 257.8 ± 6.0 -0.469 ± 0.018 0.01 ± 0.07 0.9991 
7.0 158.3 ± 2.0 -0.378 ± 0.045 0.47 ± 0.06 0.9980 
8.0 103.4 ± 1.3 -0.317 ± 0.005 3.23 ± 0.16 0.9979 
PEG + K3C6H5O7/C6H8O7 + water 
600 7.0 149.8 ± 2.4 -0.398 ± 0.006 3.3 ± 0.19 0.9975 
1000 7.0 179.4 ± 8.4 -0.480 ± 0.016 4.8 ± 0.41 0.9961 
The experimental TLs in each ABS, along with their respective length, and at the compositions 
for which the extraction studies of ovalbumin were determined are reported in Table 2.3.3. An 
example of the TLs obtained is depicted in Figure 2.3.3. 
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Table 2.3.2. Experimental TLs and TLLs of the ABS composed of IL + K3C6H5O7/C6H8O7 + H2O at 
25°C. 
Weight fraction composition / (wt %) 
PEG 400 + K3C6H5O7/C6H8O7 + water 
pH [PEG]PEG [salt]PEG [PEG]M [salt]M [PEG]salt [salt]salt TLL 
5.0 
41.56 18.86 30.01 29.99 9.93 49.38 43.96 
54.60 12.43 35.00 29.99 6.70 55.36 64.33 
6.0 
42.57 14.74 29.96 25.02 14.54 37.87 37.87 
45.94 13.52 29.99 29.85 8.60 51.76 53.45 
7.0 
38.35 13.82 29.72 19.92 21.39 25.80 20.76 
45.44 10.79 29.75 25.20 8.13 45.03 50.63 
49.27 9.46 29.98 29.97 3.50 58.13 66.80 
36.00 15.02 25.28 24.75 13.50 35.45 30.38 
48.82 9.61 25.22 34.66 3.03 60.09 68.15 
67.33 5.10 40.08 30.01 2.09 64.73 88.38 
8.0 
53.36 4.32 25.06 24.99 1.09 42.50 64.72 
64.69 2.19 30.13 29.84 0.06 53.90 82.77 
PEG + K3C6H5O7/C6H8O7 + water at pH 7.0 
PEG [PEG]PEG [salt]PEG [PEG]M [salt]M [PEG]salt [salt]salt TLL 
600 
73.68 3.16 30.17 25.92 1.19 41.08 81.81 
74.70 3.04 30.13 30.33 0.21 48.66 87.35 
63.64 4.57 29.98 19.99 6.19 30.88 63.18 
60.27 5.15 25.01 25.02 2.14 37.89 66.71 
86.69 1.87 35.05 24.96 1.47 39.96 93.34 
1000 
57.95 5.45 29.95 25.09 0.05 46.04 70.70 
59.43 5.21 29.94 30.03 0.00 55.16 77.63 
46.49 7.64 29.97 20.06 0.04 46.87 60.80 
58.47 5.37 35.05 25.03 0.00 54.44 76.33 
41.72 8.79 25.04 25.00 0.01 49.29 58.13 
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Figure 2.3.3. Phase diagram for the system composed of PEG 400 + K3C6H5O7/C6H8O7 + H2O at 25°C 
and pH 7.0: binodal curve data (); TL data (); adjusted binodal data using Equation (2.3.1) (__). 
 
Extraction of bovine serum albumin (BSA). Figure 2.3.4. shows the partitioning of 
commercial ovalbumin, expressed both in partition coefficient and in extraction efficiency, in an 
ABS composed of PEG 400 and C6H5K3O7/C6H8O7 at different pH values. All these experiments 
were carried out at a common mixture composition (30 wt% of PEG 400 + 30 wt% of 
C6H5K3O7/C6H8O7). For all investigated systems, ovalbumin preferentially migrates to the top phase 
(PEG-rich phase) with KOva > 1. The partition coefficients range between 12.67 and 54.74 and the 
extraction efficiencies between 94.8 and 97.7%. Amongst the pH values investigated, the higher 
partition coefficients and extraction efficiencies were obtained with the buffered systems at pH 7 
and 8. Given that the isoelectric point of ovalbumin is 4.55, in all systems evaluated the protein is 
negatively charged. In PEG–salt ABS it has been reported that proteins prefer the top or the 
bottom phase depending on the nature of the phase forming-components and their 
concentration41,42. At pH 7.0, ovalbumin is negatively charged and still prefers the phase of lower 
ionic strength (polymer-rich) in all systems evaluated. Based on the overall results, the salting-out 
effect exerted by the salt plays an important role since the higher extraction efficiencies for the 
polymer-rich phase were obtained at higher pH values – those in which the amount of the 
strongest salting-out species (C6H5O7
3-) is higher. 
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Figure 2.3.4. Influence of the pH in the extraction efficiency (EEOva%, bars) and partition 
coefficient (KOva, symbols) of ovalbumin in ABS composed of 30 wt% of PEG 400 + 30 wt% of 
K3C6H5O7/C6H8O7 ABS at 25°C and different pH values. 
Given that the best results were obtained at pH 7-8 (which further imply a lower loss of the 
target protein for the opposite phase and higher recovery yields), further mixtures at pH 7 for 
various concentrations of PEG 400, 600 and 1000 (from 20 to 30 wt%) and K3C6H5O7/C6H8O7 (from 
25 to 35 wt%) were investigated and their impact on the protein partition evaluated. Figure 2.3.5 
depicts the effect of the salt concentration. Interestingly, depending on the PEG employed, 
opposite trends are observed. An increase in the salt content leads to an increase in the partition 
coefficients and extraction efficiencies of ovalbumin for the polymer-rich phase in systems 
composed of PEG 1000, while the opposite effect is observed with PEG 400. With ABS constituted 
by PEG 600 there are no major differences on the partition coefficients and extraction efficiencies 
as a function of the salt concentration. Therefore, there is a combined effect of the forces acting 
on the protein migration in ABS composed of polymers of different molecular weight. For ABS 
composed of PEG of higher molecular weight, an increase in the salt content supports the salting-
out of the protein (exerted by the citrate-based salt) favoring thus its migration to the polymer-
rich phase. The volume exclusion effects derived from the high molecular weight polymers do not 
seem to play a significant role, whereas higher amounts of salt seem to exert a large effect on the 
protein preferential migration. On the other hand, for more hydrophilic polymers, i.e. those of 
lower molecular weight, an increase in the salt content is not favorable for the proteins migration 
for the phase of lower ionic strength. According to the TLs data given in Table 2.3.2, the amount 
 
10
20
30
40
50
60
90
92
94
96
98
100
pH 5 pH 6 pH 7 pH 8
K ova%EE ova
2. Screening of aqueous biphasic systems as alternative extraction and purification platforms for proteins 
76 
of PEG 1000 in the salt-rich phase is almost negligible, supporting the salting-out mechanism 
exerted by the citrate-based salt and favorable protein-PEG hydrophobic interactions, while for 
PEG 400 an increase in the salt content leads to a decrease of the PEG amount at the salt-rich 
phase, with its concomitant increase at the polymer-rich phase, which seems to be not favorable 
for the preferential protein partitioning.  Nevertheless, for an ABS constituted by 30 wt% of salt 
and 30 wt% of polymer there are no major differences in the partition coefficients and extraction 
efficiencies afforded by PEGs of different molecular weight. Even so, in all the evaluated 
situations, ovalbumin preferentially migrates to the most hydrophobic-(PEG)-rich phase 
confirming that protein-polymer interactions and salting-out effects play a significant role. 
 
Figure 2.3.5. Extraction efficiency (EEOva%, bars) and partition coefficient (KOva, symbols) of 
ovalbumin in ABS composed of 30 wt% of PEG 400 (green bars and  ), PEG 600 (red bars and ) 
and PEG 1000 (orange bars and ) and different concentrations of K3C6H5O7/C6H8O7 at 25°C and 
pH = 7.0.  
Figure 2.3.6 shows the effect of the PEG concentration on the ovalbumin partitioning 
process. The ABS investigated are composed of 25 wt% of K3C6H5O7/C6H8O7 and PEG 
concentrations ranging from 25 to 35 wt%. At all concentrations, the partition coefficients 
decrease in the following order: PEG 400 > PEG 600 > PEG 1000 (based ABS). For PEG 600 and 
1000, an increase in the PEG concentration leads to a decrease on both partition coefficients and 
extraction efficiencies of ovalbumin to the polymer-rich phase. At higher concentrations of PEG, 
ovalbumin starts to lose its affinity for the polymer-rich phase that is predominately less rich in 
 
0
20
40
60
80
100
75
80
85
90
95
100
20 25 30
K ova
%EE ova
[K3C6H5O7/C6H8O7]/(wt%)
2. Screening of aqueous biphasic systems as alternative extraction and purification platforms for proteins 
77 
water (cf. Table 2.3.2.  with the TLs data). This effect is less notorious in systems composed of PEG 
400 (the most hydrophilic polymer investigated), and therefore no major differences are observed 
amongst the partition coefficients and extraction efficiencies of ovalbumin at different 
concentrations of PEG 400. 
 
Figure 2.3.6. Extraction efficiency (EEOva%, bars) and partition coefficient (KOva, symbols) of 
ovalbumin in ABS composed of 25 wt% of K3C6H5O7/C6H8O7 and different concentration of PEG 400 
(green bars and ), PEG 600 (red bars and ) and PEG 1000 (orange bars and ) at 25°C and pH = 
7.0.  
Extraction/separation of ovalbumin directly from egg white. After optimizing the 
extraction/separation process with commercial ovalbumin, the ABS with better performance were 
then applied to extract and separate ovalbumin from a real matrix, egg white. A constant mixture 
composition (25 wt% of PEG + 25 wt% of K3C6H5O7/C6H8O7 (pH 7) + 50 wt% of an aqueous solution 
containing egg white at 1:10 (v:v)) was used and the effect of the molecular weight of PEG was 
evaluated. In all these experiments the pH was maintained at 7, since according to the previous 
optimization experiments carried out with commercial ovalbumin a lower loss of the target 
protein for the opposite phase was observed, which imply higher recovery yields at pH 7. Several 
mixtures at pH 7 for various concentrations of PEG 400, 600 and 1000 (from 20 to 30 wt%) and 
K3C6H5O7/C6H8O7 (from 25 to 35 wt%) were investigated and their impact on the protein partition 
evaluated. The total amount of proteins in egg white, partition coefficients and extraction 
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efficiency are provided in Appendix C. Figure 2.3.7 depicts the partition coefficient and extraction 
efficiency values obtained for the total proteins extracted from egg white. 
 
Figure 2.3.7. Extraction efficiency (EEOva%, bars) and partition coefficient (KOva, symbols) of 
commercial ovalbumin (green bars and ) and proteins from egg white dissolved in water (1:10, 
v:v) (blue bars and ) in ABS composed of 25 wt% of PEG  + 25 wt% K3C6H5O7/C6H8O7 at 25°C and 
pH = 7.0. 
Although the partition coefficients and extraction efficiencies of commercial ovalbumin and 
the total protein extracted from egg white are similar, a large amount of precipitated proteins at 
the interface was observed when working with the water soluble fraction of proteins from egg 
white. Based on the UV spectroscopy quantification there are no guarantees that the protein 
extracted to the PEG-rich phase is preferentially ovalbumin. Therefore, all the coexisting phases 
and the precipitated proteins at the interface (after the respective recovery and re-suspension in 
a phosphate buffer solution) were analyzed by SDS-PAGE. It is visible from Figure 2.3.8 that only 
ovalbumin is present in the PEG-rich phase, whereas the contaminant proteins were precipitated 
at the interface. The precipitated proteins were identified according to molecular weight markers 
and are estimated to be ovotransferrin, ovoinhibitor, ovomucin and a smaller fraction of 
ovalbumin. Moreover, from the SE-HPLC chromatograms used for the proteins quantification, 
shown in Figure 2.3.9, it can be concluded that only ovalbumin is present at the PEG-rich phase 
since no other peaks were identified (meaning that pure ovalbumin was obtained in the one-step 
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ABS process). These SE-HPLC chromatograms also indicate that there is no significant ovalbumin 
aggregation or fragmentation under the studied conditions since no other peaks were identified. 
Thus, and although polymers such as PEG are used in the precipitation and aggregation of 
proteins43, the amount of water in the PEG-rich phase, as well as its low molecular weight, is 
favorable for maintaining a protein-friendly environment for ovalbumin. Previously, it was showed 
that chicken egg white lysozyme tends to cluster into aggregates in presence of PEG 1000 after 
incubation at 90°C for 30 min44,45. At high temperatures, and due to the lower critical solution 
temperature behavior of PEG-water systems, there is a decrease on the hydration shell of the 
proteins44,45. In this work, the extractions were carried out at a low temperature, 25°C, and using 
polymers of low molecular weight (from 400 to 1000 g.mol-1).  
 
Figure 2.3.8. SDS-PAGE of the (a) egg white in water (1:10 (v:v, egg white:buffer)), and (b) PEG–
rich phase, (c) precipitated proteins re-dissolved in a buffer solution and (d) salt-rich phase of the 
ABS composed of 25 wt% of PEG 400 + 25 wt% of K3C6H5O7/C6H8O7 + 50 wt% of an egg white 
aqueous solution (1:10, v:v). 
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According to the quantification of ovalbumin in the coexisting phases of the system 
composed of 25 wt% of PEG 400 + 25 wt% of K3C6H5O7/C6H8O7 (pH 7) + 50 wt% of an aqueous 
solution containing egg white at 1:10 (v:v)) carried out by SE-HPLC, (32.6 ± 0.2)% of ovalbumin 
precipitates at the interface, whereas the remaining ovalbumin from egg white (64.8 ± 2.5)% is 
extracted and remains stable in the PEG-based ABS. Despite this loss in ovalbumin, no other 
proteins were detected by SE-HPLC at the PEG-rich phase, in agreement with the results obtained 
by SDS-PAGE. These results confirm that PEG-based ABS can be used for the extraction and 
purification of ovalbumin from egg white, with a recovery yield of 65%, supporting thus their 
viability for the extraction/purification of proteins from complex matrices. Moreover, it is shown 
that a simple and easily scalable single-step process can be used to purify ovalbumin from egg 
white without using sophisticated equipment, such as CCC or centrifugal partition 
chromatography (CPC), as previously attempted 27–29. 
Figure 2.3.10 displays the FT-IR spectra of ovalbumin in water and in several aqueous 
solutions of PEG 400 at different concentrations (up to 50 wt%) in equilibrium for 12h. FT-IR 
spectroscopy provides information about the secondary structure of proteins based on energy 
absorption bands of their functional groups or chemical bonds. Most analyses are between 1690-
1600 cm-1 (in the spectra range) for the specific investigation of the protein structure which 
corresponds to the vibration of the amide I group46. The results obtained show that aqueous 
solutions of PEG 400 do not change the absorbance peaks of amide I suggesting that the protein 
maintains its spatial structure in the PEG-rich phase. 
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Figure 2.3.9. Size exclusion chromatograms of (a) egg white in water (1:10, v:v, egg white:buffer), 
(b) PEG–rich phase, (c) precipitated proteins re-dissolved in a buffer solution, (d) salt-rich phase of 
the ABS composed of 25 wt% of PEG 400 + 25 wt% of K3C6H5O7/C6H8O7 + 50 wt% of an egg white 
aqueous solution (1:10, v:v), (e) commercial ovalbumin; and (f) recovered ovalbumin after the 
purification and precipitation steps. 
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Figure 2.3.10. FT-IR spectra of a standard aqueous solution containing ovalbumin (1 g.L-1) (──); 
ovalbumin in a 12.5 wt% PEG 400 aqueous solution (──); ovalbumin in a 25 wt% PEG 400 aqueous 
solution (-----); ovalbumin in a 50 wt% PEG 400 aqueous solution (∙∙─∙∙∙─∙∙); and precipitated 
ovalbumin re-suspended in a buffer solution. 
Recovery of ovalbumin from the PEG-rich phase. After the purification step, the ovalbumin 
recovery from the PEG-rich phase was achieved by an induced precipitation step, and separated 
by centrifugation at 4°C. This procedure was adapted from literature35 and is based on the low 
solubility of proteins in polymers aqueous solutions at low temperatures. The pellet obtained was 
then resuspended in a phosphate buffer solution (50 mM and pH 7.4). This “new” aqueous 
solution rich in ovalbumin was further evaluated by FT-IR and SE-HPLC. The PEG-rich phase was 
also analyzed by SE-HPLC confirming the complete precipitation of ovalbumin. According to the 
FT-IR results, shown in Figure 2.3.10, there are no changes in the absorbance peaks of amide I 
suggesting that the recovered protein maintained its structure. Moreover, from the SE-HPLC 
results, depicted in Figure 2.3.9, the recovered protein does not present the formation of 
aggregates or even complexation (monomers and dimers). A comparison between the 
chromatograms of commercial ovalbumin and the extracted, purified and isolated ovalbumin 
from egg yolk achieved in this work is also provided in Figure 2.3.9. In summary, the obtained 
results confirm the viability of using the proposed ABS for the extraction of ovalbumin from egg 
white and a following precipitation step for its recovery from the PEG-rich phase. This “cleaning” 
step also allows the reuse of the coexisting phases of ABS for further purification stages.  
14001500160017001800
Wavenumber (cm-1)
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Since ABS separations do not require a solid support matrix, adsorptive loss and denaturation 
of proteins are minimized, as previously confirmed by the stability studies of the recovered 
protein. According to the identification and quantification of ovalbumin and remaining proteins 
(by SDS-PAGE and SE-HPLC) in the coexisting phases of the optimized system, only ovalbumin is 
present at the PEG-rich phase while the remaining and contaminant proteins present in egg white 
precipitate at the interface. If only ovalbumin is identified at the PEG-rich phase it thus confirms 
the selective nature of the studied systems for albumin and their ability to act as purification 
routes, with a recovery yield of (64.8 ± 2.5)% of the total ovalbumin present in egg white.  
Only three works27–29 were found in the literature with values of ovalbumin purity similar to 
those found in this work, obtained from egg white. Shibusawa et al.27,28 separated the proteins 
present in chicken egg white by counter-current chromatography (CCC) and high-speed counter-
current chromatography (HSCCC) using ABS composed of 16 wt% of PEG 1000 and 12.5% wt% of 
K2HPO4. The authors
27,28 separated ovotransferrin, ovalbumin, ovomucin and lysozyme by 
collecting different fractions at different times of elution and by applying reverse modes when 
required. Zhi et al.29 successfully purified ovalbumin from hen egg white using an ABS formed by 
16 wt% of PEG 1000 and 17 wt% of K3PO4 at pH 9.2 with HSCCC, using the PEG-rich phase as the 
stationary phase. CCC is essentially a form of liquid-liquid partition chromatography. Amongst 
other chromatographic methods, this method does not require the use of a solid support as the 
stationary phase; instead, one of the ABS phases acts as the stationary phase by being retained in 
the column by gravity or centrifugal force. In CPC (centrifugal partition chromatography) and CCC 
it is necessary first to equilibrate the ABS in a separatory funnel and then to separate the two 
phases for further use as mobile and stationary phases. Also, individual partition coefficients (in 
separated experiments) need to be determined first for each protein to optimize the 
chromatographic conditions. In this context, and according to our results, the major novelty of our 
work consists on the development of a simpler, cheaper and less time-consuming method that 
does not require the use of chromatographic equipment. In fact, in our work, only one stage of 
equilibrium is required to successfully separate ovalbumin from the remaining proteins in egg 
white. Contrarily to previous works27–29, we also used a lower molecular weight polymer (PEG 400 
instead of PEG 1000) and a biodegradable and less toxic salt (citrate-based instead of phosphate-
based) which could justify the high performance obtained in a single-step ABS separation without 
requiring the multiple stages of equilibrium occurring in CPC and CCC. Finally, we were also able 
to demonstrate the recovery of ovalbumin from the PEG-rich phase and the viability of recovering 
and reusing the coexisting phases, which certainly decreases the cost of the process and increases 
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its sustainable nature. In summary, in this work, it is shown that a simple and easily scalable and 
recyclable single-step process can be used to purify ovalbumin from egg white without requiring 
the use of sophisticated chromatographic equipment. The flowchart of the developed process for 
purifying ovalbumin directly from egg white is shown in Figure 2.3.11. The developed process 
allows to purify ovalbumin from a crude sample solution prepared from fresh egg white, in an 
one-step operation and in a relatively short time. 
 
Figure 2.3.11. Flow chart of the developed process for the purification of ovalbumin from egg 
white. 
2.3.5. Conclusions  
The extraction and purification of ovalbumin using a cost-effective method based on ABS 
formed by polymers and a salt, followed by a precipitation step for the protein recovery, is here 
proposed. The ABS phase diagrams were initially determined, at different pH values and with 
PEGs of different molecular weight, to ascertain on the biphasic/monophasic regimes. These two-
phase systems where then employed in studies concerning the partition of commercial ovalbumin 
aiming at identifying the best ABS. In all model systems, ovalbumin preferentially migrates to the 
PEG-rich phase and the best results were obtained with PEGs of lower molecular weight and at pH 
7. Extraction efficiencies of ovalbumin to the PEG-rich up to 98.9% were attained in a single-step. 
After the optimization study conducted with the model systems using a standard solution of 
ovalbumin, the enhanced ABS were then applied in the extraction and purification of ovalbumin 
from egg white. The extraction efficiency values obtained range between 90.6% and 97.8%. The 
separation of albumin was also confirmed by SDS-PAGE and SE-HPLC analysis in the extraction 
carried out with the ABS constituted by PEG 400. The systems investigated reveal to be a 
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promising approach to extract ovalbumin from egg white since all contaminant proteins 
precipitate at the interface while ovalbumin selectively migrates to the polymer-rich phase. The 
complete purification of ovalbumin from egg white with a recovery yield of 65% was achieved in 
one-step using an ABS composed of 25 wt% of PEG 400 + 25 wt% of K3C6H5O7/C6H8O7 + 50 wt% of 
an egg white aqueous solution (1:10, v:v). An induced precipitation step was also optimized to 
allow the recovery of the protein from the polymer-rich phase aiming at guarantying its further 
applicability while decreasing the cost of the overall process and enhancing its sustainable nature. 
The protein stability after the recovery step was confirmed by FT-IR and SE-HPLC.  In summary, in 
this work, it was shown that a simple and easily scalable and recyclable single-step process can be 
used to purify ovalbumin from egg white without requiring the use of sophisticated 
chromatographic equipment. 
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2.4. Extraction and purification of Major Royal Jelly Proteins from honey in a 
single step using aqueous biphasic systems formed by ionic liquids and 
carbohydrates  
This chapter is based on an unpublished work with the following authors involved:  
Matheus M. Pereira, Maria V. Quental, Sónia N. Pedro, Aminou Mohamadou, João A. P. Coutinho 
and Mara G. Freire 
2.4.1. Abstract 
Nowadays there is a strong demand for efficient and sustainable purification processes capable of 
industrial implementation. Although much interest has been devoted to ionic-liquid-based 
aqueous biphasic systems (IL-based ABS), most studies rely on inorganic salts and imidazolium-
based ILs. In this work we propose novel ABS composed of phosphonium-based ILs, analogues of 
natural glycine-betaine, and carbohydrates. The respective ternary phase diagrams, as well as the 
tie-lines and tie-line lengths, were determined at 25°C. This type of systems was then investigated 
to recover and purify Major Royal Jelly Proteins (MRJPs) from honey. In all systems investigated 
MRJPs precipitate in the ABS interface, allowing a recovery yield ranging between 84 and 97%, 
and high levels of purification (80-90%) of MRJP1. This work demonstrates that novel bio-based 
ABS can be used to extract and/or selectively precipitate proteins from complex samples in a 
single-step. 
 
2.4.2. Introduction 
In recent years, liquid-liquid extractions based on aqueous biphasic systems (ABS) have 
proved themselves as alternative, more biocompatible and low-cost techniques for the extraction, 
purification and concentration of several biocompounds, such as proteins1–5, enzymes6,7, drugs8,9 
and other biomolecules10,11. ABS are “greener” alternatives to the traditional organic solvent-
water biphasic systems12. In addition to the more traditional ABS composed of polymer-polymer 
or polymer-salt combinations, more recent and interesting are the ABS formed by ionic liquids 
(ILs)12. The success of ILs has been attributed to their unique physico-chemical characteristics and 
high adaptive ability under a wide range of conditions and applications13,14. 
Despite the large number of publications dealing with IL-based ABS12, most of these studies 
are focused on the determination of the respective ternary phase diagrams, and on extraction 
studies with model systems/biomolecules to appraise their ability to extract given products. To 
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move further on this field, as well as to prove their applicability to real systems, it is now crucial 
that research on IL-based ABS is aimed at the separation and purification of valuable products 
directly from complex biological media or industry residues. Although a large number of IL-based 
ABS has been investigated, most of these studies were carried out with ABS formed by 
imidazolium-based ILs and inorganic salts12. This trend is a result of the high ability of inorganic 
salts to salt-out ILs from aqueous media, and thus their high aptitude to form two-phase systems. 
Nevertheless, taking into account the use of these systems for the purification and recovery of 
target products with biological activity, considering the human consumption of the end products, 
as well as some environmental issues related to the use of non-toxic phase-forming components, 
it is critical to find alternative IL-based ABS with more benign characteristics. To this end, more 
benign ILs and alternatives to the widely studied inorganic salts should be appraised. More 
biocompatible systems were recently proposed through the use of carbohydrates, instead of 
inorganic salts, as phase separation promoters in aqueous systems comprising ILs15–18. This 
perception arose from special benefits offered by carbohydrates, as non-toxic substances that can 
be obtained from renewable natural resources. Even though, there is still only a small number of 
possible IL-carbohydrate-based ABS due to the low salting-out ability of carbohydrates, as well as 
on their investigation as potential platforms to purify and isolate added-value compounds from 
real matrices, with published works up to date only addressing ILs composed of fluorinated-based 
anions and imidazolium- or pyridinium-based cations15,16,18–25.  
Honey is a natural supersaturated solution of sugars (60-80% of the total content) produced 
by honeybees26. In addition to its high carbohydrates content, honey is also rich in phenolic 
compounds, aliphatic acids, vitamins, amino acids, proteins and inorganic compounds27. In the last 
decade, honey has been the focus of many studies, mostly due to their antioxidant 
characteristics28. Honey was already identified as a product able to reduce the risks of diseases 
triggered by reactive oxygen species and other free radicals, such as degenerative diseases, 
including cancer29. In addition to the valuable phenolic compounds present in honey, honey 
proteins display valued properties, namely anti-inflammatory30, anti-microbial31, and anti-cancer32 
activities. Several proteins were already identified in honey samples, corresponding to 
approximately 0.1–0.5% of the honey content, with molecular weights ranging from 22 to 75 
kDa33. In 1992 it was identified the first royal jelly (RJ) protein in honey, termed as major protein 
1, and since then, eight more royal jelly proteins (MRJP) were identified34. Among them, MRJP1 is 
likely to promote liver regeneration and to have a cytoprotective action on hepatocytes35 , MRJP3 
can exhibit potent immunoregulatory effects in vitro and in vivo36, and both MRJP4 and MRJP5 are 
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important sources of essential amino acids37. Besides their valued properties, the extraction and 
recovery of proteins from honey samples remain a challenge. During the last decade, several 
studies on the precipitation of proteins from honey were reported, by the addition of 
ammonium sulfate, tungstic acid or trichloroacetic acid38. Dialysis, centrifugation and 
chromatographic techniques (adsorption, ion exchange, and affinity chromatography) have also 
been attempted for the honey proteins separation from sugars and other small compounds34. In 
general, complex multi-step approaches are required, often involving the use of volatile 
compounds, which also compromise the proteins integrity.  
Herein we investigated the formation of more biocompatible ABS formed by phosphonium-
based ILs and carbohydrates, and their further use as a strategy to extract and purify MRJP from 
honey on a single step. 
2.4.3. Experimental procedures 
Materials. The carbohydrates used were sucrose (>99.5 wt.% pure from Himedia), D-(+)-
maltose (>98.0 wt.% pure from Sigma), D-(+)-glucose (>99.5 wt.% pure from Scharlau), D-sorbitol 
(>99.0 wt.% pure from Fluka), xylitol (>99.0 wt.% pure from Sigma), maltitol (>95.0 wt.% pure 
from Acros Organics), D(+)-Fructose (>98.0 wt.% pure from Panreac), D(+)-Galactose (>95 wt.% 
pure from Prolabo), L(+)-Arabinose (>99 wt.% pure from Acros Organics), D-(+)-Mannose (>99.0 
wt.% pure from Aldrich), D-(+)-xylose (≥ 99.0 wt% pure,. from Carlo Erba). Commercial honey was 
purchased at a local market.  
The commercial ILs used in this study were tetrabutylphosphonium bromide ([P4444]Br, > 
96 wt % pure), tetrabutylphosphonium chloride ([P4444]Cl, > 95% pure), 
triisobutylmethylphosphonium tosylate ([Pi(444)1][TOS], > 95 wt% pure), and 
tributylmethylphosphonium methylsulphate ([P4441][MeSO4], > 99 wt% pure), all kindly provided 
by Cytec Ind. The tri(n-butyl)[2-ethoxy-2-oxoethyl]phosphonium bromide ([Bu3PC2]Br) and tri(n-
butyl)[2-butoxy-2-oxoethyl]phosphonium bromide ([Bu3PC4]Br) were synthesized by us and 
characterized according to protocols described in Appendix D. The materials used in the ILs 
synthesis were 2-bromoacetic acid ethyl ester, 4-bromobutyric acid ethyl ester, ethyl acetate and 
tri(n-butyl)phosphine, all purchased from Sigma-Aldrich. The molecular structures of 
carbohydrates and ILs investigated are depicted in Figure 2.4.1. All ILs were dried in vacuum. The 
purity of the synthesized ILs is > 98%.  
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Figure 2.4.1. Chemical structures of the studied ILs: (i) [P4441][MeSO4], (ii) [P4444]Br, (iii) [Bu3PC2]Br 
and (iv) [Bu3PC4]Br; Chemical structures of the studied carbohydrates: (i) D-(+)-glucose, (ii) D-(+)-
mannose, (iii D(+)-galactose, (iv) D(+)-fructose, (v) D(+)-arabinose, (vi) D-(+)-xylose, (vii) D-(+)-
maltose, (viii) sucrose, (ix) xylitol, (x) D-sorbitol and (xi) maltitol. 
Phase diagrams and tie-lines. Aqueous solutions of each IL ([P4444]Br, [P4444]Cl, 
[Pi(444)1][TOS], [P4441][MeSO4], [Bu3PC2]Br, [Bu3PC4]Br), at concentrations ranging between 80 and 
90 wt%, and aqueous solutions of each carbohydrate, at concentrations between 50 and 80 wt%, 
(i) (ii)
(iii) (iv)
IL
Carbohydrates
(i) (ii)
(iii)
(iv)
(v)
(viii)
(vi)
(vii)
(ix)
(x) (xi)
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were initially prepared, and used for the determination of the binodal curves. Dropwise addition 
of the aqueous ionic liquid solution to each carbohydrate aqueous solution was carried out until 
the detection of a cloudy (biphasic) solution, followed by the dropwise addition of ultrapure water 
until the formation of a clear and limpid solution (monophasic region). Dropwise additions were 
carried out under constant stirring. The ternary system compositions were determined by weight 
quantification of all components within 10-4 g, using an analytical balance (Mettler Toledo 
Excellence XS205 DualRange). The experimental binodal curves were correlated according to the 
approach proposed by Merchuk et al.39, described by Equation (2.4.1): 
[𝐶𝐻] = 𝐴𝑒𝑥𝑝[(𝐵[𝐼𝐿]0.5) − (𝐶[𝐼𝐿]3)] (2.4.1) 
where [𝐶𝐻] and [𝐼𝐿] are the IL and the carbohydrate mass fraction percentages, and A, B and C 
are constants obtained by the regression of the experimental binodal data. The determination of 
the TLs was accomplished through the solution of the following system of four equations 
(Equations (2.4.2) to (2.4.5)) to determine four unknown values  ([𝐶𝐻]CH, [𝐶𝐻]IL, [𝐼𝐿]CH and 
[𝐼𝐿]IL): 
[𝐶𝐻]𝐼𝐿 = 𝐴𝑒𝑥𝑝[(𝐵[𝐼𝐿]𝑃𝐸𝐺
0.5 ) − (𝐶[𝐼𝐿]𝐶𝐻
3 )] (2.4.2) 
 
[𝐶𝐻]𝐼𝐿 = 𝐴𝑒𝑥𝑝[(𝐵[𝐼𝐿]𝐼𝐿
0.5) − (𝐶[𝐼𝐿]𝐼𝐿
3 )] (2.4.3) 
 
[𝐶𝐻]𝐶𝐻 =
[𝐶𝐻]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝐶𝐻]𝐼𝐿 (2.4.4) 
 
[𝐼𝐿]𝐶𝐻 =
[𝐼𝐿]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝐼𝐿]𝐼𝐿 (2.4.5) 
where the subscripts "CH", "IL" and "M" represent the top and the bottom phases and the 
mixture composition, respectively. The parameter α is the ratio between the weight of the top 
phase and the weight of the overall mixture. For the calculation of each tie-line length (TLL), 
Equation (2.4.6) was used:  
𝑇𝐿𝐿 = √([𝐶𝐻]𝐼𝐿 − [𝐶𝐻]𝐶𝐻)2 + ([𝐼𝐿]𝐼𝐿 − [𝐼𝐿]𝐶𝐻)2 (2.4.6) 
In all systems the top phase corresponds to the IL-rich phase, whereas the bottom phase is mainly 
constituted by the carbohydrate and water. In ABS constituted with honey the opposite occurs, 
been the top phase composed mainly by carbohydrate and the bottom phase correspond to the 
IL-rich phase. 
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Purification and Recovery of Proteins from Honey. The ABS mixtures compositions used in 
the extraction and purification of proteins from honey were chosen based on the phase diagrams 
determined in this work. It was used a common mixture composition (25 wt% of IL, 25 wt% of 
water, and 50 wt% of carbohydrates from honey, knowing that honey contains ca. 80 wt% of 
carbohydrates). Each mixture was vigorously stirred, centrifuged for 30 min (7500 rpm), and left 
to equilibrate for 10 min at 25°C to allow the complete phase separation and proteins extraction. 
After, a careful separation of the phases was performed and the amount of total proteins in each 
phase was quantified by the Bradford’s method40, using a previous calibration curve established 
with bovine serum albumin (BSA). UV-Vis spectroscopy was carried out for quantification 
purposes (using a SYNERGYIHT microplate reader, BioTek, at 595 nm). To eliminate the influence 
of the IL and carbohydrates present on the protein concentration analysis, a blank control for 
each mixture was used. It should be remarked that a solid interphase is created when preparing 
these mixtures, mainly composed of proteins as discussed below. This interphase was recovered, 
resuspended in phosphate-buffered saline (PBS) concentration of 10 mM and pH 6.8, and the 
proteins content quantified by UV-Vis spectroscopy as described before. At least three 
independent ABS were prepared for each mixture and three samples of each phase quantified, 
allowing to determine the associated uncertainty of the recovery yield and purity of proteins. 
The recovery yield of honey proteins, 𝑹𝒀𝑷𝑹𝑶𝑻%, was determined as the percentage ratio 
between the total amount of proteins as part of the interphase to that in the initial honey, 
defined according to Equation (2.4.7): 
𝑅𝑌PROT% =
𝑤𝑃𝑅𝑂𝑇
𝐼𝑁𝑇
𝑤𝑃𝑅𝑂𝑇
𝐻𝑜𝑛𝑒𝑦  𝒙100  (2.4.7) 
where 𝑤𝑃𝑅𝑂𝑇
𝐼𝑁𝑇  and 𝑤𝑃𝑅𝑂𝑇
𝐻𝑜𝑛𝑒𝑦
 are the total weight of protein in the interphase and in honey, 
respectively. 
The purity level percentage of MRJ1 was determined according to Sodium Dodecyl Sulphate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) results, considering the intensity corresponding to 
the target protein and the total intensity corresponding to all proteins in the interphase (taking 
into account all the dilution factors applied to each solution), according to Equation (2.4.8):  
𝑃𝑌𝑃𝑅𝑂𝑇% =
𝐼𝑃𝑅𝑂𝑇
𝐼𝑁𝑇
𝐼𝑃𝑅𝑂𝑇
𝐻𝑜𝑛𝑒𝑦   100 (2.4.8) 
where 𝐼𝑃𝑅𝑂𝑇
𝐼𝑁𝑇  and 𝐼𝑃𝑅𝑂𝑇
𝐻𝑜𝑛𝑒𝑦
 are the intensity corresponding to MRJ1 and the total intensity 
corresponding to all proteins present in the interphase, respectively.  
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Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Taking into 
account the UV-spectroscopy quantification of the total amount of proteins in each phase, all 
samples were diluted so that the amount of total proteins in each gel lane in the SDS-PAGE was 
circa 0.5 µg. Samples of the aqueous phases of each ABS containing ovalbumin were diluted at 2:1 
(v:v) in a dissociation buffer consisting of 2.5 mL of 0.5 M Tris-HCl pH 6.8, 4.0 mL of 10 % (w/v) SDS 
solution, 2.0 mL of glycerol, 2.0 mg of bromophenol blue and 310 mg of dithiothreitol (DTT). This 
overall solution was heated at 95°C for 5 min to denature the proteins by reducing disulfide 
linkages, and thus overcoming some forms of the tertiary protein folding and breaking up the 
quaternary protein structure. Electrophoresis was run on polyacrylamide gels (stacking: 4 % and 
resolving: 20 %) with a running buffer constituted by 250 mM Tris-HCl, 1.92 M glycine, and 1 % 
SDS. Proteins were stained with Coomassie Brilliant Blue G-250 0.1 % (w/v), methanol 50 % (v/v), 
acetic acid 7 % (v/v), and water 42.9 % (v/v). All gels were placed in an orbital shaker at a 
moderate speed during 2-3 h at room temperature. Gels were further distained in a solution 
containing acetic acid at 7 % (v/v), methanol at 20 % (v/v), and water at 73 % (v/v) in an orbital 
shaker at a moderate speed during 3-4 h at room temperature. SDS-PAGE Molecular Weight 
Standards, namely marker molecular weight full-range from VWR, were used as protein 
standards. All gels were analyzed using the Image Lab 3.0 (BIO-RAD) analysis tool. 
2.4.4. Results and discussion 
Phase diagrams and tie-lines. Aiming at the development of more biocompatible ABS, in this 
work we evaluated the potential of several carbohydrates in the formation of ABS combined with 
non-fluorinated phosphonium-based ILs. To this end, the ability of two-phase formation was 
addressed by combining several carbohydrates and ILs, followed by the determination of the 
corresponding ternary phase diagrams at 25°C. The respective ternary phase diagrams are 
depicted in Figure 2.4.2 and Figure 2.4.3. Detailed weight fraction data are provided in Appendix 
D. In all phase diagrams, the monophasic region is located below the binodal curve, whereas the 
biphasic regime is located above. Amongst the studied ILs, [P4444]Cl and [P4441][TOS] were found as 
not able to form ABS with carbohydrates. Regarding the studied carbohydrates, D-(+)-xylose, D-
(+)-maltose and sucrose were not able to form ABS at 25°C with any of the ILs investigated. 
Figure 2.4.2 displays the ternary phase diagrams of the ABS composed of [Bu3PC4]Br and 
several carbohydrates. According to these results, the ability of monosaccharides to create IL-
based ABS follows the rank: D-(+)-mannose > D-(+)-galactose > D-(+)-glucose > D-(-)-fructose >  
D-(-)-arabinose. Taking into account the carbohydrates chemical structures provided in Figure 
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2.4.1, it seems that the number of –OH groups has a significant impact in the ABS formation. 
Carbohydrates with 5 –OH groups (D-(+)-mannose, D-(+)-galactose and D-(+)-glucose) have a 
higher ability to form two phases than carbohydrates with 4 –OH groups (D-(-)-fructose and D-(-)-
arabinose). The results obtained in this work are in agreement with the trend previously reported 
for ABS composed of other ILs and carbohydrates16. All the works reported up to date on IL-based 
ABS formed by the addition of carbohydrates were achieved with fluorinated imidazolium-, or 
pyridinium-based ILs15,16,18–25. However, these fluoride-based ILs display important disadvantages 
when considering the development of more sustainable processes since besides being more 
expensive they tend to be recalcitrant to biodegradation and more toxic41. Furthermore, some 
fluorinated ILs are also non-water stable42. 
 
Figure 2.4.2. ABS phase diagrams for the systems composed of [Bu3PC4]Br + Carbohydrates + H2O 
at 25°C: (a) D-(+)-mannose (); D(+)-galactose (); D-(+)-glucose (); D(+)-fructose (); D(+)-
arabinose, (); maltitol (); D-sorbitol (); xylitol (). 
In Figure 2.4.2 are displayed the phases diagrams for ABS composed of [Bu3PC4]Br + polyols + 
water at 25°C. The polyols ability to undergo liquid–liquid demixing follows the rank: maltitol > D-
sorbitol > xylitol. The effect of –OH groups on the ABS formation ability is also important for 
polyols, as discussed before for monosaccharides. The results here obtained also are in close 
agreement with the trends previously observed for polyols to act as two-phase promoters of ABS 
composed of other ILs15. From the results obtained, it is clear that hydrogen bonding between 
carbohydrates and water is essential, and that these compounds act as “salting-out” species. 
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Figure 2.4.3. Phase diagrams for the systems composed of IL + D(+)-fructose + H2O at 25 °C: 
[P4441][MeSO4] (), [P4444]Br (), [Bu3PC2]Br (), [Bu3PC4]Br (). 
Figure 2.4.3. depicts the binodal curves for the systems composed of phosphonium-based ILs 
+ D-(-)-fructose, allowing the evaluation of the effect of the IL on the formation of ABS. The ability 
of phosphonium-based ILs to form ABS follows the order: [Bu3PC4]Br > [Bu3PC2]Br > [P4444]Br > 
[P4441][MeSO4]. Since ILs are constituted by different cations and anions, a comparison of the IL 
effect as phase-forming agents needs to take into account the contribution of both ions to be 
hydrated. Generally, ILs with longer alkyl side chains are more hydrophobic and require lower 
amounts of salting-out agents (in this work the carbohydrates) to form a two-phase system43. 
Accordingly, [P4444]Br requires a higher amount of D-(-)-fructose for the liquid-liquid demixing, 
when compared with [Bu3PC2]Br and [Bu3PC4]Br. On the other hand, [P4441][MeSO4] presents the 
lowest ability to form ABS. This is mostly due to its higher affinity for water, which results in the 
need to use a larger carbohydrate amount to promote the “salting-out” of the IL.  
The experimental data corresponding to the binodal curves were fitted using Equation 
(2.4.1). The regression parameters estimated by least-squares regression, standard deviations (σ) 
and correlation coefficients (R2) are displayed in Table 2.4.1. Equation (2.4.1) is able to correlate 
the experimental binodal curves, as shown by the high correlation coefficients obtained (R2 > 
0.9934). 
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Table 2.4.1. Correlation parameters used to describe the experimental binodal data by Equation 
(2.4.1)  
IL Carbohydrate A ± σ B ± σ 105 (C ± σ) R2 
[Bu3PC4]Br 
D(+)-fructose 136.9 ± 1.8 -0.21 ± 0.03 1.02 ± 0.01 0.9988 
D-(+)-mannose 254.0 ± 3.1 -0.46 ± 0.34 0.01 ± 0.25 0.9934 
D(+)-galactose 120.0 ± 1.8 -0.20 ± 0.05 1.56 ± 0.15 0.9992 
D-(+)-glucose  118.7 ± 2.1 -0.18 ± 0.05 1.12 ± 0.04 0.9971 
D(+)-arabinose 120.7 ± 2.9 -0.16 ± 0.08 1.68 ± 0.15 0.9979 
xylitol 82.0 ± 8.8 -0.07 ± 0.02 1.21 ± 0.07 0.9995 
D-sorbitol 178.1 ± 5.6 -0.26 ± 0.08 0.91 ± 0.05 0.9998 
maltitol 100.1 ± 2.9 -0.10 ± 0.01 3.56 ± 0.03 0.9964 
[P4441][MeSO4] 
D(+)-fructose 
118.7 ± 7.5 -0.13 ± 0.01 0.71 ± 0.08 0.9969 
[P4444]Br 123.5 ± 3.3 -0.15 ± 0.08 1.43 ± 0.05 0.9929 
[Bu3PC2]Br 158.7 ± 2.2 -0.23 ± 0.03 0.99 ± 0.02 0.9994 
 
Extraction and Purification of Proteins from Honey. Aiming to reduce the amount of 
compounds required to promote the creation of ABS to act as separation platforms, the sugar 
present in honey was used directly as a phase-forming agent. A common mixture composition of 
25 wt% of IL, 50 wt% of honey and 15 wt% of water was prepared. This mixture was prepared 
considering that honey contains ca. 80% (in weight) of carbohydrates according to thr nutritional 
composition described on the label of the commercial honey used. The results obtained are 
reported in Figure 2.4.4. Detailed data are given in Appendix D. In all systems, the top phase is 
mostly composed of carbohydrate and the bottom phase corresponds to the IL-rich phase. For all 
systems it was observed a large amount of precipitated proteins as an interphase. The protein 
quantification was carried out only in the top and bottom phases, and the precipitated proteins 
recovered at the interphase were resuspended in a phosphate buffer solution for further 
analysis/quantification.  
The recovery yield of the total proteins at the interphase ranges between 83.34 and 97.30%, 
whereas the ILs ability to promote the proteins recovery increases according to the following 
rank: [P4444]Br > [P4441][MeSO4] > [Bu3PC4]Br > [Bu3PC2]Br (based ABS). Phosphonium based-ILs are 
more hydrophobic than their imidazolium counterparts44. Due to their more hydrophobic 
characteristics it is possible that specific interactions create an unfavorable environment in the 
aqueous phases for the honey proteins, inducing their precipitation at the ABS interface, creating 
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thus an interphase rich in proteins. The same behavior was previously observed with other 
proteins from serum and egg white using IL-salt and polymer-salt-based ABS45,46. It was already 
reported that IL-salt-based ABS allow the complete precipitation of BSA in systems constituted by 
[P4444]Br and K3C6H5O7/C6H8O7
45. Polymer-salt-based ABS lead to the extraction and purification of 
ovalbumin from egg white, while precipitating the major contaminant proteins46. 
The extraction, purification and isolation of honey proteins was already investigated using 
other physical and/or chemical methods47,48. Ultracentrifugation, ion exchange chromatography 
and dialysis are normally used to obtain amylase from honey47,48. Aqueous solutions of sodium 
tungstate combined with sulfuric acid are usually applied to induce the honey proteins 
precipitation48. However, this method requires not only the use of high temperatures, but is also 
necessary the sample centrifugation and washing (for several times) until the supernatant 
becomes sugar-free. 
 
Figure 2.4.4. Recovery yield (RYPROT%, bars) and purification level (PYPROT, symbols) of proteins 
from honey in ABS composed of 25 wt% of IL + 50 wt% honey + 25 wt% water at 25°C. 
Although a large amount of proteins was precipitated, UV spectroscopy quantification did 
not allow to confirm the purification levels of the proteins isolated. To this end, the precipitated 
proteins were re-suspended in a 10 mM phosphate buffer solution (1g.L-1) and analyzed by SDS-
PAGE. The results obtained are given in Figure 2.4.5. Detailed data are given in Appendix D. 
According to molecular weight markers, the precipitated proteins correspond to MRJPs, identified 
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as MRJP 1, MRJP 3 and MRJP 5. Moreover, according to the bands intensity, the system composed 
of 25 wt% of [Bu3PC2]Br + 50 wt% of honey and 15 wt% of water, was the ABS that results in the 
MRJP1 precipitation at the interface with the highest purity level (90.98 ± 0.49 %). Despite the loss 
of others MRJPs, as detected in the aqueous phases of the studied ABS, this ABS allows us to 
purify and isolate MRJP1, with a recovery yield of 97.30% and a purity level of 90.98%. MRJP1 is 
particularly relevant because of its antibacterial activity against multi-drug resistant bacteria, 
been a natural antibacterial compound49. MRJP1 was obtained in a single-step using ABS 
composed of phosphonium-based ILs and carbohydrates, which can be further envisioned as 
extraction platforms to obtain proteins from other carbohydrate-rich complex matrices. 
 
Figure 2.4.5. SDS-PAGE of the (a) protein molecular weight marker, precipitated proteins on 
interphase and re-dissolved in a buffer solution of the ABS composed of (b) [P4444]Br, (c) 
[P4441][MeSO4], (d) [Bu3PC2]Br, (e) [Bu3PC4]Br and (f) commercial honey.  
As already discussed, processes currently applied to obtain MRJPs are based on the use of 
less biocompatible solvents and under harsher conditions47,48. In addition, significant amounts of 
wastes are produced due to the several steps required to achieve the proteins extraction, 
purification and isolation. The advantages of the proposed process are summarized in Figure 
2.4.6. It should be remarked that the carbohydrate-rich fraction can proceed to additional 
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applications, while the IL-rich phase can be used again to create novel ABS to recover MRJPs from 
honey samples. 
The ABS reported in this work have the following advantages: (i) the use of non-fluorinated 
and non-imidazolium/pyridinium ILs to form ABS with carbohydrates; (ii) the possibility to directly 
use matrices rich in carbohydrates as phase-forming components of ABS, requiring only the 
addition of IL and water; (iii) they allow a remarkable recovery and purification of MRJP1 in one-
step; and (iv) are a low-cost sustainable process with the possibility of reusing/recycling the 
applied ILs and to further process the carbohydrate matrix.  
 
 
Figure 2.4.6. Flow chart of the developed process for the isolation of proteins from honey, 
including the steps of the ILs recycling and possible applications of the carbohydrates aqueous 
solutions.  
2.4.5. Conclusions  
In this work, novel ABS with more biocompatible characteristics constituted by 
phosphonium-based ILs and carbohydrates were investigated. The respective ternary phase 
diagrams, tie-lines and tie-line lengths were determined at 25°C and at atmospheric pressure. The 
ability of the carbohydrates to promote the two phase separation depends on the number of -OH 
groups present in the molecule and to establish hydrogen-bonds with water. These systems were 
then investigated to purify proteins from complex honey samples. Proteins from honey 
preferentially precipitate at the interphase, with recovery yields of total proteins ranging between 
83.84 and 97.30%, and a purity level of MRJP1 ranging from 80.02 to 90.08%. Therefore, the ABS 
here developed are valuable to recover value-added proteins from complex raw matrices. 
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3.1. Simultaneous depletion of human serum albumin (HSA) and immunoglobulin 
G (IgG) from human serum using ionic-liquid-based aqueous biphasic systems  
This chapter is based on an unpublished work with the following authors involved  
Matheus M. Pereira, Sónia N. Pedro, Joana Gomes, Aminou Mohamadou,  João A. P. Coutinho and 
Mara G. Freire 
3.1.1. Abstract 
In recent years, advances in clinical analysis allowed the identification of several metabolites in 
human fluids. Nevertheless, the accurate identification and quantification of low-abundance 
proteins in human serum is still very difficult to achieve due to masking effects exerted by other 
abundant proteins, namely human serum albumin (HSA) and immunoglobulin G (IgG). Therefore, 
the development of more efficient, and ideally more sustainable, depletion methods has been a 
hot topic of research envisaging the accurate quantification of low-abundance human metabolites 
or proteins. This work aims at the development of novel depletion methods for human serum 
samples based on aqueous biphasic systems (ABS) composed of ionic liquids (ILs). To this end, 
novel ABS formed by glycine-betaine-based ILs and buffered aqueous solutions of 
K3C6H5O7/C6H8O7 (pH=7.0) were investigated. Novel analogous of glycine-betaine-based ILs were 
synthesized and characterized, followed by their use as phase-forming agents of ABS to be used in 
the depletion of the human serum most abundant proteins. According to the results here 
reported, the investigated ABS lead to a complete and simultaneous depletion of HSA and IgG 
from human serum in a single-step, allowing to identify transferrin, a low abundant protein. The 
IL-based ABS here reported are thus appropriate systems for the depletion of highly abundant 
proteins from human serum, a process that can be extended to other biological samples. 
3.1.2. Introduction 
Human biological samples (serum, plasma, urine, blood and saliva) have been used for long in 
the diagnosis of several diseases1–3. Human serum comprises several proteins, nucleic acids and 
other metabolites, and thus is one of the most used biological samples for the detection and 
monitoring of several diseases4,5. In fact, this strategy is already applied in clinical practice, such as 
in the early-stage cancer diagnosis and prognosis6. Nevertheless, clinical diagnosis based on 
biological fluids is not straightforward due to the large diversity of metabolites in biological fluids, 
therefore requiring the biological samples pretreatment mainly to remove high-abundant proteins 
which can mask the diagnosis results7. 
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The human serum proteomic profile is mostly constituted by human serum albumin (HSA) 
and immunoglobulin G (IgG), accounting for up to 80% of the total serum proteins content3. The 
high abundance of these two proteins masks the detection of low-abundant ones by the 
commonly used analytical methods. In order to overcome these problems, depletion methods for 
abundant serum proteins are a mandatory step. The depletion of HSA and IgG was already 
investigated applying different methodologies, such as solid-phase extraction8–12, liquid-liquid 
extraction13,14, and precipitation9. Amongst these, solid-phase extractions are the most applied 
pretreatment strategy to reduce the proteomic content of HSA and IgG.  
Within the liquid-liquid extraction approaches, aqueous biphasic systems (ABS) are an 
environmentally-friendly technique (since they are mainly composed of water) that received 
increased attention in the last decades for extracting and purifying bioactive molecules or 
compounds15. ABS are usually constituted by non-volatile pairs of compounds dissolved in water 
(a mixture of two polymers, a polymer and a salt or two salts), that undergo liquid-liquid demixing 
above given concentrations. In the past decade, ionic-liquid-(IL)-based ABS were proposed by 
Gutowski et al.16, further receiving a remarkable attention in the separations field17. ILs are 
molten salts composed of a large organic cation and an inorganic/organic anion, usually liquid at 
temperatures below 100°C. Since ILs display an ionic character, they exhibit a negligible volatility 
at atmospheric conditions, high thermal and chemical stabilities, and an impressive solvation 
ability for several compounds18,19. However, one of the most important properties that arise from 
ILs is the large number of possible cation-anion combinations, making possible the IL tailoring for 
specific applications, being this advantage extended to IL-based ABS. Combining the large content 
of water and the outstanding features of ILs, IL-based ABS can be envisioned as alternative 
depletion methods. In addition to the well-studied imidazolium-based ILs17, more recent studies 
are focused on the ILs derived from natural sources, mainly cholinium-based ILs20–22. Among these 
more “benign” alternatives, ILs derived from glycine-betaine analogues (AGB-ILs) are also viable 
phase-forming components of ABS. Glycine-betaine is an amino acid derivative naturally found in 
plants, already applied in food and cosmetic industries23,24. 
This chapter aims at the study of the development of novel depletion methods using IL-based 
ABS, and for which ILs derived from glycine-betaine analogues (AGB-ILs) were chosen to increase 
the biocompatible character of the process. 
3.1.3. Experimental procedures 
Materials. All tertiary amines, ethyl acetate and 4-bromobutyrate acid ethyl ester were 
acquired from Sigma-Aldrich. Silver saccharinate, silver lactate, silver pyruvate, silver 
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dicyanamide, silver salicylate and silver salicylate were prepared from mixtures (mole ratio of = 
1:1.1) of AgNO3 and NaX (X = saccharinate, lactate, pyruvate, dicyanamide and salicylate). AgNO3 
and all sodium salts were acquired from Sigma-Aldrich. The ABS studied in this work are 
composed of a buffer aqueous solution constituted by potassium citrate (K3C6H5O7·H2O, ≥ 99 wt% 
pure) from Sigma–Aldrich, and citric acid (C6H8O7·H2O, 100 wt% pure) from Fisher Scientific. 
Synthesis and characterization of AGB-ILs. The synthesis pathway for the AGB-based ILs is 
provided in Appendix E. The chemical structures of all ILs synthesized were confirmed by 1H and 
13C NMR, Infrared spectroscopy and elemental analysis, showing purity levels > 99 %. All ILs were 
dried in vacuum. The chemical structures and abbreviations of the synthesized ILs are given in 
Figure 3.1.1.  
Microtox® toxicity tests. To evaluate the ecotoxicity of the synthetized ILs, the Standard 
Microtox® liquid-phase assay was applied. Microtox® is a bioluminescence inhibition method 
based on the bacterium Vibrio fischeri (strain NRRL B- 11177) luminescence after its exposure to 
each sample solution at 15°C. In this work, the standard 81.9% test protocol was followed25. The 
microorganism was exposed to a range of diluted aqueous solutions of each compound (from 0 to 
81.9 wt%), where 100% corresponds to the IL stock solution with a known concentration. After 5, 
15, and 30 min of exposure to each aqueous solution, the bioluminescence emission of Vibrio 
fischeri was measured and compared with the bioluminescence emission of a blank control. The 
corresponding 5 min-, 15 min- and 30 min-EC50 values (EC50 being the estimated concentration 
yielding a 50% of inhibition effect) were then determined with a 95% confidence interval, by non-
linear regression using the least-squares method to fit the data. 
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Figure 3.1.1. Chemical structures of the synthesized ILs: (i) [Et3NC4]Br, (ii) [Pr3NC4]Br, (iii) 
[Bu3NC4]Br, (iv) [MepyrNC4]Br, (v) [Pr3NC4][Sac], (vi) [Pr3NC4][Lac], (vii) [Pr3NC4][Pyr], (viii) 
Pr3NC4][Dca], (ix) [Pr3NC2][Sal] and (x) [Pr3NC4][Sal], 
ABS phase diagrams and tie-lines. Aqueous solutions of each IL ([MepyrNC4]Br, 
[Et3NC4]Br, [Pr3NC4]Br, [Bu3NC4]Br, [Pr3NC4][Pyr], [Pr3NC4][Lac], [Pr3NC2][Sal], [Pr3NC4][Sal], 
[Pr3NC4]][Sac] and [Pr3NC4][Dca]) at circa 90 wt% and aqueous solutions of the mixture 
K3C6H5O7/C6H8O7 (as a buffer solution at pH = 7.0, mole ratio of ≈ 15:1) at ≈ 50 wt% were prepared 
and used for the determination of the binodal curves. The phase diagrams were determined 
through the cloud point titration method26,27 at 25°C and atmospheric pressure. The system 
compositions were determined by the weight quantification of all components added within   10-
4 g. Further details on the experimental procedure can be found elsewhere27,28. 
Tie-lines (TLs) were determined by a gravimetric method originally proposed by Merchuk 
et al.29. Different mixture points at the biphasic region were prepared, vigorously stirred, 
centrifuged for 10 min and allowed to reach equilibrium by the separation of the phases for at 
least 10 min at 25°C. After separation of the two phases, both the top and bottom phases were 
weighted. Each individual TL was determined by application of the lever-arm rule to the 
ii iiii
iv v
vi vii viii
ix x
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relationship between the top weight phase composition and the overall system composition. The 
experimental binodal curves were correlated using Equation (3.1.1): 
[𝐼𝐿] = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]0.5) − (𝐶[𝑠𝑎𝑙𝑡]3)] (3.1.1) 
where [𝐼𝐿] and [𝑠𝑎𝑙𝑡] are the IL and the salt weight fraction percentages, respectively, and 𝐴, 𝐵, 
and 𝐶 are constants obtained by the regression of the experimental data (see Appendix E).  
The determination of the TLs was then accomplished through the solution of the following 
system of four equations (Equation (3.1.2) to (3.1.5)) aiming at determining four unknown 
values  ([𝐼𝐿]IL, [𝐼𝐿]salt, [𝑠𝑎𝑙𝑡]IL and [𝑠𝑎𝑙𝑡]salt): 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝐼𝐿
0.5) − (𝐶[𝑠𝑎𝑙𝑡]𝐼𝐿
3 )] (3.1.2) 
 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
0.5 ) − (𝐶[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
3 )] (3.1.3) 
 
[𝐼𝐿]𝐼𝐿 =
[𝐼𝐿]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝐼𝐿]𝑠𝑎𝑙𝑡 (3.1.4) 
 
[𝑠𝑎𝑙𝑡]𝐼𝐿 =
[𝑠𝑎𝑙𝑡]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡 (3.1.5) 
where the subscripts "IL", "salt" and "M" represent the top and the bottom phases and the 
mixture composition, respectively. The parameter α is the ratio between the weight of the top 
phase and the weight of the overall mixture. For the calculation of each tie-line length (TLL), 
Equation (3.1.6) was employed: 
𝑇𝐿𝐿 = √([𝑠𝑎𝑙𝑡]𝐼𝐿 − [𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡)2 + ([𝐼𝐿]𝐼𝐿 − [𝐼𝐿]𝑠𝑎𝑙𝑡)2 (3.1.6) 
Depletion of human serum albumin (HSA) and Immunoglobulin G (IgG). The ternary mixtures 
compositions used in the depletion experiments were chosen based on the phase diagrams 
determined in this work for each IL-salt-water system. Human serum was directly used as the 
aqueous solution. Each mixture was vigorously stirred, centrifuged for 10 min, and left to 
equilibrate for 10 min at 25°C to reach the HSA and IgG depletion, that precipitates at the ABS 
interface. After, a careful separation of the phases was performed and the amount of HSA and IgG 
in each phase was quantified by SE-HPLC (Size Exclusion High-Performance Liquid 
Chromatography). Each phase was diluted at a 1:10 (v:v) ratio in a phosphate buffer solution 
before injection. A Chromaster HPLC (VWR, Hitachi) coupled to an UV detector was used. SE-HPLC 
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was performed with an analytical column (25 cm  2 mm i.d., 25 m), Lichrospher 100 RP-18, 
from Merck. A 100 mM phosphate buffer in MiliQ water (mobile phase) was run isocratically with 
a flow rate of 1 mL·min-1. The temperature of the column and auto-sampler was kept constant at 
25°C. The injection volume was of 25 µL. The wavelength was set at 280 nm whereas the 
retention time of IgG and HSA was found to be circa 15.7 and 17.1 min, respectively, within an 
analysis time of 40 min. The quantification of HSA and IgG in each phase was carried out by an 
external standard calibration method (R2=0.9997 and R2=0.9991) - cf. the Appendix E with the 
established calibration curves.  
The depletion efficiency of HSA and IgG, 𝑫𝑬𝑩𝑺𝑨%, and  𝑫𝑬𝑰𝒈𝑮% are the percentage ratio 
between the amount of protein in the solid interface to that in the total mixture, and is defined 
according to Equation (3.1.7) and Equation (3.1.8): 
𝐷𝐸HSA% =
𝑤𝐻𝑆𝐴
𝐼𝑛𝑡
𝑤𝐻𝑆𝐴
𝐼𝐿 + +𝑤𝐻𝑆𝐴
𝑆𝑎𝑙𝑡 + 𝑤𝐻𝑆𝐴
𝐼𝑛𝑡   100 (3.1.7) 
𝐷𝐸IgG% =
𝑤𝐼𝑔𝐺
𝐼𝑛𝑡
𝑤𝐼𝑔𝐺
𝐼𝐿 + +𝑤𝐼𝑔𝐺
𝑆𝑎𝑙𝑡 + 𝑤𝐼𝑔𝐺
𝐼𝑛𝑡   100 
(3.1.8) 
where 𝑤𝐻𝑆𝐴
𝐼𝐿 , 𝑤𝐻𝑆𝐴
𝑆𝑎𝑙𝑡 ,𝑤𝐻𝑆𝐴
𝐼𝑛𝑡  , 𝑤𝐼𝑔𝐺
𝐼𝐿 , 𝑤𝐼𝑔𝐺
𝑆𝑎𝑙𝑡 and 𝑤𝐼𝑔𝐺
𝐼𝑛𝑡 are the total weight of HSA or IgG in the IL-rich 
aqueous phases, salt-rich aqueous phases and solid interphase, respectively. For all systems the 
top phase corresponds to the IL-rich phase whereas the bottom phase is mainly constituted by 
the citrate-based salt and water.  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Taking into 
account the UV-spectroscopy quantification of the total amount of proteins in each phase, all 
samples were diluted so that the amount of total protein in each gel lane in the SDS-PAGE was 
circa 0.5 µg. Samples of the aqueous phases of each ABS were diluted at 2:1 (v:v) in a dissociation 
buffer consisting of 2.5 mL of 0.5 M Tris-HCl pH 6.8, 4.0 mL of 10 % (w/v) SDS solution, 2.0 mL of 
glycerol, 2.0 mg of bromophenol blue and 310 mg of dithiothreitol (DTT). This overall solution was 
heated at 95°C for 5 min to denature proteins by reducing disulfide linkages, and thus overcoming 
some forms of the tertiary protein folding and breaking up the quaternary protein structure. 
Electrophoresis was run on polyacrylamide gels (stacking: 4 % and resolving: 20 %) with a running 
buffer constituted by 250 mM Tris-HCl, 1.92 M glycine, and 1 % SDS. The proteins were stained 
with Coomassie Brilliant Blue G-250 0.1 % (w/v), methanol 50 % (v/v), acetic acid 7 % (v/v) and 
water 42.9 % (v/v). All gels were placed in an orbital shaker at a moderate speed during 2-3 h at 
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room temperature. The gels were further distained in a solution containing acetic acid at 7 % 
(v/v), methanol at 20 % (v/v) and water at 73 % (v/v) in an orbital shaker at a moderate speed 
during 3-4 h at room temperature. SDS-PAGE Molecular Weight Standards, namely molecular 
weight full-range marker from VWR, were used as protein standards. All gels were analyzed using 
the Image Lab 3.0 (BIO-RAD) analysis tool. 
Molecular Docking. The interaction sites of HSA, IgG and transferrin with the IL ions were 
identified using the Auto-dock vina 1.1.2 program30. The crystal structures of HSA (PDB:1e71), IgG 
(PDB:1hzh) and Transferrin (PDB:1d3k) were used in the molecular docking, where the Auto 
DockTools (ADT)31 was used to prepare the proteins input files by merging non-polar hydrogen 
atoms, adding partial charges and atom types. Ligand (IL ions) 3D atomic coordinates were 
computed by Gaussian 03w and ligand rigid root was generated using AutoDockTools (ADT), 
setting all possible rotatable bonds defined as active by torsions. The grid center at the center of 
mass (x-, y-, and z-axes, respectively) to cover the whole interaction surface of HSA was 94 Å × 64 
Å × 90 Å, of IgG was 126 Å × 112 Å × 126 Å and of transferrin was 100 Å × 124 Å × 102 Å. The 
binding model that has the lowest binding free energy was searched out from 9 different 
conformers for each ligand (IL ions). 
3.1.4. Results and discussion 
Ecotoxicity of AGB-ILs. In order guarantee the development of more sustainable depletion 
procedures, the ecotoxicity of the AGB-based ILs was evaluated by exposition of aqueous 
solutions of each IL to marine bacterium Vibrio fischeri. EC50 values were determined after 5, 15 
and 30 min of exposure applying different concentrations of ILs. The EC50 values obtained at 30 
min are displayed in Figure 3.1.2. The EC50 data for 5 and 15 min, as well as the EC50 detailed data 
for 30 min, are given in Appendix E. After the exposure time of 30 min, the EC50 values of the 
synthesized GB-ILs decrease according to the following sequence: [MepyrNC4]Br > [Et₃NC4]Br ≈ 
[Pr₃NC4]Br > [Bu₃NC₄]Br ≈ [Pr3NC4][Pyr] > [Pr3NC4][Sac] ≈ [Pr3NC4][Dca] > [Pr3NC4][Lac] ≈ 
[Pr3NC2][Sal] > [Pr3NC4][Sal]. Since not all GB-based ILs cations and anions are common there is a 
balanced effect of both ions in bacterium luminescence deactivation. All studied ILs share the 
common central atom (N); nevertheless, the different structures synthesized allow to evaluate the 
effect of the alkyl side chain length, cyclic vs. non-cyclic cations, and anion nature.  
According to the results obtained (Figure 3.1.2.) the alkyl side chain length effect in the IL 
ecotoxic nature follows the rank: [MepyrNC4]Br < [Et₃NC4]Br ≈ [Pr₃NC4]Br < [Bu₃NC₄]Br. More 
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hydrophobic ILs, particularly with longer alkyl side chains, have a higher ability to interact and 
permeate within the membrane phospholipid bilayers, leading to a decrease on the Vibrio fischeri 
bioluminescence. In summary, ILs that exhibit longer alkyl side chains in their structure have a 
more toxic character, in agreement with the literature32. 
Figure 3.1.2. also  depicts the ecotoxicity for ILs with a common cation and different anions, 
following the rank: [Pr₃NC4]Br < [Pr₃NC4][Pyr] < [Pr3NC4][Sac] ≈ [Pr3NC4][Dca] < [Pr3NC4][Lac] < 
[Pr3NC4][Sal]. The addition of hydroxyl groups into AGB-ILs ([Lac]
- vs. [Pyr]-) increases the ecotoxic 
nature of ILs, in agreement with the literature 33. The changes in the IL polarity induced by the 
addition of aromatic rings ([Sal]- vs. [Lac]-) have no major effects towards the IL toxicity for V. 
fischeri. It should, however, be remarked that the toxic effect afforded by phenolic groups in the 
IL anion structure has not been well-understood33. Overall, in comparison to low-toxic and 
commercial ammonium based-ILs ([N4444]Br)
34, as shown in Figure 3.1.2., most AGB-ILs prepared in 
this work display an even lower toxicity. All the synthesized ILs are classifiable as harmless or 
practically harmless according to Passino and Smith35. 
 
Figure 3.1.2. EC50 values, in mg L
−1
, for 30 min of exposure of the marine bacteria Vibrio fischeri to IL 
aqueous solutions and values obtained from literature for [N4444]Br 
34
. 
Phase diagrams and tie-lines. Novel phase diagrams for several ternary systems consisting of 
glycine-betaine IL analogues + water + K3C6H5O7/C6H8O7 buffer (pH = 7.0) at 25°C and atmospheric 
pressure were determined. The respective phase diagrams are displayed in Figure 3.1.3 and Figure 
3.1.4. The corresponding experimental data are available in the Appendix E. All values considering 
the weight fraction of the phase-forming components were carried out taking into account the 
complexed water in the citrate-based salt. In all ternary phase diagrams, the biphasic and 
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monophasic regions are above and below the solubility curve, respectively. Phase diagrams with 
the lowest area above the binodal curve correspond to ILs with a lower ability to undergo phase 
separation, i.e. the IL is less easily salted-out in aqueous solution17. Figure 3.1.3 also shows the 
phase diagrams for the commercial [N4444]Br, under the same conditions. In general, most AGB-ILs 
here prepared present a higher ability to create ABS with K3C6H5O7/C6H8O7 buffer (pH = 7.0) than 
commercial tetraalkylammonium-based ILs with similar alkyl chain, i.e., they require a lower 
amount of IL and salt to undergo liquid-liquid demixing. The high hydrophobicity of ammonium-
based ILs, and particularly of the AGB-ILs studied in this work, is reflected in the larger biphasic 
area of the respective systems. 
 
Figure 3.1.3. Phase diagrams for the systems composed of IL + K3C6H5O7/C6H8O7 + H2O at 25°C and 
pH 7.0: (a) [MepyrNC4]Br (); [Et₃NC4]Br (); [Pr₃NC4]Br (); [Bu₃NC₄]Br ();[N4444]Br ()
37; (b) 
[Pr3NC2][Sal] (); [Pr3NC4][Sal] (); and adjusted binodal data through Equation 3.1.1. (
__). 
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In Figure 3.1.3a are depicted the phase diagrams for the systems composed of [Bu3NC4]Br, 
[Pr3NC4]Br, [Et3NC4]Br and [MepyrNC4]Br, and in Figure 3.1.3b for [Pr3NC2][Sal] and [Pr3PC4][Sal], 
allowing the evaluation of the cation alkyl chain length for liquid-liquid demixing. The ability of 
AGB-ILs to form ABS with the citrate-based salt follows the order: [Bu3NC4]Br > [Pr3NC4]Br > 
[Et3NC4]Br > [MepyrNC4]Br. ILs that contain cations and/or anions with longer alkyl side chains are 
of a higher hydrophobicity (lower ability to form hydration complexes) and more easily undergo 
phase separation in aqueous solution, or are salted-out by the organic salt. Therefore, [Bu3NC4]Br 
requires a lower amount of K3C6H5O7/C6H8O7 to create an ABS. In the same line, [Pr3NC2][Sal] 
displays a lower ability to promote ABS than [Pr3PC4][Sal] (Figure 3.1.3b). The trend observed is in 
agreement with previous reports28,36. Furthermore, [MepyrNC4]Br displayed the lowest capacity to 
create ABS, due to a lower number of CH2 groups than the remaining ILs shown in Figure 3.1.3a.  
Figure 3.1.4 shows the IL anion nature impact on ABS formation, following the rank: 
[Pr3NC4][Pyr] > [Pr3NC4][Lac] > [Pr3NC4]Br > [Pr3NC4][Sal] ≈ [Pr3NC4][Sac] > [Pr3NC4][Dca]. According 
to the results here presented, ABS formation is driven by the IL anion hydrogen-bond ability with 
water38.  
  
Figure 3.1.4. Phase diagrams for the systems composed of IL + K3C6H5O7/C6H8O7 + H2O at 25°C and 
pH 7.0: (a) [Pr3NC4][Pyr] (); [Pr3NC4][Lac] (); [Pr3NC4]Br (); [Pr3NC4][Sal] (); [Pr3NC4]][Sac] 
(); Pr3NC4][Dca] (); and adjusted binodal data through Equation 3.1.1. (
__). 
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In summary, the AGB-ILs here synthesized display two remarkable advantages when 
compared with commercial tetraalkylammonium-based ILs ([N4444]Br): (i) most AGB-ILs display a 
higher ability to undergo phase separation in ABS; and (ii) most AGB-ILs display a lower 
ecotoxicity. These two features contribute to the development of more sustainable and 
biocompatible separation processes.  
 
Table 3.1.1. Correlation parameters of Equation (3.1.1) used to describe the experimental binodal 
data at 25°C. 
IL + salt + water 
IL Salt A ± σ B ± σ 10
5 
(C ± σ) R
2
 
[MepyrNC4]Br 
K3C6H5O7/ 
C6H8O7 
95.36 ± 2.44 -0.245 ± 0.009 1.79 ± 1.45 0.9994 
[Et3NC4]Br 81.02 ± 4.04 -0.214 ± 0.020 2.29 ± 0.43 0.9915 
[Pr3NC4]Br 81.40 ± 1.84 -0.264 ± 0.009 3.25 ± 0.23 0.9952 
[Bu3NC4]Br 103.38 ± 2.52 -0.372 ± 0.011 6.92 ± 0.54 0.9937 
[Pr3NC4][Pyr] 91.64 ± 1.465 -0.290 ± 0.007 2.78 ± 0.17 0.9904 
[Pr3NC4][Lac] 128.16 ± 9.66 -0.268 ± 0.021 2.31 ± 0.01 0.9995 
[Pr3NC2][Sal] 138.70 ± 8.83 -0.472 ± 0.027 0.21 ± 1.39 0.9985 
[Pr3NC4][Sal] 108.30 ± 1.87 -0.403 ± 0.009 0.35 ± 1.08 0.9951 
[Pr3NC4][Sac] 93.89 ± 2.70 -0.212 ± 0.020 3.11 ± 0.36 0.9939 
[Pr3NC4][Dca] 126.75 ± 5.91 -0.875 ± 0.036 0.19 ± 5.50 0.9926 
 
The experimental data corresponding to the solubility curves were fitted using Equation 
(3.1.1), as shown in Figure 3.1.3. and Figure 3.1.4. The regression parameters estimated by least-
squares regression, standard deviations (σ) and correlation coefficients (R2) are given in Table 
3.1.1. The experimental TLs in each system, along with their respective length, and at the 
compositions for which the depletion studies of HSA and IgG were conducted, are reported in 
Table 3.1.2. 
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Table 3.1.2. Experimental TLs and TLLs of the ABS composed of IL + K3C6H5O7/C6H8O7 + H2O at 25°C. 
Weight fraction composition / (wt %) 
IL + K3C6H5O7/C6H8O7 + water 
IL [IL]IL [salt]IL [IL]M [salt]M [IL]salt [salt]salt TLL 
[MepyrNC4]Br 
57.83 4.15 30.25 24.63 4.05 44.07 66.97 
59.63 3.66 30.38 29.17 0.79 54.98 78.07 
[Et3NC4]Br 
58.23 2.38 34.65 20.05 2.85 43.86 69.20 
76.07 0.09 30.02 29.57 1.51 47.83 88.54 
[Pr3NC4]Br 
66.80 0.56 39.73 20.18 0.30 48.75 82.13 
72.38 0.20 30.22 29.57 0.19 50.51 87.96 
[Bu3NC4]Br 
60.31 2.09 25.33 19.69 1.39 31.73 65.95 
62.76 1.80 29.64 29.53 9.88E
-05
 54.35 81.85 
[Pr3NC4][Pyr] 
53.85 3.35 30.02 19.98 2.93 38.89 62.10 
68.09 1.05 30.26 30.31 0.15 53.60 85.89 
[Pr3NC4][Lac] 
57.88 8.49 32.93 22.38 9.07 35.67 55.87 
67.62 5.62 30.00 29.31 1.84 47.04 77.73 
[Pr3NC2][Sal] 
67.09 2.35 29.56 29.61 2.90E
-12
 51.08 82.92 
61.34 2.95 29.01 16.16 0.11 27.97 66.14 
[Pr3NC4][Sal] 
71.14 1.08 19.81 20.59 4.60E
-03
 28.12 76.10 
79.33 0.60 29.52 29.75 5.12E
-16
 47.03 91.92 
[Pr3NC4][Sac] 
55.17 6.12 30.16 20.06 13.79 29.18 47.37 
80.30 0.54 29.62 29.99 0.94 46.65 91.79 
[Pr3NC4][Dca] 
64.59 0.59 20.11 15.63 2.15 21.70 65.91 
80.33 0.27 30.54 29.17 0.32 46.71 92.51 
 
Depletion of human serum albumin (HSA) and Immunoglobulin G (IgG). The depletion 
efficiencies of HSA and IgG in all AGB-IL-based ABS were investigated for a common mixture 
composition in the biphasic area (30 wt% of AGB-IL, 30 wt% of K3C6H5O7/C6H8O7 and 40 wt% of 
human serum). The results obtained are displayed in Figure 3.1.5. In all systems, the top phase is 
mostly constituted by IL and water, and the bottom phase by water and the citrate-based salt. 
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Figure 3.1.5. Depletion efficiency (DEPROT%) of IgG (blue bars) and HSA (green bars) in ABS 
composed of 30 wt% of IL + 30 wt% of K3C6H5O7/C6H8O7 at 25°C and pH = 7.0. The comparison 
with other protocols is also included:  Dye-affinity chromatography (HSA) + 
immunochromatography (IgG)39 and metal-affinity chromatography39. 
The ABS constituted by [Pr3NC4][Sac] and [Pr3NC4][Dca] lead to the creation of a large solid 
interphase that also jellifies the IL-rich phase. However, even in these ABS, HSA and IgG were not 
detected in the phases, at least at levels quantifiable by SE-HPLC with an UV detector. These ILs 
are amongst the most hydrophobic (according to the ILs ability to promote ABS displayed in Figure 
3.1.4), with a low water content in the IL-rich phase at the studied mixture composition. This low 
water content seems to be the main reason behind the observed IL-rich phase jellification. 
Remarkably, all remaining ILs or ABS are able to precipitate the abundant serum proteins at the 
interphase and present well defined IL-rich and salt-rich phases. These show depletion efficiencies 
of 100% for HSA and IgG, obtained in a single-step. In all systems, the SE-HPLC chromatograms 
were applied for HSA and IgG quantification, which can confirm the absence of HSA and IgG at the 
IL-rich phase, as well as at salt-rich phase. The high hydrophobic nature of the ILs investigated 
seems to be the main responsible for the protein precipitation, favoring protein-protein 
interactions (protein-protein aggregation) in low water content environments, as shown before 
with other ABS40.  
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The depletion efficiencies obtained by IL-based ABS are higher than those by traditional 
depletion methods39,41, which are also shown in Figure 3.1.5 for comparison purposes. For 
instance, Altıntasü et al.39,41 developed a modified poly-(glycidyl methacrylate) [poly(GMA)] 
monosize beads with chelated Cu2+ ions to remove IgG from human serum, for which the metal 
affinity adsorption method allows 98.2% of IgG depletion. However, this method needs to be 
combined with the anti-HSA antibody-Sepharose column. Vestergaard et al. also described IgG 
and HSA depletion protocols39,41. For the removal of HSA, the authors applied a dye-based method 
(Cibacron Blue 3G-A Sepharose (SB)), and for IgG an immunochromatography method (sepharose 
beads cross-linked with protein G (S-PG)). Even with a high depletion efficiency (> 97%), this 
method requires 2 steps to remove each of the highly abundant proteins in serum, namely IgG 
and HSA. Thus, the IL-based ABS here reported outstands as remarkable depletion methods able 
to simultaneously perform the depletion of two highly abundant proteins.  
As previously mentioned, HSA and IgG were not found in the IL- and salt-rich phases; 
nevertheless. a low abundance protein was identified at the IL-rich phase (Figure 3.1.6). In order 
to guarantee the applicability of these new IL-based ABS for the pretreatment of samples for 
diagnosis purposes, the IL-rich phase was analyzed by SDS-PAGE. According to Figure 3.1.7, the 
protein present in IL-rich phase after the depletion procedure is identified as transferrin, 
according to the molecular weight and serum proteomic profile. Transferrin is a glycoprotein (679 
amino acids) present in human serum (2.0–3.5 g.mL-1) with a relevant physiological function that 
consists in iron transport42. Transferrin levels in human serum are higher for individuals with 
habits of alcohol consumption, being thus an important biomarker for alcohol abuse and 
dependence43,44. According to previous reports regarding the quantification of transferrin in 
human serum, sample preparation always required several steps and a long period of storage45–47. 
Attempting the development of a HPLC measurement procedure for transferrin glycoforms, 
Helanderi and co-workers developed a serum samples treatment procedure based on salt 
precipitation, storage at low temperature (overnight), and centrifugation45,46. In another work 
focused on transferrin quantification, a similar sample treatment procedure was applied47. Renner 
and Kanitz pretreated human serum samples before the transferrin quantification by ion-
exchange chromatography, additionally requiring 2 more steps of storage and centrifugation47. 
Therefore, the outstanding results here reported with IL-based ABS constituted by biocompatible 
ILs and benign organic salts prove the remarkable potential of ABS for the depletion of abundant 
proteins from human serum in a single-step, allowing to identify other low-abundance proteins 
with potential as biomarkers. 
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Figure 3.1.6. Size exclusion chromatography results of Human Serum (a); IL rich-phase (b); salt 
rich-phase (c); IgG standard solution (d); and HSA standard solution (e); corresponding to the ABS 
composed of [Bu₃NC₄]Br (30 wt%) + K3C6H5O7/C6H8O7 (30 wt%). 
  
Figure 3.1.7. SDS-PAGE of proteins on IL-rich phase of the ABS composed of (a) [MepyrNC4]Br (b) 
[Et3NC4]Br, (c) [Pr3NC4]Br, (d) [Bu3NC4]Br, (e) [Pr3NC4][Lac], (f) [Pr3NC4][Pyr], (g) [Pr3NC4]][Sac], (h) 
[Pr3NC4][Dca], (i) [Pr3NC4][Sal], (j) [Pr3NC2][Sal] and (L) human serum in PBS (1:10 (v:v, human 
serum)). 
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Molecular Docking. The molecular docking of HSA, IgG and transferrin were carried out for 
each IL ion, in order to evaluate at a molecular level the preferential depletion of HSA and IgG 
over other proteins present in serum. The role of each IL cation and anion binding on HSA, IgG and 
transferrin surfaces were studied. The IL ions bind pose with lowest absolute value of affinity 
(kcal/mol) for HSA, IgG and transferrin with [MepyrNC4]
+, [Bu3NC4]
 +, [Lac]- and [Dca]- are displayed 
in Figures 3.1.8 and 3.1.9, while the pose for all others IL ions is shown in Apendix E. Moreover, 
the molecular interactions diagrams are displayed in Apendix E. The best binding pose and 
docking affinities, interacting amino acids residues, type of interaction and geometry distance (Å) 
of each ILs ions individually are also exhibited in the Apendix E. Molecular docking analysis was 
carried out in previous works providing specific insights on the molecular interactions occurring 
between IL ions and proteins22,48,49.  
 
Figure 3.1.8. Molecular docking with AGB-IL cations of HSA and (a) [MepyrNC4]
+ or (b) [Bu3NC4]
+ ; 
IgG  and (c) [MepyrNC4]
+  or (d) [Bu3NC4]
+; and Transferrin and (e) [MepyrNC4]
+ or (f) [Bu3NC4]
+. 
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The bind pose with lowest absolute value of affinity (kcal/mol) for HSA, IgG and transferrin 
for [Bu3NC4]
+and [MepyrNC4]
+ is shown in Figure 3.1.8 to demonstrate the effect of the most 
hydrophilic and hydrophobic IL cation (according to the data given in Figure 3.1.3) on protein 
stability. The IL cation docking affinities to HSA follow the rank: [MepyrNC4]
+ > [Et3NC4]
+ = 
[Pr3NC4]
+ > [Bu3NC4]
+ > [Pr3NC2]
+; for IgG they are according to: [Bu3NC4]
+ > [MepyrNC4]
+ > 
[Pr3NC4]
+ >[Pr3NC2]
+ > [Et3NC4]
+; and for transferrin they follow the order: [MepyrNC4]
+ > [Pr3NC4]
+ 
> [Bu3NC4]
+ > [Et3NC4]
+ = [Pr3NC2]
+. No major differences have been found between the several IL 
cations and the several anions, with no well-defined trends found for the alkyl chain length effect. 
Therefore, the studied IL cations present similar interactions and interaction strength with HSA, 
IgG and Transferrin.  
A molecular docking study was also carried out to investigate the binding affinity of the IL 
anions to HSA, IgG and transferrin. In Figure 3.1.9. are depicted the [Lac]- and [Dca]- docking bind 
poses, while the others anions docking bind poses are displayed in Appendix E. The IL anion 
binding energies for the 3 proteins follows the same rank: [Sac]- > [Sal]- > [Lac]- > [Pyr]- > [Dca]- > 
Br. All IL anions show preferential interactions by hydrogen-bonding with the proteins. In 
summary, the molecular docking results allow to conclude that no specific IL-protein interactions 
are responsible for the depletion of the highly abundant proteins. It seems that the low hydrated 
environment in the IL-rich phase combined with the high salting-out effect exerted by the salt 
mostly present at the bottom phase play the major role to promote protein-protein interactions 
and their precipitation. The ions in aqueous solution may disrupt the hydration layer on the 
protein surface, inducing the depletion of the highly abundant proteins in serum (HSA and IgG), 
enabling low abundant proteins, in particular Transferrin, to be maintained in the IL-rich phase. 
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Figure 3.1.9. Molecular docking with AGB-IL cations for HSA and (a) [Lac]- or (b) [Dca]-; for IgG and 
(c) [Lac]- or (d) [Dca] -; and for transferrin and (e) [Lac]- or (f) [Dca] -. 
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3.1.5. Conclusions  
The depletion of HSA and IgG using a cost-effective method based on ABS formed by AGB-ILs 
and a salt is here proposed. Novel AGB-ILs were synthesized and characterized, and further used 
as phase-forming agents combined with K3C6H5O7/C6H8O7 to create two-phase systems. The 
respective ABS phase diagrams, tie-lines and tie-line lengths were initially determined at 25°C. All 
studied ABS induce the simultaneous depletion of HSA and IgG. Remarkable depletion efficiencies 
of 100% of HSA and IgG were obtained in a single-step, allowing to identify low-abundance 
proteins in the IL-rich phase, such as transferrin. The IL-based ABS depletion method here 
developed provides higher depletion efficiencies and requires less steps than more traditional 
depletion methods. According to results here achieved, IL-based ABS represent a sustainable and 
cost-effective alternative for the pretreatment of biological samples.  
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3.2. Concentration of tumour biomarkers for an early-stage diagnosis of prostate cancer 
using ionic-liquid-based aqueous biphasic systems 
This chapter is based on an unpublished work with the following authors involved 
Matheus M. Pereira, João D. Calixto, Ana C. A. Sousa, Bruno J. Pereira, Álvaro S. Lima, João A. P. 
Coutinho and Mara G. Freire 
3.2.1. Abstract 
Prostate cancer (PCa) is the second most common type of cancer in men, being responsible for 
more than 300,000 annual deaths. Prostate specific antigen (PSA) quantification in serum is still 
the “gold standard” procedure for an initial screening on PCa. Immunoassays are commonly used 
for PSA quantification, therefore requiring an extensive sample processing and the use of 
sophisticated technical equipment, not available in all laboratories, particularly in those from 
developing nations where PCa mortality is higher. Furthermore, the current diagnosis methods 
require the collection of blood; yet, PSA also occurs in other biological fluids, including urine. This 
work aims to develop a cost-effective method for the extraction and concentration of PSA from 
urine samples using aqueous biphasic systems (ABS) composed of Good’s buffers ionic liquids (GB-
ILs). Initially, the phase diagrams of a set of aqueous biphasic systems were determined and their 
ability to extract PSA ascertained. The protein-friendly properties of GB-ILs were confirmed by 
molecular docking analysis, showing that the IL ions binding sites are far from the PSA catalytic 
center. After demonstrating that PSA can be completely extracted to the IL-rich phase in a single 
step, with no losses of protein, the applicability of the investigated ABS for the concentration of 
PSA was evaluated, first from model aqueous solutions and afterwards from urine samples. The 
obtained results demonstrated that it is possible to extract and concentrate PSA up to 250 times 
in a single-step. Given the high concentration factors achived, the quantification of PSA may be 
performed in urine samples using less expensive laboratory equipment and methods. Overall, 
these new ABS can be foreseen as alternative and cost-effective platforms for the extraction and 
concentration of cancer biomarkers from non-invasive samples (urine), while allowing their 
identification and quantification by more expedite equipment.  
3.2.2. Introduction 
Prostate cancer (PCa) is the second most common type of cancer in men and the fifth leading 
cause of cancer death worldwide, with the highest mortality rates found in the Caribbean and 
Southern and Middle Africa1. Age is considered the greatest risk factor2,3 with 97% of PCa cases 
occuring in men over 50 years old. Thus, in an aging society, the incidence of PCa is likely to 
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increase. In order to decrease the burden associated with the increasing incidence of PCa, 
effective diagnosis and treatment monitoring are of utmost relevance. 
In the last decades, the importance of biomarkers in cancer diagnosis and prognosis 
increased significantly4. A wide range of cancer biomarkers are currently used in clinical practice, 
and are approved by the Food and Drug Administration (FDA)5. For prostate cancer, the “gold 
standard” biomarker is the prostate-specific antigen (PSA). This glycoprotein, produced by the 
prostate gland, is usually found at higher levels in the blood of prostate cancer patients. It was 
approved by FDA as a biomarker of PCa in 1986 in the United States, and since then it has been 
used for the early-stage diagnosis of PCa. Over more recent years, conflicting studies have 
debated the accuracy of PSA as a biomarker, mainly as a consequence of overdiagnosis6. 
Nevertheless, PSA is still the most reliable clinical biomarker recurrently used in PCa diagnosis7, 
before proceeding to more invasive diagnostic tests, such as transrectal ultrasound (TRUS) guided 
biopsy. Currently, there are several commercial techniques for the PSA quantification in blood 
samples, but they generally require the use of  immunoassay-specific antibodies and skilled 
technical operators8–11.  
In addition to blood, PSA can also be found in other human fluids, including semen and urine. 
Some authors proposed the use of urinary PSA levels as a useful biomarker for the differential 
diagnosis  of PCa, particularly when serum PSA levels are between  2.5 and 10 ng.mL-1, the so 
called “grey zone”, in which the differentiation between PCa and benign prostate hyperplasia 
(BPH) is difficult12. Furthermore, urine biomarkers possess a set of unique advantages, mainly 
associated to the non-invasive collection of urine, further reducing sampling costs and the need of 
trained personnel to collect samples. Thus, the evaluation of PSA levels in urine using simpler and 
cost-effective techniques is highly desirable for PCa screening. However, in order to quantify PSA 
using equipment not based on immunoassays, such as size-exclusion HPLC (SE-HPLC), it is 
necessary to perform the pretreatment of the urine sample to increase its levels. However, the 
total recovery and simultaneous concentration of PSA is not an easy task given the labile nature of 
proteins. In this context, it is required to find cost-effective alternatives to traditional liquid-liquid 
extraction strategies, which in the past mainly comprised organic-solvent-water systems or 
polymer-based aqueous biphasic systems (ABS)13,14. ABS are formed by two structurally different 
compounds that undergo phase separation when dissolved in water above given concentrations. 
Although these systems are seen as amenable media for proteins due to their high water content 
(up to 70-90%), they display a high viscosity, which hinders the mass transfer and also lead to a 
slower phase separation, and a limited polarity range between the two phases, hampering high 
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extraction efficiencies and high selectivity to be achieved in one-step. This limited tailoring of the 
phase polarities can be however overwhelmed by the introduction of ionic liquids (ILs) as phase-
forming components of ABS15–17. ILs belong to the molten salts group (with melting temperatures 
below 100°C) and are usually constituted by a large organic cation and an inorganic/organic 
anion18. Due to their large chemical diversity and high number of possible cation-anion 
combinations, the ABS phases’ polarities can be tailored by an appropriate choice of the IL ions16. 
Therefore, it is expected that IL-based ABS can be properly designed for the effective extraction of 
a multitude of proteins, while being able to keep their native form and stability. However, most of 
the ILs investigated up to date for the formation of IL-based ABS to carry out extraction of 
proteins are of low biocompatible nature and do not allow the pH control16, a crucial request 
when aiming the total recovery and the stability maintenance of protein biomarkers such as PSA. 
To both increase the biocompatible nature and the control of the medium pH, ionic liquids 
derived from biological Good’s buffers (GBs)19–21, with self-buffering characteristics, appear as 
promising alternatives22. Up to date, no works have been published aiming the extraction of PSA 
(or other cancer biomarkers) with IL-based ABS, and to the best of our knowledge, there is only 
one work in which the PSA partition coefficient using polymer-based ABS23 was addressed, but 
with limited results23. The main goal of this work is to develop a new pretreatment strategy for 
increasing the concentration of PSA from human urine samples using IL-based ABS, so that the 
cancer biomarker at the IL-rich phase may be detectable and quantified using less laborious 
techniques. 
3.2.3. Experimental procedures 
Materials. Potassium citrate tribasic monohydrate (K3C6H5O7·H2O, purity ≥ 99 wt%) was 
obtained from Sigma-Aldrich Chemical Co. (USA). Prostate Specific Antigen from human semen 
(purity ≥ 95 %) was obtained from Sigma-Aldrich Chemical Co. Methanol (purity > 99.9%) was 
obtained from Fisher Scientific. Acetonitrile (purity > 99.7%) was supplied from Lab-Scan. The 
buffers required for the ILs synthesis, namely n-Cyclohexyl-2-aminoethanesulfonic acid (CHES, 
purity > 99 wt%), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, purity > 99.5 wt%), 
2-(N-morpholino)ethanesulfonic acid (MES, purity> 99 wt%), n-(Tri(hydroxymethyl)methyl)glycine 
(Tricine, purity > 99 wt%) and 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-
yl]amino]ethanesulfonic acid (TES, purity > 99 wt%) were purchased from Sigma-Aldrich Chemical 
Co. The cation precursor, tetrabutylphosphonium hydroxide ([P4444][OH], 40 wt% in H2O) was 
supplied by Sigma–Aldrich Chemical Co. Tetramethylsilane (TMS, purity > 99.9 wt%) and 
deuterium oxide (D2O purity > 99.9 wt%) were obtained from Sigma–Aldrich Chemical Co. Purified 
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water passed through a reverse osmosis and a Milli-Q plus 185 water purifying system was used in 
all experiments. For the quantification of PSA using the BLItz Pro System, Super Streptavidin 
biosensors acquired from VWR were used. 
Synthesis of Good-buffers-ionic liquids (GB-ILs). The GB-ILs ([P4444][MES], [P4444][TES], 
[P4444][CHES], [P4444][HEPES] and [P4444][Tricine] – chemical structures and complete descriptions 
(given in Figure 3.2.1) were synthesized via neutralization of the base with the appropriate acid, 
according to previously reported protocols22. Briefly, a slightly excess of an equimolar aqueous 
solution (1:1.1) of buffer was added drop-wise to a tetrabutylphosphonium hydroxide solution. 
The mixture was stirred continuously for at least 12 h at room temperature (≈ 25°C) to produce 
the IL and water as by-product. The mixture was then subjected to 50-60°C under reduced 
pressure, resulting in a viscous liquid. A mixture of acetonitrile and methanol (1:1, v:v) was added 
and vigorously stirred at room temperature for 1 h. The solution was then filtered to remove any 
excess buffer. The organic solvents were evaporated and the GB-IL products dried under vacuum 
(10 Pa) for 3 days at room temperature. The water content in each GB-IL was measured by Karl-
Fischer (KF) titration, using a KF coulometer (Metrohm Ltd., model 831) – data given in Appendix 
F. The chemical structures or purity of the GB-ILs were confirmed by 1H and 13C NMR spectroscopy 
(Bruker AMX 300) operating at 300.13 and 75.47 MHz, respectively. Chemical shifts are expressed 
in δ (ppm) using tetramethylsilane (TMS) as internal reference and D2O as deuterated solvent. The 
ILs synthetized in this work showed high purity levels without signs of decomposition. The 
chemical structures of the synthesized ILs are shown in Figure 3.2.1., while the respective 1H and 
13C NMR spectra are provided in Appendix F. 
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Figure 3.2.1. Chemical structures of the studied GB-ILs: (i) [P4444][MES]; (ii) [P4444][TES]; (iii) 
[P4444][CHES]; (iv) [P4444][HEPES]; (v) [P4444][Tricine]. 
Phase diagrams and tie-lines. To ascertain the mixture compositions required to form two-
phase systems that can be used as extraction/concentration platforms, the binodal curve of each 
ABS were initially determined through the cloud point titration method16 at 25°C (± 1°C) and 
atmospheric pressure. Aqueous solutions of K3C6H5O7 at circa 60 wt % and aqueous solutions of 
the different ILs (≈ 80 wt %) were prepared and used for the determination of the binodal curves, 
followed by the drop-wise addition of water until the finding of the monophasic region. The 
(i) (ii)
(iii) (iv)
(v)
3. IL-based abs as effective concentration and purification tools for cancer biomarkers 
130 
opposite procedure also was carried out to better describe the binodal curves, particularly at the 
salt-rich region, which is of extreme relevance to deal with ABS as concentration strategies. The 
ternary system compositions were determined by weight quantification within ± 10-4 g. The 
experimental binodal curves at 25°C were fitted by Equation (3.2.1)24: 
 
[𝐼𝐿] = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]0.5) − (𝐶[𝑠𝑎𝑙𝑡]3)] (3.2.1) 
where [𝐼𝐿] and [𝑠𝑎𝑙𝑡] are the IL and the salt weight fraction percentages, respectively, and 𝐴, 𝐵, 
and 𝐶 are constants obtained by the regression of the experimental data.  
Tie-lines (TLs), i.e. the composition of each phase for a given initial mixture composition at 
the biphasic region, were determined through the solution of the following system of four 
equations (Equation (3.2.2) to (3.2.5)) with four unknown values  ([𝐼𝐿]IL, [𝐼𝐿]salt, [𝑠𝑎𝑙𝑡]IL and 
[𝑠𝑎𝑙𝑡]salt): 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝐼𝐿
0.5) − (𝐶[𝑠𝑎𝑙𝑡]𝐼𝐿
3 )] (3.2.2) 
 
[𝐼𝐿]𝑠𝑎𝑙𝑡 = 𝐴𝑒𝑥𝑝[(𝐵[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
0.5 ) − (𝐶[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡
3 )] (3.2.3) 
 
[𝐼𝐿]𝐼𝐿 =
[𝐼𝐿]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝐼𝐿]𝑠𝑎𝑙𝑡 (3.2.4) 
 
[𝑠𝑎𝑙𝑡]𝐼𝐿 =
[𝑠𝑎𝑙𝑡]𝑀
𝛼
−
1 − 𝛼
𝛼
[𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡 (3.2.5) 
where the subscripts "IL", "salt" and "M" represent the top and the bottom phases and the 
mixture composition, respectively. The parameter α is the ratio between the weight of the top 
phase and the weight of the overall mixture. The respective tie-line lengths (TLLs were 
determined by Equation (3.2.6): 
𝑇𝐿𝐿 = √([𝑠𝑎𝑙𝑡]𝐼𝐿 − [𝑠𝑎𝑙𝑡]𝑠𝑎𝑙𝑡)2 + ([𝐼𝐿]𝐼𝐿 − [𝐼𝐿]𝑠𝑎𝑙𝑡)2 (3.2.6) 
Extraction of Prostate Specific Antigen (PSA) using IL-based ABS. An initial screening on the 
several ILs performance and mixture compositions was carried out, particularly to appraise the 
ABS ability to extract PSA from aqueous solutions without protein losses. To this end, different 
ABS, involving all the prepared ILs, and two mixture compositions (30 wt% salt + 30 wt% IL + 40 
wt% H2O and 30 wt% salt + 40 wt% IL + 30 wt% H2O) were studied to evaluate the effect of the 
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concentration of the phase-forming components. Aqueous solutions of PSA at concentrations 
circa 50 ng.mL-1 were used as the “water” added to each ABS. The used PSA concentration was 
chosen after optimization using the BLItz® Pro system. This type of quantification was chosen 
since it allows also to address the PSA stability and activity, since only active PSA binds with PSA-
antibody. After, a careful separation of the phases was performed and the amount of PSA in each 
phase was quantified using the BLItz® Pro system equipment, by an external standard calibration 
method using protein concentrations ranging from 1 to 100 ng.mL-1 (calibration curve given in 
Appendix F). At least three independent ABS were prepared and 2 samples of each phase 
quantified. The percentage extraction efficiency of PSA (𝑬𝑬𝑷𝑺𝑨%) is the percentage ratio 
between the amount of PSA in the IL-rich aqueous phase to that in the total mixture, and is 
defined according to Equation (3.2.7): 
𝐸𝐸PSA% =
𝑤𝑃𝑆𝐴
𝐼𝐿
𝑤𝑃𝑆𝐴
𝐼𝐿 + 𝑤𝑃𝑆𝐴
𝑆𝑎𝑙𝑡   100 (3.2.7) 
where 𝑤𝑃𝑆𝐴
𝐼𝐿  and 𝑤𝑃𝑆𝐴
𝑆𝑎𝑙𝑡 are the total weight of PSA in the IL-rich and in the salt-rich aqueous 
phases, respectively. In all systems the top phase corresponds to the IL-rich phase whereas the 
bottom phase is mainly constituted by the salt and water. 
Lever-arm Rule. The lever-arm rule was used to determine the weight percentages ratio of 
the coexisting phases in the respective phase diagrams for given mixture compositions. Several 
extractions were carried out at different compositions in the same TL, allowing to work with 
different concentration factors. A fixed and long TL was initially selected, and the lever-arm rule 
was used to determine the weight fraction of each phase-forming component (IL and K3C6H5O7) to 
be used in each extraction corresponding to a given concentration factor (CF). The CF is defined as 
the ability along the same TL to maintain the composition of each phase while varying only the 
volume or weight ratio of the phases. Several ternary mixtures were prepared within the biphasic 
region with the “theoretical” weight percentages of salt, IL and H2O/PSA, corresponding to CF of 
5, 20, 50, 100, 150, 200 and 250-fold. ABS were first prepared as a control without adding PSA, 
and once achieved the CF of 250-fold, the extractions were performed adding an aqueous 
solution of PSA at a concentration of 150 ng. mL-1 (the cut-off value found in urine12). Each 
mixture was vigorously stirred, centrifuged for 10 min, and left to equilibrate for at least 10 min at 
(25 ± 1)°C. 
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Size-exclusion HPLC (SE-HPLC). After a careful separation of the phases, both were analyzed 
by SE-HPLC. Each phase was diluted at a 1:9 (v:v) ratio in a phosphate buffer solution before 
injection. A Chromaster HPLC (VWR Hitachi) was used. The SE-HPLC was performed on an 
analytical column Shodex Protein KW- 802.5 (8 mm x 300 mm). A 100 mM phosphate buffer + 
NaCl 0.3 M was run isocratically with a flow rate of 0.5 mL.min-1. The column oven and 
autosampler temperatures were kept at 25°C and at 10°C, respectively. The injection volume was 
25 μL. The wavelength was set at 280 nm using a DAD detector. The obtained chromatograms 
were treated and analyzed using the OriginPro8 software. 
Molecular Docking. The interaction sites of PSA with the GB-ILs ions were identified using the 
Auto-dock vina 1.1.2 program25. The crystal structure of PSA (PDB:1hrc) was adapted and used in 
the molecular docking. Auto DockTools (ADT)26 was used to prepare the protein input files by 
merging non-polar hydrogen atoms, adding partial charges and atom types. Ligand (GB-IL cation 
and anions) 3D atomic coordinates were computed by Gaussian 03w and ligand rigid root was 
generated by AutoDockTools (ADT), setting all possible rotatable bonds defined as active by 
torsions. The grid center at the center of mass (x-, y-, and z-axes, respectively) to cover the whole 
interaction surface of PSA was 86 Å × 100 Å × 86 Å. The binding model that has the lowest binding 
free energy was searched out from 9 different conformers for each ligand (GB-ILs cation and 
anions).  
3.2.4. Results and discussion 
Phase diagrams and tie-lines. The ABS phase-diagrams at 25°C and at atmospheric pressure, 
for the systems composed of water, K3C6H5O7 and GB-ILs, are illustrated in Figure 3.2.2. The 
experimental data are shown in weight fraction to allow a direct screening of the mixture 
compositions required to form two-phase systems to further carry out the PSA extraction and 
concentration. 
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Figure 3.2.2. Phase diagrams for the systems composed of GB-IL + K3C6H5O7 + H2O at 25°C: 
[P4444][Tricine] (); [P4444][HEPES] (); [P4444][TES] (); [P4444][MES] (); [P4444][CHES] (); and 
adjusted binodal data through Equation 3.2.1 (__). 
In all ABS, the biphasic region is positioned above the solubility curve while the monophasic 
region is localized below. Diagrams with the largest area above the binodal curve have therefore a 
higher ability to form two phases, i.e. the IL is more easily salted-out by the salt. The citrate-based 
salt used is composed of a trivalent charged anion and is a strong salting-out species according to 
the Hofmeister series27. Therefore, it has a high affinity for water, and thus, there is a preferential 
exclusion of the IL ions from the aqueous solution, promoting the two-phases separation. 
Since the salt, temperature, pressure and pH are constants in the studied two-phase systems, 
the ABS formation ability is a result of the type of IL. For instance, at 10 wt% of K3C6H5O7, the 
ability of GB-ILs to create ABS follows the order: [P4444][CHES] > [P4444][MES] > [P4444][HEPES] ≈ 
[P4444][TES] > [P4444][Tricine]. The ILs investigated are formed by a tetrabutylphosphonium ([P4444]
+) 
cation and GB-derived anions. The cation is the same for all the investigated ILs and its effect 
cannot be appraised from the obtained phase diagrams. However, it was already demonstrated 
that [P4444]-based ILs display a high ability to promote the phase split when compared with 
ammonium-, pyridinium- and imidazolium-based ionic liquids28. [P4444]-based salts have highly 
shielded charges, located mostly on the heteroatom surrounded by four alkyl chains, thus leading 
to a higher tendency towards their salting-out from aqueous media. On the other hand, the 
anions have a higher aptitude for creating hydration complexes because they are more 
polarizable and present more diffuse valence electronic distribution29. This means that anions, 
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when compared with cations, have a more relevant influence in ABS formation and behavior. 
Anions with lower hydrogen-bond basicity values present lower ability to form coordinative 
hydrogen-bonds and to create hydration complexes, and therefore are more easily salted-out by 
conventional salts29. The hydrogen-bond basicity values for the ILs used in this work have not 
been reported up to date; yet, relevant conclusions can be achieved using the octanol-water 
partition coefficients (Kow) of each GB. The higher the value of log(Kow) the higher the affinity of 
the anion for the octanol-rich phase, meaning that it has a lower affinity for the water-rich phase 
and to be hydrated. In this context, higher log(Kow) values correspond to anions that are more 
easily separated by a salting-out phenomenon. As expected, the ILs composed of anions with –OH 
groups and lower values of log(Kow) ([Tricine]-: -5.25; [TES]-: -4.48; [HEPES]-: -3.11)30 are those 
that correspond to ILs that are more distant from the axis in Figure 3.2.2. Thus, these GB-ILs 
require higher amounts of salt for phase separation. On the other hand, GBs with no –OH groups 
display higher log(Kow) values ([MES]-: -2.48; [CHES]-: -0.59)30 reflecting their lower aptitude to 
hydrogen-bond with water and higher ability for liquid-liquid demixing in ABS. 
The detailed experimental data corresponding to the ternary phase diagrams with the 
compositions of the coexisting phases are presented in Appendix F. For the studied systems, the 
experimental binodal data were fitted by the empirical relationship described by Equation (3.2.1). 
The regression parameters A, B and C, were estimated by the least-squares regression method, 
and their values and corresponding standard deviations (σ), as well as the respective tie-lines and 
tie-line lengths are provided in Table 3.2.1. and Table 3.2.2.  
Table 3.2.1. Correlation parameters of Equation (3.2.1) used to describe the experimental binodal 
data at 25°C. 
IL + salt + water 
IL Salt A ± σ B ± σ 105 (C ± σ) R2 
[P4444][MES]  
K3C6H5O7 
98.33 ± 0.54  -0.327 ± 0.022  3.96 ± 0.06  0.9996  
[P4444][CHES]  111.92 ± 2.49  -0.450 ± 0.009  10.50 ± 0.44  0.9929  
[P4444][HEPES]  105.17 ± 1.19  -0.295 ± 4.257  2.78 ± 0.08  0.9978  
[P4444][Tricine]  105.15 ± 5.10  -0.248 ± 0.016  1.71 ± 0.02  0.9992  
[P4444][TES]  99.63 ± 0.51  -0.356 ± 0.007  5.40 ± 0.29  0.9971  
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Table 3.2.2. Experimental TLs and TLLs of the ABS composed of IL + K3C6H5O7 + H2O at 25°C. 
Weight fraction composition / (wt %) 
IL + K3C6H5O7 + water 
IL [IL]IL [salt]IL [IL]M [salt]M [IL]salt [salt]salt TLL 
[P4444][MES] 
65.71  1.51  29.42  20.48  2.89  34.36  70.89  
90.81  0.06  29.36  30.33  0.37  44.12  100.60  
94.29  0.01  30.21  39.87  0.27.10-3  58.64  111.04  
[P4444][CHES] 
67.45  1.26  29.70  19.83  0.11  34.38  75.04  
75.58  0.76  29.64  30.25  0.17×10-4  49.27  89.81  
93.56  0.16  30.11  39.95  0.18×10-8  58.83  110.44  
[P4444][HEPES] 
57.51  4.14  29.89  20.14  6.59  33.63  57.80  
83.11  0.63  30.24  29.49  0.95  46.00  93.84  
90.97  0.24  29.72  40.13  0.03  59.46  108.52  
[P4444][Tricine] 
52.11  7.75  30.08  24.73  4.42  44.50  60.20  
70.02  2.64  30.45  29.71  2.53  48.78  81.75  
94.31  0.19  29.78  40.11  0.54  58.20  110.26  
[P4444][TES] 
50.61  5.97  30.28  19.70  0.39  39.87  60.59  
93.58  0.05  30.69  29.89  0.08  44.32  103.45  
96.00  0.02  30.43  39.48  0.11×10-3  57.80  112.05  
 
Extraction and concentration of prostate specific antigen (PSA). The extraction efficiencies 
of PSA in ABS composed of [P4444][GB] + K3C6H5O7 at given mixture compositions are shown in 
Table 3.2.3. PSA was added to each system as an aqueous solution at a concentration circa 50 
ng.mL-1. The obtained results show the absence of PSA in the bottom phase, demostrating that 
PSA is completely extracted to the top phase (IL-rich) in all the studied systems. Furthermore, only 
small losses of PSA were obtained. In fact, because PSA is a labile protein some denaturation is 
possible. Nevertheless, as displayed in Appendix F the mass balance of protein reveals losses of 
PSA below 10%. Given that only those systems with the lowest losses (<5%) were selected for the 
future concentration step, these values are negligible and will not have an impact in the PSA 
quantification by SE-HPLC. To optimize the procedure, several ABS without PSA were prepared at 
different compositions along the same TLL (Figure 3.2.3) in order to reduce the IL-rich phase and 
to attain the required CF. The representation of each system with the corresponding TLs and real 
CF is depicted in Appendix F. With the exception of [P4444][Tricine], concentration factors up to 
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250-fold were achieved for all the IL-based ABS investigated. [P4444][Tricine] is the most 
hydrophilic GB-IL used in this work and, the respective phase diagram is the farthest from the axis. 
Consequently, it has a smaller biphasic region and the theoretical information provided by the 
lever-arm rule is only valid up to concentration factors of 150-fold. 
Table 3.2.3. Extraction efficiency of PSA (EEPSA%) at 25° C in the ABS composed of ILs and K3C6H5O7. 
IL 
Weight fraction composition / 
(wt %)  EEPSA% 
[IL]IL [salt]IL 
[P4444][MES] 
30.35 ± 0.15  30.84 ± 0.53  100  
30.01 ± 0.04  40.03 ± 0.14  100 
[P4444][CHES] 
30.13 ± 0.25  30.54 ± 0.63  100 
29.94 ± 0.13  40.12 ± 0.57  100 
[P4444][HEPES] 
30.16 ± 0.35  30.44 ± 0.29  100 
30.09 ± 0.34  39.97 ± 0.27  100 
[P4444][Tricine] 
30.90 ± 0.28  30.70 ± 0.31  100 
30.37 ± 0.17  39.98 ± 0.07  100 
[P4444][TES] 
29.95 ± 0.24  30.08 ± 0.69  100 
30.63 ± 0.37  39.85 ± 0.17  100 
After validating the CF achievable with each system, the procedure was repeated by adding 
an aqueous solution of PSA (at 150 ng/mL) for the mixtures able to lead to a CF of 250. These 
mixture compositions allow to reduce the volume of the IL-rich phase down to a minimum 
capable of concentrate PSA in a factor of interest while allowing its detection and quantification 
by SE-HPLC. CFs of 250-fold were also achieved in the presence of PSA for all ABS, except for that 
composed of [P4444][Tricine]. The CFs were experimentally confirmed by weighting both the IL-rich 
phase and the aqueous solutions containing PSA (Appendix F). For comparison the HPLC spectrum 
of an aqueous solution of pure PSA is also provided, with the PSA peak appearing 13.5 minutes 
under the operational conditions used (Figure 3.2.5). The HPLC peak corresponding to PSA is not 
seen in the bottom phase of any extraction. However, the system composed of [P4444][Tricine] 
results in no peak of PSA detectable by HPLC since the CF of 250-fold was not achieved with this 
system. In addition, a tendency is clearly seen in the HPLC spectra; the peak intensity, and thus, 
the PSA concentration, decreases in the following order: [P4444][CHES] > [P4444][MES] > [P4444][TES] 
> [P4444][HEPES] > [P4444][Tricine]. This trend is in close agreement with the PSA losses discussed 
before and that depend on the hydrophobic character of each IL. It is possible to see that the 
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most intense peak corresponds to the more hydrophobic IL, [P4444][CHES], with the highest 
log(Kow) value and thus this IL is the most promising one to be used in PSA extraction and 
concentration from real urine samples. 
 
Figure 3.2.3. Schematic representation of lever-arm rule for the systems composed of [P4444][MES]  
+ K3C6H5O7 + H2O at 25°C, and adjusted binodal data through Equation (3.2.1) (
__). 
Molecular docking. Aiming at elucidating the molecular interactions that drive the 
remarkable extraction efficiency of PSA to IL-rich phase, it was carried out a molecular docking 
analysis. Binding sites of each GB-IL ions in PSA were selected from the lowest binding energy 
structure amongst 9 different chemical conformers. PSA is a 30 kDa serine protease (kallikrein 
family)31, with a proteolytic mechanism based on three amino acids (HIS57/ASP102/SER195) that 
constitute PSA catalytic triad32. 
The lowest absolute value of affinity bind pose (kcal/mol) for all GB-ILs ions ([P4444]
+,[CHES]-, 
[MES]-, [TES]-, [HEPES]- and [Tricine]-) and the molecular interactions diagrams are exhibited in 
Appendix F. The best binding pose and docking affinities, interacting amino acids residues, type of 
interaction and geometry distance (Å) of each GB-IL ion also are provided in Appendix F. All GB-ILs 
studied in this work are constitued by a coomom tetrabutylphosphonium-based cation; therefore, 
the docking affinity values of GB-ILs on PSA were ranked according to IL anion, following the 
sequence: [TES]- > [MES]- > [CHES]- > [HEPES]- > [Tricine]-. According to docking affinity values, all 
anions present higher binding energies than [P4444]
+ (-3.1 kcal/mol), with exception of [Tricine]- 
that displays the same docking affinity energy (Appendix F). 
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Figure 3.2.4. Catalytic triad and molecular docking of PSA with GB-IL ions: (a) PSA Catalytic triad, 
(b) [P4444]
+, (c) [CHES]-, and (d) [MES]-. 
The specific interactions (hydrogen bonding, electrostatic and hydrophobic interactions) 
between the GB-IL ions and PSA amino acids residues were also analyzed by molecular docking. In 
Figure 3.2.4 the PSA catalytic triad and binding of [P4444]
+ and [CHES]- are displayed. According to 
the results obtained, GB-IL anions bind amino acids residues not surrounding the PSA catalytic 
triad, with the exception of [MES]- that binds in SER195. On the other hand, in Figure 3.2.4c the 
[CHES]- best binding position is also presented. [CHES]- binds adjacent to PHE95, SER192 and 
GLY193. The anions [TES]-, [CHES]-, [HEPES]- and [Tricine]- display binding sites in amino acids 
residues that do not affect the PSA stability (Appendix F). Overall, the molecular docking results 
disclose that the synthesized GB-ILs do not exibit specific interactions with the PSA catalytic site, 
being therefore protein-friendly. 
Extraction and concentration of prostate specific antigen (PSA) from human urine. It has 
been demonstrated that PSA can be concentrated up to 250-fold in ABS composed of K3C6H5O7 
and [P4444][CHES], [P4444][MES], [P4444][HEPES] or [P4444][TES]. However, HPLC analyses of the IL-rich 
phase reveal a tendency for obtaining higher peaks with the ABS composed of more hydrophobic 
GLY193
SER192
PHE95
(A)
(B)
(C)
ASP102
HIS57
SER195
(D)
SER195
3. IL-based abs as effective concentration and purification tools for cancer biomarkers 
139 
GB-ILs, meaning lower losses of protein. Taking into account these results, [P4444][CHES] was the IL 
selected to  extract and concentrate (CF = 250) PSA from real human urine samples.  
At first we analyzed PSA in pure water and afterwards we evaluated the extraction and 
concentration of PSA in real human urine samples donated by healthy volunteers (male and 
female). The top and the bottom phases were analyzed by SE-HPLC, together with a sample of 
pure PSA in water and human urine for terms of comparison. Because women do not produce 
PSA, the female urine sample maybe regarded as a negative control. As expected, the analysis of 
the female urine sample revealed no peak in both phases (see Appendix F). The SE-HPLC profile of 
pure PSA in water, of human urine from a healthy man and of the top and bottom phases of an 
extraction performed with [P4444][CHES] + salt + urine is depicted in Figure 3.2.5. The peak of 
standard PSA in aqueous solution appears at 13.5 min. No peak corresponding to PSA can be 
observed in the urine sample (Figure 3.2.5b) from a healthy male donor as its levels cannot be 
identified by SE-HPLC. Remarkably, after extraction and concentration, the PSA peak is clearly 
seen in the top phase of the [P4444][CHES]-based ABS (Figure 3.2.5.c), while it is not found in the 
respective bottom phase (Figure 3.2.5.d). Therefore, PSA from healthy male donors has been 
extracted to the GB-IL-rich phase and concentrated up to a factor that allows it to be analyzed by 
SE-HPLC.  
The HPLC profiles also revealed that there is another small peak, between 16 and 17 min. A 
previous study already revealed a similar profile of PSA by SE-HPLC, where this small band was 
identified as bPSA33. PSA is a glycoprotein that can be found in different forms, and the levels of 
those different forms and their respective ratio have been used in PCa differential diagnosis 33. 
Thus, our system composed of GB-ILs is able not only to concentrate PSA but also bPSA which 
opens new perspectives for the use of IL-GB-based ABS in PCa differential diagnosis.  
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Figure 3.2.5. SE-HPLC profile of pure PSA in aqueous solution, human urine (from a healthy male 
donor) and in the top and bottom phases of an ABS composed of [P4444][CHES] + salt + human 
urine: (a) PSA in aqueous solution (150 mg/ml); (b) Urine sample; (c) IL rich-phase (pure urine); (d) 
Salt rich-phase (pure urine); (e) IL rich-phase (150 ng/mL of PSA added to urine); (f) Salt rich-phase 
(150 ng/mL of PSA added to urine). 
 
3.2.5. Conclusions  
In this work we described the ability of IL-based ABS to act as concentration platforms of PSA 
from urine samples.  GB-ILs were synthesized and the respective phase diagrams, tie-lines and tie-
line lengths were determined. The ability of GB-ILs to form ABS follows the order: [P4444][CHES] > 
[P4444][MES] > [P4444][HEPES] ≈ [P4444][TES] > [P4444][Tricine]. In all the studied ABS systems, PSA 
migrates to the IL-rich phase. Remarkable extraction efficiencies of 100% were obtained in a 
single-step. Molecular docking results demonstrate that GB-ILs do not interact with the PSA 
catalytic site and therefore are protein-friendly. The most promising ABS were finally used to 
concentrate PSA from human urine samples, for which a concentration factor was successfully 
achieved allowing its quantification by more expedite equipment. Furthermore, the urine samples 
pretreatment with ABS allowed to detect a peak that probably corresponds to different forms of 
PSA. The possibility to extract and concentrate different PSA forms with IL-based ABS opens an 
exciting new possibility for future research on the prostate cancer differential diagnosis.  
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3.3. Extraction of lactate dehydrogenase (LDH) from human serum using ionic-
liquid-based systems 
This chapter is based on an unpublished work with the following authors involved  
Matheus M. Pereira, Sónia N. Pedro,  João A. P. Coutinho and Mara G. Freire 
3.3.1. Abstract 
Most cancer biomarkers are proteins and their accurate quantification in human serum is a 
difficult task due to the presence of highly abundant proteins, such as human serum albumin 
(HSA) and immunoglobulin G (IgG). Therefore, in order to accurately quantity biomarkers the 
deplection of high abundant proteins is necessary. In this work, a series of liquid-liquid systems, in 
particular aqueous biphasic systems (ABS) composed of phosphonium-based ionic liquids (ILs) and 
buffered aqueous solutions of K3C6H5O7/C6H8O7 (pH=7.0), were investigated as novel 
extraction/purification platforms for Lactate Dehydrogenase (LDH), a prognostic biomarker of 
melanoma, lung cancer, prostate cancer, osteosarcoma and kidney cell carcinoma, from human 
serum. ABS were evaluated through their ability to simultaneously promote the HSA and IgG 
depletion and the extraction of LDH. According to results here reported, IL-based ABS lead to a 
complete depletion of HSA and IgG and to the extraction of LDH to the IL-rich phase in a single-
step, allowing a better identification and quantification of the cancer biomarker and thus 
contributing to more accurate cancer diagnosis and prognosis. 
3.3.2. Introduction 
Cancer is one of the worldwide leading causes of death, with approximately 14 million new 
cases each year1. By 2012, 8.2 million deaths have been reported, being this number expected to 
increase up to 70% in the next two decades2. Given these values, in the last years, the interest on 
the use of biological markers to evaluate the risk of cancer has significantly increased, 
accompanied by the search on new and more specific biomarkers3. These biomolecules can be 
used for the patient’s helath assessment in multiple clinical settings, including diagnosis, in the 
estimation of the disease risk, to distinguish between benign and malignant tumours, and in the 
prognosis and follow-up of patients who have been diagnosed with cancer4. Cancer biomarkers 
can be detected in several biological fluids, such as whole blood (and serum or plasma), urine, 
saliva and tears, for which threshold values usually exist and are well-established5,6. In addition to 
the research of more specific and reliable biomarkers, the development of pretreatment 
strategies of human fluids is also an area of increasing interest. These pretreatment strategies by 
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increasing the accuracy in biomarker quantification will avoid a significant number of false-
positive results and as a consequence unnecessary biopsies, and underestimated or 
overtreatment7.  
Within the cancer biomarkers, lactate dehydrogenase (LDH) is usually associated with several 
anaerobic types of cancer, such as myeloma, lung cancer, prostate cancer, osteosarcoma and 
kidney cell carcinoma, and is particularly used in prognosis8–11. In these cancer types, LDH levels in 
biological fluids increase due to the upregulation of LDH by tumor cells and by tumor cell necrosis, 
causing the spillover of the enzyme into bloodstream12. Therefore, contrarily to normal levels in 
healthy patients serum, which range between 100 and 300 U/L, levels higher than 300 U/L might 
be associated with cancer13. Currently, the LDH enzyme is quantified by kinetic assay systems 
under reversible reactions14. Although spectrophotometric assays are easy to perform and robust, 
they have some limitations. The reading must occur in the first seconds of reaction after adding 
the serum samples since most of the times all NADH is consumed before the first reading15. 
Furthermore, interferences display a significant role over the kinase activity when dealing with 
biological fluids16. Therefore, preliminary steps of sample preparation, such as protein 
precipitation are usually performed17. Based on the exposed, there is an essential need for the 
development of alternative pretreatment strategies to avoid interferences of the main proteins 
present in serum samples when the identification and quantification of cancer biomarkers is 
required for diagnosis and prognosis. 
Aqueous biphasic systems (ABS) constituted by ionic liquids (ILs) have recently emerged as 
new platforms for the extraction and purification of biomolecules of interest, such as proteins18. 
IL-based ABS have been reported for the extraction of lysozyme, trypsin, myoglobin, bovine serum 
albumin, peroxidase, cytochrome c, γ-globulins, hemoglobin, among others, without 
compromising the enzymatic activity or the protein stability19,20. Although most of these works are 
focused on providing high extraction abilities while keeping the proteins stability, in a previous 
work21 we found that ABS formed by phosphonium-based ILs are capable not only of extracting 
proteins of interest, but also of selectively denaturating proteins, like albumin. These results 
support the idea that it is possible to tailor the IL chemical structure and ABS composition to 
induce the precipitation of target proteins from complex matrices. ILs composed of chaotropic 
ions were already used in the pretreatment of liquid biological sample to the analysis of 
xenobiotics17,22. Li et al.23 successfully reported a pretreatment method for the quantitative 
determination of glycocholic acid (GCA) in urine and plasma samples, thereby supporting the 
potential use of IL-based ABS in clinical diagnosis.  
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Although protein extraction and serum pretreatment to identify small metabolites have been 
reported with IL-based ABS, to the best of our knowledge, there are no works on IL-based ABS to 
simultaneous act as a depletion method, induding the precipitation of highly abundant proteins, 
and to completely extract cancer biomarkers from serum samples. In this work we investigate IL-
based ABS as a pretreatment strategy of serum samples envisioning the extraction and improved 
quantification of LDH. This step allows the use of more accurate equipment, such as size exclusion 
high performance liquid chromatography (SE-HPLC), for the quantification of the enzyme effective 
concentration instead of its activity as typically carried out14,24. 
3.3.3. Experimental procedures 
Materials. The ABS studied in this work are composed of a buffer aqueous solution 
constituted by potassium citrate (K3C6H5O7·H2O, ≥ 99 wt% pure) from Sigma–Aldrich, and citric 
acid (C6H8O7·H2O, 100 wt% pure from Fisher Scientific), and the ILs tetrabutylphosphonium 
chloride ([P4444]Cl, > 96 % pure) and tetrabutylphosphonium bromide ([P4444]Br, > 96 % pure) from 
Cytec Ind. Phosphate buffered saline (PBS), 100 wt% pure from Sigma-Aldrich, aqueous solutions 
were also used. For HPLC analysis, sodium phosphate monobasic (NaH2PO4, purity 99- 100.5 %), 
sodium phosphate dibasic heptahydrated (Na2HPO4.7H2O, purity 98.2- 102.0 %) and sodium 
chloride (NaCl), acquired from Sigma Aldrich, were used. 
Simultaneous extraction of lactate dehydrogenase (LDH) and depletion of human serum 
albumin (HSA) and immunoglobulin G (IgG). The ternary mixtures compositions used in the 
partitioning experiments were chosen based on the phase diagrams determined in a previous 
work21. Aqueous solutions containing LDH (100 U.L-1) and human serum were used as the aqueous 
solution. Each mixture was vigorously stirred, centrifuged for 10 min, and left to equilibrate for 10 
min at 25°C to reach the LDH complete extraction and the HSA and IgG complete depletion (that 
precipitate as a solid interphase between the two liquid phases). After, a careful separation of the 
phases was performed and the amount of LDH, HSA and IgG in each phase was quantified by SE-
HPLC (Size Exclusion High-Performance Liquid Chromatography). Each phase was diluted at a 1:10 
(v:v) ratio in a phosphate buffer solution before injection. A Chromaster HPLC (VWR, Hitachi) 
coupled to an UV detector was used. SE-HPLC was performed with an analytical column (25 cm  
2 mm i.d., 25 m), Lichrospher 100 RP-18, from Merck. A 100 mM phosphate buffer in MiliQ 
water (mobile phase) was run isocratically with a flow rate of 1 mL·min-1. The temperature of the 
column and auto-sampler was kept constant at 25°C. The injection volume was of 25 µL. The 
wavelength was set at 280 nm whereas the retention time of IgG, LDH and HSA was found to be 
circa 15.7, 16.2 and 17.1 min, respectively, within an analysis time of 40 min. The quantification of 
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LDH, HSA and IgG in each phase was carried out by an external standard calibration method 
(R2=0.9993 R2=0.9997 and R2=0.9991, respectively) - cf. Appendix G with the established 
calibration curves. The extraction efficiency of LDH (𝑬𝑬𝑳𝑫𝑯% ) and the depletion efficiencies of 
HSA and IgG, 𝑫𝑬𝑩𝑺𝑨%, and  𝑫𝑬𝑰𝒈𝑮%,  respectively, are defined according to Equation (3.3.1), 
Equation (3.3.2) and Equation (3.3.3): 
𝐸𝐸LDH% =
𝑤𝐿𝐷𝐻
𝐼𝐿
𝑤𝐿𝐷𝐻
𝐼𝐿 + +𝑤𝐿𝐷𝐻
𝑆𝑎𝑙𝑡 + 𝑤𝐿𝐷𝐻
𝐼𝑛𝑡   100 (3.3.1) 
𝐷𝐸HSA% =
𝑤𝐻𝑆𝐴
𝐼𝑛𝑡
𝑤𝐻𝑆𝐴
𝐼𝐿 + +𝑤𝐻𝑆𝐴
𝑆𝑎𝑙𝑡 + 𝑤𝐻𝑆𝐴
𝐼𝑛𝑡   100 (3.3.2) 
𝐷𝐸IgG% =
𝑤𝐼𝑔𝐺
𝐼𝑛𝑡
𝑤𝐼𝑔𝐺
𝐼𝐿 + +𝑤𝐼𝑔𝐺
𝑆𝑎𝑙𝑡 + 𝑤𝐼𝑔𝐺
𝐼𝑛𝑡   100 
(3.3.3) 
where 𝑤𝑃𝑟𝑜𝑡𝑒𝑖𝑛
𝐼𝐿 , 𝑤𝑃𝑟𝑜𝑡𝑒𝑖𝑛
𝑆𝑎𝑙𝑡  and 𝑤𝑃𝑟𝑜𝑡𝑒𝑖𝑛
𝐼𝑛𝑡  are the total weight of protein in the IL-rich aqueous 
phase, salt-rich aqueous phase and solid interphase, respectively. In all systems the top phase 
corresponds to the IL-rich phase whereas the bottom phase is mainly constituted by the citrate-
based salt and water. In the cases were depletion occurs, the solid middle phase is mostly 
composed of proteins. 
The percentage recovery yield of LDH, 𝑹𝒀𝑳𝑫𝑯%, is the percentage ratio between the amount 
of protein in the IL-rich aqueous phase to that in the initial LDH aqueous solution, and is defined 
according to Equation (3.3.4):  
𝑅𝑌LDH% =
𝑤𝐿𝐷𝐻
𝐼𝐿
𝑤𝐿𝐷𝐻
𝐴𝑞𝑢𝑒𝑜𝑢𝑠 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
 𝒙100  (3.3.4) 
where 𝑤𝐿𝐷𝐻
𝐴𝑞𝑢𝑒𝑜𝑢𝑠 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
 and 𝑤𝐿𝐷𝐻
𝐼𝐿  are the total weight of LDH in the LDH aqueous solution and in 
the IL-rich phase, respectively.  
Molecular Docking. The interaction sites of HSA, IgG and LDH with the IL ions were identified 
using the Auto-dock vina 1.1.2 program25. The crystal structure of HSA (PDB:1e71), IgG (PDB:1hzh) 
and LDH (PDB:5ixs) were adapted and used in the molecular docking. Auto DockTools (ADT)26 was 
used to prepare the proteins input files by merging non-polar hydrogen atoms, adding partial 
charges and atom types. Ligand (IL cation and anions) 3D atomic coordinates were computed by 
Gaussian 03w and ligand rigid root was generated using AutoDockTools (ADT), setting all possible 
rotatable bonds defined as active by torsions. The grid center at the center of mass (x-, y-, and z-
axes, respectively) to cover the whole interaction surface of HSA was 94 Å × 64 Å × 90 Å, of IgG 
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was 126 Å × 112 Å × 126 Å and of LDH was 94 Å × 90 Å × 98 Å. The binding model that has the 
lowest binding free energy was searched out from 9 different conformers for each ligand (IL ions). 
3.3.4. Results and discussion 
Extraction of lactate dehydrogenase (LDH) and depletion of human serum albumin (HSA) 
and immunoglobulin G (IgG). The extraction of LDH and the depletion efficiencies of HSA and IgG 
in [P4444]Br-based ABS were investigated at a common mixture composition (30 wt% of 
K3C6H5O7/C6H8O7 + and 30 wt% of [P4444]-based ILs + 40 wt% of an aqueous solution containing 
LDH at 100 U.L-1 or serum spiked with LDH at the same concentration) in the biphasic area 
according to phase diagrams previously reported21.  
 
Figure 3.3.1. Extraction efficiency of LDH (EELDH%) and simultaneous depletion efficiency of IgG 
and HSA (DEPROT%) using ABS composed of 30 wt% of IL + 30 wt% K3C6H5O7/C6H8O7 at 25°C and 
pH = 7.0.  
Figure 3.3.1. displays the effect of the IL anion on the extraction of LDH and on the 
simultaneous depletion efficiencies of HSA and IgG. The ABS investigated are composed of 30 wt% 
of K3C6H5O7/C6H8O7 + and 30 wt% of [P4444]-based ILs + 40 wt% of an aqueous solution containing 
LDH at 100 U.L-1 or serum spiked with LDH. For the two IL-based ABS, LDH is completely extracted 
to the top phase (IL-rich phase) - extraction efficiencies of 100% attained in a single-step (Figure 
3.3.1.). However, only the ABS constituted by [P4444]Br induces the precipitation of proteins 
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creating a solid interphase, with depletion efficiencies of 100% for HSA and IgG obtained in a 
single-step. 
In Figure 3.3.2 and Figure 3.3.3. are depicted the SE-HPLC chromatograms corresponding to 
the extractions carried out with LDH, and corresponding to the depletion efficiencies studies from 
human serum allowing to confirm the effect of the IL on the proteomic profile, respectively. 
According to the results obtained, both IL-based ABS allow the complete partitioning of LDH to 
the IL-rich phase in a single-step. Moreover, no losses of protein by precipitation at the interface 
where observed. The chromatographic peak of LDH is visible between 15 and 17 min.  
 
Figure 3.3.2. Size exclusion chromatography results of a aqueous solution containing LDH at 100 
U.L-1 (a); [P4444]Cl-rich phase (b); salt rich-phase; (c) [P4444]Br-phase (d); salt rich-phase; 
Corresponding to the ABS composed of IL (30 wt%) + K3C6H5O7/C6H8O7 (30 wt%) at 25°C and pH = 
7.0.  
In the [P4444]Cl-based ABS an evident peak between 17 and 18 min is detected, which mainly 
corresponds to the highly abundant protein HSA (Figure 3.3.3b). However, in the the ABS 
composed of [P4444]Br a complete precipitation of the highly abundant serum proteins was 
observed (HSA and IgG) (Figure 3.3.3d). No proteins have been identified in the ABS bottom 
phases (salt-rich phases). [P4444]Br is more hydrophobic, which may justify the complete 
precipitation and/or denaturation observed. The changes in the protein structure leading to 
precipitation may result from specific interactions occurring between the protein and the IL. 
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Hydrophobic interactions responsible for proteins precipitation have been  reported with 
polymers, organic solvents and salts27,28. The protein behaviour in presence of ions is in part 
explained by the Hofmeister series29. Therefore, protein stability and enzyme activity can be 
strongly influenced by the type of salts or ILs present in aqueous solution30. In this case, Br- has a 
weaker ability to hydrogen-bond with water and to form hydration complexes; therefore, the 
respective IL-rich phase has a lower water content when compared with the chloride-based 
system – cf. the Appendix G with the compositions of the phases. This low water content seems 
not appropriate to dissolve proteins while keeping them stable, leading thus to their precipitation. 
 
Figure 3.3.3. Size exclusion chromatography results of human serum samples (a); [P4444]Cl-rich 
phase (b); salt-rich phase; (c) [P4444]Br-phase (d); salt-rich-phase; corresponding to the ABS 
composed of IL (30 wt%) + K3C6H5O7/C6H8O7 (30 wt%) at 25°C and pH = 7.0. 
Given that the best results were obtained with [P4444]Br + K3C6H5O7/C6H8O7 (pH=7)  (which 
imply the extraction of LDH to the IL-rich phase and simultaneous depletion of HSA and IgG from 
serum samples), further mixtures for various concentrations of [P4444]Br (from 15 to 45 wt%) and 
K3C6H5O7/C6H8O7 (from 10 to 30 wt%) were investigated and their impact on the LDH partition and 
HSA and IgG depletion evaluated. Figure 3.3.5 depicts the effect of the K3C6H5O7/C6H8O7 and IL 
concentrations. Interestingly, independently of the salt or IL concentration employed, the same 
trends is observed. All compositions studied allow the complete extraction of LDH to the IL-rich 
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phase, without observing the precipitation and/or denaturation of the target biomarker, and the 
complete depletion of HSA and IgG. However, in systems composed of 30 wt% of IL and 10 wt% of 
salt it was observed the formation of a relatively small top-phase compared to the bottom phase, 
which did not allow to separate the interphase (depleted serum proteins).  
 
Figure 3.3.4. Extraction efficiency of LDH (EELDH%) and depletion efficiency of IgG and HSA 
(DEPROT%) of: (a) ABS composed of 20 wt% of K3C6H5O7/C6H8O7 + different concentrations of 
[P4444]Br and (b) 30 wt% of [P4444]Br + different concentrations of K3C6H5O7/C6H8O7 at 25°C and pH 
= 7.0. 
On the other hand, the mixture composed of 20 wt% of K3C6H5O7/C6H8O7 + 15 wt% [P4444]Br + 
serum leads to small top-phase, not allowing its separation from the interphase. However, in 
these situations it was not observed the presence of proteins in the opposite phase, assuming 
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that 100% of precipitation of LDH and HSA occurs. Even so, in all the evaluated situations for the 
salt and IL effect, LDH preferentially migrates to the IL-rich phase confirming that protein-IL 
interactions and salting-out effects play a significant role. 
The mixtures studied lead however to different recovery yields of LDH, as shown in Figure 
3.3.5. The mixture formed by 20 wt% of salt+ 30wt % IL is the one that leads to lower losses of 
LDH. However, the mixture composed of 20 wt% of K3C6H5O7/C6H8O7 and 45 wt% of [P4444]Br 
appears as the most promising in terms of handling, due to the larger volume of the top-phase (IL-
rich phase where LDH is enriched), and due to a well-defined third phase corresponding to 
precipitated HSA and IgG. 
 
Figure 3.3.5. Extraction efficiency of LDH (EELDH%) and recovery yields of LDH (RYLDH%) of in ABS 
composed of different concentrations of K3C6H5O7/C6H8O7 and [P4444]Br at 25°C and pH = 7.0. 
 
The ABS contituted by 45 wt% of [P4444]Br + 20 wt% of K3C6H5O7/C6H8O7 was finally 
investigated to extract LDH directly from serum samples, with the simultaneous depletion of HSA 
and IgG. To this end, serum samples were spiked with LDH in a concentration of 100 U/L. LDH was 
added at a know concentration since the commercial serum samples acquired correspond to 
healthy volunteers. Figure 3.3.6. displays the SE-HPLC chromatograms corresponding to non-
treated serum samples, standard LDH, and to the ABS top and bottoms phases. At the IL-rich 
phase, only LDH is identified, with the absence of LDH aggregates or the protein fragmentation. 
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The peak of LDH in aqueous solution for concentration of 100 U/L at around 16.2 minutes is 
clearly seen in the LDH standard aqueous solution and in the IL-rich phase after the sample pre-
treatment. Given that LDH has an intermediate molecular weight between IgG and HSA, 
remarkably, HSA and IgG were not detected in the HPLC chromatograms, thereby not acting as 
interferents in the quantification.  
 
Figure 3.3.6. SE-HPLC chromatograms of human serum without pre-treatment (a), standard LDH 
(b), IL-rich phase after extraction (c), and salt-rich phase (d) of the ABS composed of 45 wt% 
[P4444]Br + 20 wt% K3C6H5O7/C6H8O7 + serum samples with LDH at 100 U/L.  
 
Molecular Docking. The molecular docking of HSA, IgG and LDH for each IL ion were carried 
out, allowing to better understand the preferencial depletion of HSA and IgG. Molecular docking 
analysis was carried out in previous works, providing valuable insights on the interactions occuring 
betwen ILs and proteins31–33. The IL cation ([P4444]
+) and anion (Cl- and Br-) binding on HSA, IgG and 
LDH surfaces were studied. The IL ions bind pose with lowest absolute value of affinity (kcal/mol) 
for HSA, IgG and LDH with Cl- and Br- are displayed in Figure 3.3.7, while the pose corresponding to 
the IL cation is shown in Apendix G. The molecular interactions diagrams, the best binding pose 
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and docking affinities, interacting amino acids residues, type of interaction and geometry distance 
(Å) of each IL ion individually also are provided in Apendix G.  
 
Figure 3.3.7. Molecular docking of has and (a) Cl- and (b) Br-; IgG and (c) Cl- and (d) Br-; and LDH 
and (e) Cl-  and (f) Br-. 
 
The [P4444]
+ binding energies with the 3 proteins follow the rank: HSA > LDH > IgG. For Br- 
and Cl- the trend is as follows: HSA > LDH > IgG and HSA > LDH = IgG, respectively. However, there 
are no stronger binding energies between each ion and each protein, demonstrating that IL-
protein preferential interactions are not the major ones responsible for the HSA and IgG 
precipitation. Therefore, the molecular docking results allow to conclude that low hydrated 
enviroments in the IL-rich phase combined to the high salting-out effect exerted by the salt 
promote protein-protein interactions, which are more relevant for high abundant proteins. 
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3.3.5. Conclusions  
The depletion of HSA and IgG and extraction of LDH using ABS formed by phosphonium-
based ILs and salts is here proposed. Remarkable depletion efficiencies of 100% to HSA and IgG 
were obtained, whereas LDH can be completely extracted to the IL-rich phase, in a single-step. 
This possibility only occurs with more hydrophobic ILs with a low water content at the IL-rich 
phase. No specific IL-protein interactions have been found to be responsible for this behavior. 
Low water contents promote protein-protein interactions and their further precipitation. 
According to results here achieved, these studied IL-based ABS represent a cost-effective 
alternative for the pretreatment of biological samples before clinical analysis, particularly in 
cancer diagnosis and prognosis. The proposed method reduces other proteins interferences in the 
LDH quantification, thus allowing to use SE-HPLC chromatography for its quantification instead of 
the commonly applied enzymatic activity assays, therefore leading to more accurate results. 
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Investments on the development of effective techniques for the early-stage diagnosis of 
cancer is a crucial priority in order to decrease the burden associated to cancer epidemics. In this 
context, this thesis was focused on the development of pretreatment strategies of biological fluids 
to improve the identification and quantification of cancer biomarkers, while allowing the use of 
more versatile equipment. Aqueous biphasic systems (ABS) were investigated for this purpose. 
Since the target cancer biomarkers are proteins, initially, the ability of IL-based and polymer-
based ABS for the extraction of amino acids, model proteins and proteins from biological complex 
media was investigated. Novel ABS composed of commercial ILs or novel AGB-ILs with salts, as 
well as novel ABS formed by ILs and carbohydrates were evaluated, aiming at developing more 
sustainable separation/isolation strategies. The recovery of the proteins from IL-rich phase, 
followed by the recyclability/reusability of the ILs, was also demonstrated. This set of results 
allowed to better understand the proteins behavior in IL-based ABS, namely which factors allow 
their extraction with no denaturation or those that induce the proteins precipitation.  
Based on the first set of results, IL-based ABS were then investigated as pretreatment 
strategies of human fluids envisaging a more accurate cancer diagnosis and prognosis. Novel AGB-
ILs were synthesized and characterized, followed by their use as phase-forming agents of ABS for 
the depletion of human serum highly abundant proteins, allowing the analysis of low abundance 
proteins such as transferrin, a biomarker for several diseases and alcohol abuse and dependence. 
Given the labile nature of proteins, ABS constituted by GB-based ILs were then investigated to 
extract and concentrate PSA from human urine samples. After the ABS pretreatment, PSA can be 
identified and quantified by SE-HPLC in a non-invasive sample (urine), contributing to 
improvements on CaP diagnosis. Finally, IL-based ABS were investigated for the depletion of 
highly abundant serum proteins, such as IgG and HSA, with the simultaneous extraction of LDH 
from human serum to the IL-rich phase. The gathered results allow to quantify the cancer 
biomarker LDH in serum samples by SE-HPLC, instead of the commonly used enzymatic assays, 
thus leading to better clinical diagnosis and prognosis.  
Based on the results achieved in this thesis, the following steps should be further addressed 
towards improved cancer diagnosis and prognosis: 
 To extend the use of IL-based ABS for the extraction of PSA from human urine of a 
significant number of PaC patients aiming at validating the developed technique, as well 
as to validate the use of urine as a relevant fluid for PCa diagnosis; 
 To carry out studies on the extraction of LDH and simultaneous depletion of HSA and IgG 
with other ILs to better understand the IL effect on the proteins depletion; 
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 To extend the use of IL-based ABS for the extraction of LDH from cancer patients serum 
samples; 
 To appraise the use of IL-based ABS to extract and concentrate several cancer 
biomarkers from human samples envisioning a more accurate diagnosis;  
 To test IL-based ABS as pre-treatment strategies of other human fluids (serum, saliva, 
tears, etc.) relevant for diagnosis purposes. 
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Table A1. Experimental weight fraction data for the systems composed of IL (1) + Na2SO4 (2) + H2O (3) at 
25°C. 
 
[MepyrNC2]Br [Et3NC2]Br [Pr3NC2]Br 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 
33.1378 8.3559 29.1670 8.9985 20.3311 10.9583 
34.4708 7.6320 31.6004 7.8192 21.3152 10.0477 
36.6415 6.7211 33.5676 6.9598 22.4079 9.2350 
38.4450 6.0902 34.9656 6.2954 23.1188 8.8211 
40.1111 5.4507 36.9211 5.5339 24.0998 8.3795 
42.3150 4.6771 38.8827 4.8770 25.1633 7.7507 
44.0663 4.1646 40.9810 4.1975 26.5713 7.1643 
45.2233 3.8143 43.3685 3.5852 27.6955 6.6495 
46.9720 3.3929 44.8294 3.2435 28.7305 6.1966 
50.3730 2.7154 46.7899 2.8111 29.7898 5.7869 
  49.1203 2.3680 30.7546 5.4067 
    32.2404 4.9226 
    33.5973 4.4774 
    34.9715 4.0738 
    36.4336 3.6577 
    37.7549 3.3447 
    39.1167 3.0236 
    40.0246 2.7756 
    41.4645 2.4928 
    42.7144 2.2365 
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Table A2. Experimental weight fraction data for the systems composed of IL (1) + Na2SO4 (2) + H2O (3) at 
25°C. 
 
[Bu3NC2]Br  [Bu3PC2]Br  [Bu3PC4]Br 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 
13.6713 12.0942 31.0361 4.2511 44.5013 1.7572 
15.7194 11.2106 29.7960 4.3385 42.3530 2.0145 
17.6766 10.4290 28.4314 4.6051 40.7760 2.2385 
19.2316 9.8090 26.8843 5.0331 35.2482 3.0600 
20.2670 9.0821 25.1688 5.4887 32.7655 3.4429 
21.2023 8.6881 23.9059 5.8683 29.8216 4.1393 
21.6827 8.4006 22.4596 6.2975 28.5463 4.4000 
22.3581 8.0770 20.6246 6.8615 26.3769 4.9503 
23.4242 7.6979 18.5541 7.5297 24.0975 5.4856 
23.7964 7.4287 16.6607 8.1858 21.7522 6.0716 
24.9692 7.0591 14.4647 8.9694 21.0798 6.1874 
25.7420 6.7887 11.6045 10.1799 19.4257 6.6259 
26.4669 6.4900   17.7823 7.1037 
27.0642 6.2875   17.1462 7.2825 
27.7519 6.0275   16.4858 7.4956 
28.3946 5.7589   15.7395 7.7325 
29.3150 5.5259   15.2055 7.8885 
31.1238 4.7654   14.4151 8.1583 
31.9612 4.5799   13.7455 8.3643 
33.0661 4.3011   12.3650 8.9083 
34.3332 4.0105   11.7141 9.1611 
35.2187 3.7924   10.5113 9.6710 
36.3686 3.5531     
37.4250 3.3252     
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Table A3. Extraction efficiencies (EE%TRY) of tryptophan, pH and weight fraction compositions of the 
initial mixtures at 25 °C. 
 
IL 
Weight fraction  
composition / (wt %) 
pH 
EE%TYR ± σ 
IL  Na2SO4 IL-rich phase 
NaSO4-rich 
phase 
[MepyrNC2]Br 39.87 ± 0.02 7.53 ± 0.03 3.14 ± 0.01 3.31 ± 0.01 98.52 ± 0.22 
[Et3NC2]Br 39.67 ± 0.05 7.53 ± 0.01 4.04 ± 0.08 4.76 ± 0.05 98.78 ± 0.19 
[Pr3NC2]Br 39.95 ± 0.01 7.51 ± 0.02 4.23 ± 0.07 4.40 ± 0.01 99.08 ± 0.01 
[Bu3NC2]Br 40.09 ± 0.10 7.57 ± 0.04 6.24 ± 0.05 5.12 ± 0.16 100 
[Bu3PC2]Br 39.94 ± 0.13 7.55 ± 0.04 3.24 ± 0.04 3.61 ± 0.05 93.65 ± 0.72 
[Bu3PC4]Br 39.87 ± 0.28 7.58 ± 0.01 4.68 ± 0.01 4.49 ± 0.01 76.09 ± 0.10 
 
 
Table A4. Extraction efficiencies (EE%TYR) of tyrosine, pH and weight fraction compositions of the initial 
mixtures at 25 °C. 
 
IL 
Weight fraction  
composition / (wt %) 
pH 
EE%TYR ± σ 
IL  Na2SO4 IL-rich phase 
NaSO4-rich 
phase 
[MepyrNC2]Br 39.80 ± 0.11 7.57 ± 0.02 3.14 ± 0.01 3.31 ± 0.01 96.70 ± 0.62 
[Et3NC2]Br 39.88 ± 0.05 7.59 ± 0.05 4.04 ± 0.08 4.76 ± 0.05 97.06 ± 0.29 
[Pr3NC2]Br 39.78 ± 0.11 7.52 ± 0.04 4.23 ± 0.07 4.40 ± 0.01 94.70 ± 0.31 
[Bu3NC2]Br 40.36 ± 0.09 7.53 ± 0.07 6.24 ± 0.05 5.12 ± 0.16 88.59 ± 0.73 
[Bu3PC2]Br 40.03 ± 0.07 7.52 ± 0.12 3.24 ± 0.04 3.61 ± 0.05 79.42 ± 0.25 
[Bu3PC4]Br 40.08 ± 0.07 7.55 ± 0.07 4.68 ± 0.01 4.49 ± 0.01 70.63 ± 0.83 
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Figure A1. Tryptophan calibration curve by UV-Vis. 
 
 
 
Figure A2. Tyrosine calibration curve by UV-Vis. 
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Figure A3. Phase diagram for the system composed of [MepyrNC2]Br + Na2SO4 + H2O at 25 °C: binodal 
curve data (); TL data (); and adjusted binodal data through Eq. (1) (__). 
 
Figure A4. Phase diagram for the system composed of [Et3NC2]Br + Na2SO4 + H2O at 25 °C: binodal curve 
data (); TL data (); and adjusted binodal data through Eq. (1) (__). 
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Figure A5. Phase diagram for the system composed of [Pr3NC2]Br + Na2SO4 + H2O at 25 °C: binodal curve 
data (); TL data (); and adjusted binodal data through Eq. (1) (__). 
 
 
Figure A6. Phase diagram for the system composed of [Bu3PC2]Br + Na2SO4 + H2O at 25 °C: binodal curve 
data (); TL data (); and adjusted binodal data through Eq. (1) (__). 
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Figure A7. Phase diagram for the system composed of [Bu3PC4]Br + Na2SO4 + H2O at 25 °C: binodal curve 
data (); TL data (); and adjusted binodal data through Eq. (1) (__). 
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Table B1.Experimental weight fraction data for the systems composed of IL (1) + 
C6H5K3O7/C6H8O7 (2) + H2O (3) at 25°C. 
 
[P4444]Br [P4441][MeSO4] [Pi(444)1][Tos] 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 
47.8388 0.4370 56.6986 1.3192 75.0208 4.9219 
43.1597 0.6590 47.4375 2.9804 59.0400 8.4023 
40.1121 0.8976 41.1468 4.2037 51.2389 11.3257 
38.1240 1.0659 38.3272 5.4815 46.1956 12.6033 
36.3785 1.1897 35.7905 6.0568 44.0170 13.6880 
33.5144 1.6411 31.0666 7.5380 39.8392 15.9586 
30.2567 2.1531 29.4275 8.1733 35.8389 16.3896 
19.2260 5.1635 28.1825 9.0201 33.8655 17.9247 
9.5022 15.0050 26.9444 9.6570 32.6041 18.6099 
5.7890 23.2343 25.5742 9.9455 32.0466 18.9232 
5.2514 26.3552 23.9893 11.2778 30.9711 19.3291 
4.6391 26.5561 23.0484 11.7249 29.5810 20.2982 
3.9429 28.3602 22.4124 12.0319 28.3531 20.4044 
3.2088 29.3497 21.2283 12.9313 26.3549 21.7354 
3.0881 31.0576 20.5209 13.3704 25.6420 21.9617 
2.0531 40.2288 19.9960 13.9119 24.9033 22.2586 
1.6293 42.9543 19.3293 14.1657 24.0632 23.0090 
1.4306 43.0913 18.5344 14.8994 23.4145 23.2715 
1.1906 43.9595 18.0235 15.1199 22.5863 24.0136 
  17.2124 15.9367 20.8279 24.6423 
  16.7184 16.2356 20.3996 24.8575 
  16.0916 16.7175 19.9438 25.0807 
  15.6444 17.0013 19.5664 25.3059 
  15.2076 17.3501 18.9791 25.8348 
  14.6634 17.8620 18.5981 26.0797 
  14.4839 17.6352 18.2917 26.1410 
  13.7880 18.6043 17.9134 26.3303 
  13.2213 18.8075 17.6349 26.4507 
  12.7655 19.2995 17.2022 26.8071 
  12.2857 19.7923 16.7512 27.1170 
  12.2565 19.1829 16.4947 27.2218 
  11.4734 19.0956 16.2380 27.2667 
  10.8963 19.6156 15.6235 27.8635 
  10.4880 19.6969 15.4141 28.0551 
  9.9797 20.5787 15.2192 28.0490 
  9.7096 20.9184 14.9494 28.4711 
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  9.2204 21.5358 14.6383 28.7265 
  8.8098 21.9017 14.3991 29.0902 
  8.4510 22.3908 14.1926 29.1553 
  8.0010 23.2081 13.9835 29.1822 
    13.6886 29.4696 
    13.4918 29.5053 
    12.9818 29.9173 
    12.7009 30.1312 
    12.5818 30.1172 
    12.4371 30.1693 
    12.3459 30.0383 
    12.2228 30.2212 
    12.0441 30.4163 
    11.5321 31.1580 
    11.2065 31.1134 
    10.9317 31.1274 
    10.6328 31.4308 
    10.3840 31.6882 
    10.1343 31.8178 
    9.8418 31.9182 
    9.4906 32.2824 
    9.0729 33.1904 
    8.8289 33.2905 
    8.3966 33.0807 
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Table B2. Experimental weight fraction data for the systems composed of IL (1) + C6H5K3O7/C6H8O7 (2) + 
H2O (3) at 25°C and pH 7. 
 
[P4444]Cl [N4444]Cl 
100 w1 100 w2 100 w1 100 w2 
86.4924 1.0557 50.1620 1.9141 
63.9963 2.1215 45.2156 3.4470 
54.1184 3.0299 42.0719 5.0582 
48.8418 3.8526 38.4429 7.4342 
45.1634 4.9749 36.2246 8.6956 
41.6605 5.6622 34.5441 9.5152 
38.3788 6.9352 32.5062 10.6393 
35.4859 8.1447 29.6917 12.9078 
33.2368 9.1887 27.6777 14.3710 
32.0140 10.4540 25.3324 16.1640 
31.2483 10.8314 23.7616 17.2831 
30.5379 11.2235 21.2843 19.2403 
29.8257 11.5870 19.5450 19.3433 
28.8400 12.3574 18.0172 21.1155 
28.2796 12.6258 15.9995 23.1501 
27.6475 12.9362 14.0455 25.3000 
27.0681 13.2758 12.9804 26.3039 
25.1693 14.1107 11.6673 28.1300 
24.0642 14.9879 11.0443 28.5202 
23.5031 15.3220 10.0017 29.7699 
22.8671 15.6276 9.0441 30.9635 
22.0932 16.1253 8.2642 31.9726 
21.4158 16.5200 7.8630 32.5237 
20.6174 17.1369 7.2713 33.2358 
19.8613 17.7528 6.8774 33.9086 
19.4211 17.9311 6.3816 34.5217 
18.8651 18.2848 6.0857 34.9466 
18.2412 18.8202   
17.8484 19.0146   
17.2806 19.4545   
16.9682 19.6283   
16.4548 20.0527   
15.9250 20.4714   
15.4629 20.8920   
15.1644 21.0156   
14.7427 21.3710   
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14.3337 21.7670   
14.0974 21.8658   
13.7232 22.1883   
13.3256 22.5398   
12.9924 22.8022   
12.6610 23.0760   
12.3382 23.3616   
12.0179 23.6156   
11.6960 23.8891   
11.3895 24.2068   
11.2217 24.2950   
10.9611 24.5733   
10.8120 24.6647   
10.4943 25.0120   
10.2971 25.1279   
10.0704 25.3459   
9.9706 25.3551   
9.7907 25.5576   
9.5933 25.7322   
9.4068 25.9006   
9.2592 26.0450   
9.0738 26.2066   
8.9031 26.3534   
8.7424 26.4771   
8.6448 26.5315   
8.5041 26.6767   
8.3424 26.8247   
8.1868 26.9672   
8.0522 27.1411   
7.9174 27.2373   
7.7751 27.3717   
7.6558 27.5242   
7.4726 27.7560   
7.3972 27.7587   
7.2689 27.8644   
7.0996 28.0967   
7.0320 28.1204   
6.9784 28.1906   
6.9154 28.2171   
6.7833 28.3706   
6.6517 28.5458   
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6.5472 28.6451   
6.4414 28.7360   
6.3508 28.8701   
6.2583 28.9889   
6.1654 29.0779   
6.0494 29.2289   
5.9604 29.3077   
9.5933 25.7322   
9.4068 25.9006   
9.2592 26.0450   
9.0738 26.2066   
8.9031 26.3534   
8.7424 26.4771   
8.6448 26.5315   
8.5041 26.6767   
8.3424 26.8247   
8.1868 26.9672   
8.0522 27.1411   
7.9174 27.2373   
7.7751 27.3717   
7.6558 27.5242   
5.7127 30.3562   
5.2826 31.1830   
4.2756 32.3747   
3.8831 33.5204   
3.3983 34.9449   
2.2193 36.3959   
1.9091 39.8339   
1.7341 43.2143   
1.5590 45.9750   
1.4739 48.4673   
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Figure B1. BSA calibration curve by SE-HPLC. 
 
 
Figure B2. Phase diagram for the system composed of [P4444]Cl + K3C6H5O7/C6H8O7 + H2O at 25°C and pH 
7.0: binodal curve data (); TL data (); adjusted binodal data through Equation 1 (__). 
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Figure B3. Phase diagram for the system composed of [P4444]Br + K3C6H5O7/C6H8O7 + H2O at 25°C and pH 
7.0: binodal curve data (); TL data (); adjusted binodal data through Equation 1 (__). 
 
 
Figure B4. Phase diagram for the system composed of [P4441][MeSO4] + K3C6H5O7/C6H8O7 + H2O at 25°C 
and pH 7.0: binodal curve data (); TL data (); adjusted binodal data through Equation 1 (__).  
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Figure B5. Phase diagram for the system composed of [N4444]Cl + K3C6H5O7/C6H8O7 + H2O at 25°C and pH 
7.0: binodal curve data (); TL data (); adjusted binodal data through Equation 1 (__). 
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Table C2. Experimental weight fraction data for the systems composed of PEG 400 (1) + C6H5K3O7/C6H8O7 
(2) + H2O (3) at 25°C. 
pH 5 pH 6 pH 8 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
13.8784 44.0714 12.7242 41.2876 68.0207 1.4982 
15.8030 41.1839 13.5478 39.3030 60.6933 2.8980 
17.1646 38.9245 14.7701 37.6565 57.5232 3.7124 
19.3922 36.7353 15.7787 35.3873 54.2955 4.3635 
21.0099 34.8396 16.2211 34.0678 51.6291 5.1016 
23.5517 32.7621 17.5670 32.2227 48.3830 6.0044 
25.2393 31.1759 18.7109 30.6367 44.8083 6.9456 
26.8034 29.9046 19.9625 29.1688 40.2519 8.2738 
28.2945 28.6035 21.6725 27.7436 39.5334 8.5822 
29.5790 27.4259 23.4239 26.5159 38.7919 8.9058 
31.3389 26.2354 23.8886 25.6818 38.0258 9.2458 
32.3955 25.2020 25.2992 24.6300 37.2332 9.6035 
32.6902 24.6885 26.6489 23.6464 36.3949 9.9819 
34.1753 23.6390 27.8100 22.7248 35.5420 10.3786 
35.7246 22.6037 28.9584 21.9689 34.6619 10.7976 
36.4717 21.9259 29.8614 21.2308 33.7523 11.2408 
37.6852 21.0508 30.7524 20.4976 32.8105 11.7106 
39.0763 20.1973 32.3364 19.6229 31.8337 12.2092 
41.3708 19.1531 33.2482 18.9739 30.7015 12.7517 
42.1115 18.5689 34.3542 18.2869 29.8047 13.3088 
44.3205 17.4301   28.9110 13.8516 
    27.2947 14.6005 
    26.3131 15.2395 
    25.7023 15.7740 
    25.1869 16.2964 
    23.8576 17.0889 
    22.5121 17.9341 
    21.8801 18.5595 
    20.4643 19.4835 
    19.2419 20.3042 
    18.4269 21.1170 
    16.6452 22.2122 
    15.7167 23.1358 
    13.7114 24.4315 
    11.3638 25.9401 
    10.3368 27.0210 
    6.4377 31.3587 
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Table C2. Experimental weight fraction data for the systems composed of PEG (1) + C6H5K3O7/C6H8O7 (2) 
+ H2O (3) at 25°C and pH 7. 
 
PEG 400 PEG 600 PEG 1000 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
82.6364 2.7688 85.9890 1.7175 57.8766 5.9077 
75.1384 3.7415 75.6691 3.2334 52.8615 6.5404 
69.3176 4.8225 66.0885 4.1373 47.5771 7.0310 
64.5254 5.9201 61.2011 5.2283 43.2552 8.0531 
60.4327 6.9732 57.0016 6.2553 40.5045 9.0397 
56.8465 7.0909 53.3512 7.1548 38.5181 9.3272 
53.6422 8.1477 48.9937 7.7503 37.3214 9.7977 
50.7347 9.1522 45.9932 8.3937 36.3024 10.2048 
50.3763 9.2678 43.8617 9.0435 34.8850 10.7059 
44.9721 10.9316 41.6540 9.5154 33.3928 11.0325 
42.1959 12.4068 40.2461 10.0757 32.4179 11.4377 
40.9067 12.9465 38.8544 10.6452 31.5184 11.7518 
39.3859 13.5980 37.2160 11.0289 30.6611 12.1286 
37.4982 14.6429 36.0051 11.5597 29.8253 12.4888 
36.3936 15.1547 34.9330 12.0149 29.0518 12.8247 
35.2881 15.5759 34.0072 12.4572 28.2799 13.2131 
33.4970 16.6700 33.1104 12.8165 27.6278 13.4697 
32.0660 17.4791 32.2384 13.1799 26.9766 13.6716 
30.7214 18.2968 31.3807 13.4793 26.3515 13.9313 
29.4833 19.0725 30.5355 13.8412 24.6438 14.6031 
28.5894 19.5448 29.4578 14.5832 24.1790 14.9130 
27.4451 20.3323 27.6537 15.0870 23.3543 15.3366 
26.1742 21.1703 25.0088 16.1531 22.7360 15.7350 
25.2695 21.6338 22.7269 17.7926 21.5921 16.2943 
24.0984 22.5744 22.2983 18.1895 20.3070 16.8851 
23.0210 23.3475 21.4583 18.7162 19.3895 17.4345 
22.9418 24.0731 20.7102 19.2075 17.9807 18.1916 
22.1722 24.6153 19.8200 19.7896 16.8277 18.8238 
21.4621 25.0926 18.8294 20.4667 15.9315 19.3771 
20.9712 25.4513 18.6367 21.3598 14.7080 20.0678 
20.8230 25.7781 16.6079 22.1350 13.0007 20.8642 
20.3333 26.0970 16.0212 22.5600 11.7033 21.7123 
20.4662 26.1916 14.8776 23.3935 10.9790 22.2316 
19.9953 26.5007 13.5874 24.3492 9.4577 23.0413 
19.4360 26.9010 12.1340 25.3038 8.8034 23.6258 
17.7018 29.0287 10.4744 26.5086 7.1315 24.5652 
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16.9222 30.0241 9.6662 27.1884 6.3816 25.3675 
15.8030 32.5812 8.6476 28.1055 5.3984 26.0209 
15.3813 32.7344 7.5462 29.1223 3.4627 28.1891 
14.1924 33.5291 6.5676 30.2392   
13.3104 35.7602 5.6147 31.3011   
12.4501 37.8980 3.6603 33.7064   
11.8434 39.2537     
 
Table C3. Partition coefficients (KOva) and extraction efficiencies (EE%Ova) of ovalbumin and weight 
fraction compositions of the initial mixtures at 25°C. 
 
PEG pH 
Weight fraction composition / (wt %) 
KOva ± σ EE%Ova ± σ 
PEG  C6H5K3O7/C6H8O7 
400 
5 30.01 29.99 12.6 ± 0.3 94.8 ± 0.7  
6 29.99 29.85 32.8 ± 0.3 96.1 ± 0.1 
7 29.98 29.97 54.7 ± 0.1 97.7 ± 0.7 
8 30.13 29.84 52.4 ± 0.1 96.5 ± 0.5 
 
 
Table C4. Partition coefficients (KOva) and extraction efficiencies (EE%Ova) of ovalbumin and weight 
fraction compositions of the initial mixtures at 25°C and pH 7. 
 
PEG 
Weight fraction composition / (wt %) 
KOva ± σ EE%Ova ± σ 
PEG  C6H5K3O7/C6H8O7 
400 
24.75 25.28 76.4 ± 0.4 98.8 ± 0.7  
29.98 19.97 89.5 ± 0.2 98.9 ± 0.1 
30.05 24.97 76.4 ± 0.6 98.8 ± 0.8 
30.01 29.84 54.7 ± 1.0 97.6 ± 0.5 
35.72 24.97 74.4 ± 0.4 98.4 ± 0.7 
600 
25.05 24.98 54.5 ± 0.1 97.1 ± 0.4 
30.13 20.38 55.7 ± 0.4 96.1 ± 0.3 
30.21 25.44 54.7 ± 0.5 97.1 ± 0.3 
29.79 30.01 52.7 ± 0.9 97.8 ± 0.1 
35.06 24.98 34.7 ± 0.6 97.7 ± 0.5 
1000 
24.93 25.42 35.5 ± 0.6 95.6 ± 0.4 
29.94 20.01 12.7 ± 0.2 93.6 ± 0.8 
29.87 25.06 35.5 ± 0.3 95.6 ± 0.7 
30.10 29.93 51.6 ± 0.9 97.8 ± 0.4 
34.95 25.15 22.1 ± 0.2 95.2 ± 0.9 
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Table C5. Partition coefficients (KOva) and extraction efficiencies (EE%Ova) of ovalbumin from egg white 
and weight fraction compositions of the initial mixtures at 25°C and pH 7. 
 
PEG 
Weight fraction composition / (wt %) 
KOva ± σ EE%Ova ± σ 
PEG  C6H5K3O7/C6H8O7 
400 25.43 25.28 74.4 ± 0.6 98.4 ± 0.3  
600 24.65 25.05 34.7 ± 0.6 97.7 ± 0.1 
1000 25.16 25.35 22.1 ± 0.1 95.2 ± 0.9 
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Section D3. Synthesis of GB-ILs  
Tri(n-butyl)[2-ethoxy-2-oxoethyl]phosphonium bromide ([Bu3PC2]Br) 
Tri(n-butyl)[2-ethoxy-2-oxoethyl]phosphonium bromide ([Bu3PC2]Br) was synthesized 
by the reaction : A solution of tri(n-butyl)phosphine (131.7 mL, 102.5 g 0.55 mol) in 
ethyl acetate (150 mL) cooled to 4 C was added dropwise 2-bromoacetic acid ethyl 
ester (37.5 g, 0.22 mol). The mixture was then stirred at room temperature for 1 day. 
Precipitate produced during the reaction was filtered and washed with ethyl acetate. 
Recrystallization of the residue by ethanol/ethyl acetate (10:90, V:V) gave a white 
powder which was filtered, washed with ethyl acetate and dried in vacuum yield 90%. 
 
Tri(n-butyl)[2-butoxy-2-oxoethyl]phosphonium bromide ([Bu3PC4]Br) 
Tri(n-butyl)[2-butoxy-2-oxoethyl]phosphonium bromide ([Bu3PC4]Br), was synthesized 
by the reaction : A solution of tri(n-butyl)phosphine (83.8 mL, 65.2 g, 0.35 mol) in ethyl 
acetate (150 mL) was added a solution of 4-bromobutyric acid ethyl ester (29.6 mL, 
37.5 g, 0.22 mol) in 50 mL of ethyl acetate. The mixture was refluxed for 2 days and 
then stirred at room temperature for one day. The brownish oil which separated was 
recovered and washed three times with ethyl acetate and kept in a freezer. The white 
product, which crystallised after 48 hours, was washed with ethyl acetate and diethyl 
ether and then dried in vacuum yield 85%. 
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Section D2 . Characterization of GB-ILs  
 
Tri(n-butyl)[2-ethoxy-2-oxoethyl]phosphonium bromide ([Bu3PC2]Br) 
 
 
 
1H and 13C NMR  
1H NMR (300 MHz, D2O) δ 0.83 (t, J = 7.3 Hz, 9H, 11, 15, 19), 1.20 (t, J = 7.3 Hz, 3H, 7), 
1.36 - 1.50 (p, J = 7.1 Hz, 8H, 8, 9, 10, 12, 13, 14, 16, 17, 18), 3.5 (m, 2H, 2), 4.14 – 4.22 
(q, 2H, 6).  
 
13C NMR (75 MHz, D2O) δ 12.44 (11, 15, 19), 13.14 (7), 17.97 (12, 16), 18.61 (8), 22.61 
(13, 17), 22.67 (9), 23.05 (10, 14, 18), 23.26 (2), 62.78 (6), 166.49 (3). 
 
Elemental Analysis (C16H34BrO2P) 
 
Calculated: C 55.5, H 9.8%. 
 
Experimental: C 55.2, H 9.8%. 
 
Molecular Weight: 369.32 
 
Melting Point: 95.8 
 
  
1
2
3
4
5
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Tri(n-butyl)[2-butoxy-2-oxoethyl]phosphonium bromide ([Bu3PC4]Br) 
 
 
 
1H and 13C NMR  
1H NMR (300 MHz, D2O) δ 0.90 – 0.95 (t, J = 7.3 Hz, 12H, 9, 12, 13), 1.19 -1.24 (t, J = 7.3 
Hz, 10H, 10, 11, 17, 21), 2.10 – 2.21 (p, J = 7.1 Hz, 16H, 2, 3, 14, 15, 16, 18, 19, 20), 2.51 
(m, 2H, 4), 4.09 (m, 2H, 8).  
 
13C NMR (75 MHz, D2O) δ 12.48 (3), 13.28 (13, 17, 21), 16.39 (9), 17.13 (1, 14, 18), 
17.77 (2), 22.59 (11, 15, 19), 23.32 (12, 16, 20), 34.14 (4), 61.85 (8), 174.90 (5). 
 
Elemental Analysis (C16H34BrO2P) 
 
Calculated: C 52.0, H 9.3%.  
 
Experimental: C 52.0, H 9.6%. 
 
Molecular Weight: 411.41 
 
Melting Point: 94.7 
1
2
3
4
5
6
8
10
11
12
13
14
15
16
17
18
19
20
21
7
9
 195 
Table D1. Experimental weight fraction data for the systems composed of [Bu3PC4]Br 
(1) + monosaccharide (2) + H2O (3) at 25°C. 
 
Glucose  Galactose  Fructose 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 
76.2046 5.0596 86.4755 2.7075 81.0714 5.8724 
73.2867 6.4879 65.4044 8.5725 70.0528 10.2726 
70.3418 8.0306 55.9454 13.6487 64.4838 11.7857 
67.9864 9.3671 52.3490 15.0090 61.2938 13.1946 
65.2930 10.9041 46.7844 17.9298 58.6819 14.7057 
63.1966 11.7704 39.0503 22.4056 56.3363 16.2181 
60.7889 13.0084 33.4223 25.6102 54.2426 17.7576 
57.8404 14.9106   51.6018 18.7345 
54.9762 15.5047   49.7134 19.8538 
52.6854 17.0264   48.1657 21.1593 
50.5807 17.7259   46.6294 22.1071 
49.2381 18.3758   44.9965 23.1818 
48.0083 18.9905   44.4269 22.9080 
46.7947 19.5899   42.5833 23.5524 
45.5004 20.3919   40.7628 24.6571 
44.6287 20.6342   39.6606 25.3565 
42.5999 22.0201   38.4632 26.1339 
41.5802 22.6659   37.0386 27.3864 
39.7049 24.3325   36.0612 28.0336 
39.8876 25.1501   35.0727 28.6690 
39.0395 25.6132   34.2016 29.2380 
38.2413 26.2935   33.0209 29.0094 
37.6174 26.6062   32.5855 29.7378 
36.6315 27.2277   31.9066 30.3246 
35.8935 27.4931   31.2262 30.8089 
34.0561 28.7371   30.5431 31.3683 
33.3432 29.1957   29.7131 31.6630 
32.7902 29.4116   29.0761 32.0630 
31.5541 30.2995   28.4713 32.5281 
30.9390 30.6830   27.8662 32.9669 
30.3576 31.2917   27.3673 33.3752 
29.1455 32.1477   26.7592 33.5980 
28.8277 32.1836   26.2775 33.9657 
28.1429 32.7437   25.7862 34.4290 
27.3083 33.1985   25.3592 34.8020 
26.8415 33.4510   24.7911 34.9796 
25.8495 34.0921   24.3317 35.3268 
25.2260 34.5496   23.8808 35.7083 
24.7896 34.7633   23.0314 36.6734 
23.8139 35.4569   22.5850 36.7906 
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23.4198 35.6896   22.2003 37.1706 
22.8737 36.1996   21.5038 37.8895 
22.3249 36.5749   20.7676 38.2198 
22.0319 36.7009   20.4619 38.5160 
21.5407 37.1031   20.1317 38.8125 
21.2088 37.2917   19.8242 39.0483 
20.7509 37.7042   19.5373 39.3276 
20.3274 38.0959   18.2939 40.4776 
19.2686 38.8309   17.0756 41.4320 
    16.6399 41.7835 
    16.2663 42.1000 
    15.8836 42.5766 
    15.3841 43.1937 
    15.0166 43.4171 
    14.4681 44.0375 
    14.1448 44.5302 
    13.5399 45.2959 
    12.9954 45.8808 
    12.6921 46.0258 
    12.2120 45.9004 
    11.9714 46.1179 
    11.5435 46.9953 
    11.2149 47.4557 
    10.8681 47.9758 
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Table D2. Experimental weight fraction data for the systems composed of [Bu3PC4]Br 
(1) + monosaccharide (2) + H2O (3) at 25°C. 
 
Arabinose Mannose 
100 w1 100 w1 100 w1 100 w2 
89.3082 3.0736 55.2097 11.0407 
81.1093 6.5802 48.8483 12.1263 
74.5095 8.2243 31.9643 18.358 
66.8030 12.0018 30.0462 20.2357 
62.3798 13.7638 28.7566 21.4988 
55.3122 17.2569 26.8592 23.3556 
50.3365 19.8645 21.2481 29.0164 
41.7202 24.5921 20.0189 30.3467 
36.0764 27.5139 18.3509 32.1399 
31.3416 30.1302 17.2262 33.433 
  13.7316 37.7718 
 
Table D3. Experimental weight fraction data for the systems composed of [Bu3PC4]Br 
(1) + polyols (2) + H2O (3) at 25°C. 
 
Sorbitol  Xylitol Maltitol 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 
72.4437 10.9600 46.8773 24.7859 84.1690 2.6551 
66.2891 13.4174 44.0246 26.8282 77.4722 5.8590 
62.3754 14.5225 42.5740 27.7236 72.8268 8.3624 
56.0517 16.5497 39.8600 29.6525 68.2169 10.6647 
50.9498 19.1093 38.3747 30.3143 62.6544 13.9464 
46.0666 21.9108 36.1221 31.8845 53.5050 16.6306 
43.9932 23.0065 34.1760 33.1498 44.0870 21.5703 
42.4734 23.8344 32.6039 34.1942 38.8360 23.1351 
39.0671 26.0704 31.0706 35.2508   
37.9997 26.5721 30.2977 35.6006   
36.6341 27.4801 29.0750 36.4170   
34.7270 28.7261 28.2436 36.8143   
33.0946 29.3649 27.5806 37.2200   
30.5595 30.9903     
28.8375 32.1999     
26.6611 33.5567     
26.2328 33.3580     
24.5632 34.8383     
23.2952 35.7921     
21.6718 36.9803     
19.6494 38.6823     
16.8948 41.2389     
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Table D4. Experimental weight fraction data for the systems composed of IL (1) + 
Fructose (2) + H2O (3) at 25°C. 
 
[Bu3PC2]Br [P4444]Br [P4441][MeSO4] 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 
75.7834 10.2019 84.2115 4.4238 74.9300 11.8629 
72.0334 11.1339 75.6491 11.1818 61.6603 20.5770 
69.1868 12.2178 73.6149 12.0880 56.1941 23.9891 
67.9224 12.5751 70.9021 13.3861 51.9984 26.9508 
66.0813 13.2470 67.4206 14.6601 45.8537 31.2701 
64.1281 14.2136 64.3379 15.6287 40.7686 35.3375 
61.8875 15.1468 62.5354 16.8775 37.1898 37.8258 
60.1951 15.8499 59.8745 17.6634 28.9239 41.7419 
58.6611 16.7380 57.7749 18.0574   
57.1024 17.5773 55.5168 19.0153   
55.0136 18.3791 53.8827 20.0039   
53.9019 18.9999 52.0864 20.8428   
52.4493 19.8369 47.4227 22.7050   
51.2373 20.4755 46.1664 23.4870   
49.2666 21.3005 44.8703 24.3147   
48.0859 22.0121 43.5547 25.2103   
47.0433 22.6688 42.5047 25.8726   
46.2350 22.9879 41.4130 26.5294   
45.0880 23.4559 40.5985 27.0383   
43.0300 24.6652 39.4686 27.2633   
42.1324 25.1793 38.5371 27.8256   
41.3223 25.7135 37.8072 28.1850   
40.4144 26.1943 36.5153 29.2882   
38.7647 27.2626 35.8154 29.6643   
37.3133 27.7620 35.1540 30.0182   
35.7667 28.8755 34.2505 30.7381   
35.0560 29.3385 32.7716 31.4154   
32.9650 30.6197 32.0337 31.9249   
31.3947 31.7700 30.7980 32.5882   
29.5128 33.3363 30.2783 32.7269   
29.1112 33.5484 29.3915 33.6025   
28.5566 33.8660 28.6963 33.8523   
27.2457 34.6656 28.1910 34.1209   
26.6039 35.1869 27.3901 34.7376   
26.2451 35.3693 26.9654 35.0214   
25.6839 35.8097 26.4075 35.1627   
25.5170 35.6890 25.9604 35.4735   
24.9670 35.5465 25.6112 35.7525   
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24.4053 35.9948 25.0761 36.2587   
24.0864 36.1904 24.7190 36.4571   
23.3689 36.7681 24.4384 36.6312   
22.7950 37.1854 24.1011 36.7437   
22.5760 37.2453 23.7848 36.8359   
22.1595 37.6368 23.2568 36.7869   
21.7242 37.9415 22.9557 37.0007   
21.4078 38.1918 22.8625 36.9975   
21.1537 38.3460 22.5518 37.1308   
20.2877 39.2589 21.8672 38.1219   
  21.6282 38.2370   
  21.2399 38.6251   
  20.9871 38.7536   
  20.7307 38.9909   
  20.3015 39.3040   
  20.0824 39.4197   
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Table D5. Correlation parameters of Eq. (1) used to describe the experimental binodal data at 
298 K. 
 
IL + carbohydrate + water 
IL Carbohydrate A ± σ B ± σ 105 (C ± σ) R2 
[P4441][MeSO4] 
D(+)-fructose 
118.7±7.59 -0.130±0.01 0.71±0.08 0.9969 
[P4444]Br 123.5±3.38 -0.155±0.08 1.43±0.05 0.9929 
[Bu3PC2]Br 158.7±2.24 -0.232±0.03 0.99±0.02 0.9994 
[Bu3PC4]Br 
136.9±1.76 -0.211±0.03 1.02±0.01 0.9988 
D-(+)-mannose 254.0±3.13 -0.468±0.34 0.01±0.25 0.9934 
D(+)-galactose 120.0±1.81 -0.200±0.05 1.56±0.15 0.9992 
D-(+)-glucose  118.7±2.16 -0.185±0.05 1.12±0.04 0.9971 
D(+)-arabinose 120.7±2.92 -0.163±0.08 1.68±0.15 0.9979 
xylitol 82.0±8.88 -0.075±0.02 1.21±0.07 0.9995 
D-sorbitol 178.1±5.60 -0.268±0.08 0.91±0.05 0.9998 
maltitol 100.1±2.93 -0.104±0.01 3.56±0.03 0.9964 
 
Table D6. Recovery yield (RY%PROT) and purification yield (PY%PROT) of MRJP and weight fraction 
compositions of the initial mixtures at 25 °C. 
 
IL 
Weight fraction  
composition / (wt %) RY%PROT ± σ PY%PROT ± σ 
IL  Honey 
[P4444]Br 24.95 ± 0.02 60.86 ± 0.12 83.84 ± 0.60 80.02 ± 1.36 
[P4441][MeSO4] 25.05 ± 0.07 60.83 ± 0.09 87.75 ± 0.75 89.42 ± 1.48 
[Bu3PC2]Br 24.97 ± 0.04 60.96 ± 0.07 97.30 ± 0.61 90.98 ± 0.49 
[Bu3PC4]Br 24.92 ± 0.11 60.15 ± 0.04 92.53 ± 0.23 84.12 ± 1.07 
 
 
 
 
Figure D1. Synthetic route of GB-ILs. 
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Figure D2. Proteins calibration curve (UV-Vis - 595 nm) determined by the Bradford’s 
method. 
 
 
Figure D3. Phase diagrams for the systems composed of [Bu3PC4]Br + Carbohydrates + 
H2O at 25°: maltitol (); D-sorbitol (), xylitol (). 
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Figure D4. Phase diagrams for the systems composed of [Bu3PC4]Br + Carbohydrates + 
H2O at 25°: D-(+)-mannose (), D(+)-galactose (), D-(+)-glucose (), D(+)-fructose 
(), D(+)-arabinose, (). 
 
Figure E5. Phase diagrams for the systems composed of IL + D(+)-fructose + H2O at 25°: 
[P4441][MeSO4] (), [P4444]Br (), [Bu3PC2]Br (), [Bu3PC4]Br (). 
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Section E4. Synthesis of GB-ILs  
n-(1-methylpyrrolidyl-2-butoxy-2-oxoethyl)ammonium bromide ([MePyrNC4][Br]) 
n-(1-methylpyrrolidyl-2-butoxy-2-oxoethyl)ammonium bromide ([MePyrNC4][Br]) was 
synthesized by the reaction : (90 mL , 68.85 g, 0.81 mol) in ethyl acetate (150 mL) was 
added 4-bromobutyrate acid ethyl ester (68 mL, 98.7 g, 0.51 mol) whilst stirring. The 
mixture was refluxed for 12h and the stirred at room temperature for 2h. Precipitate 
produced was filtered and washed twice with ethyl acetate and then with ethyl ether, 
and dried in vacuum. 
Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Et3NC4]Br) 
Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Et3NC4]Br) was synthesized by 
the reaction: trialkylamine (120 mL , 81.96 g, 0.81 mol) in ethyl acetate (160 mL) was 
added 4-bromobutyrate acid ethyl ester (68 mL, 98.7 g, 0.51 mol) whilst stirring. The 
mixture was refluxed for 12h and the stirred at room temperature for 2h. Precipitate 
produced was filtered and washed twice with ethyl acetate and then with ethyl ether, 
and dried in vacuum. 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Pr3NC4]Br) 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Pr3NC4]Br) was synthesized by 
the reaction : trialkylamine (160 mL , 116.03 g, 0.81 mol) in ethyl acetate (200 mL) was 
added 4-bromobutyrate acid ethyl ester (68 mL, 98.7 g, 0.51 mol) whilst stirring. The 
mixture was refluxed for 12h and the stirred at room temperature for 2h. Precipitate 
produced was filtered and washed twice with ethyl acetate and then with ethyl ether, 
and dried in vacuum. 
Tri(n-butyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Bu3NC4]Br) 
Tri(n-butyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Bu3NC4]Br) was synthesized by 
the reaction : trialkylamine (210 mL , 159.49 g, 0.81 mol) in ethyl acetate (250 mL) was 
added 4-bromobutyrate acid ethyl ester (68 mL, 98.7 g, 0.51 mol) whilst stirring. The 
mixture was refluxed for 48h and the stirred at room temperature for 2h. At rest the 
solution separates into two phases, the bottom phase was recovered and dissolved in 
100 mL of ethyl acetate and kept in the freezer for 48 h. The crystallized residue is 
filtered, washed with ethyl acetate and then with ethyl ether, and dried in vacuum. 
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Tri(n-butyl)[2-butoxy-2-oxoethyl]phosphonium bromide ([Bu3PC4]Br) 
Tri(n-butyl)[2-butoxy-2-oxoethyl]phosphonium bromide ([Bu3PC4]Br) was synthesized 
by the reaction : A solution of tri(n-butyl)phosphine (83.8 mL, 65.2 g, 0.35 mol) in ethyl 
acetate (150 mL) was added a solution of 4-bromobutyrate acid ethyl ester (29.6 mL, 
37.5 g, 0.22 mol) in 50 mL of ethyl acetate. The mixture was refluxed for 2 days and 
then stirred at room temperature for one day. The brownish oil which separated was 
recovered and washed three times with ethyl acetate and kept in a freezer. The white 
product, which crystallized after 48 hours, was washed with ethyl acetate and diethyl 
ether and then dried in vacuum. 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium saccharinate ([Pr3NC4][Sac]) 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium saccharinate ([Pr3NC4][Sac]) was 
synthesized by the reaction : Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide 
(16 g, 0.05 mol) in water (150 mL) was added silver saccharinate (17.4 g, 0.06 mol) 
whilst stirring. The mixture was refluxed for 12h and the stirred at room temperature 
for 2h. Precipitate produced was filtered and washed with ethyl acetate and ethyl 
ether, then was removed from the supernatant. Therefore, the supernatant was dried 
in vacuum to remove the organic solvents and water. 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium lactate ([Pr3NC4][Lac]) 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium lactate ([Pr3NC4][Sac]) was synthesized 
by the reaction : Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide (16 g, 0.05 
mol) in water (150 mL) was added silver lactate (11.8 g, 0.06 mol) whilst stirring. The 
mixture was refluxed for 12h and the stirred at room temperature for 2h. Precipitate 
produced was filtered and washed with ethyl acetate and ethyl ether, then was 
removed from the supernatant. Therefore, the supernatant was dried in vacuum to 
remove the organic solvents and water. 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium pyruvate ([Pr3NC4][Pyr]) 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium pyruvate ([Pr3NC4][Pyr]) was synthesized 
by the reaction : Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide (16 g, 0.05 
mol) in water (150 mL) was added silver pyruvate (11.6 g, 0.06 mol) whilst stirring. The 
mixture was refluxed for 12h and the stirred at room temperature for 2h. Precipitate 
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produced was filtered and washed with ethyl acetate and ethyl ether, then was 
removed from the supernatant. Therefore, the supernatant was dried in vacuum to 
remove the organic solvents and water. 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium dicyanamide ([Pr3NC4][Dca]) 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium dicyanamide ([Pr3NC4][Dca]) was 
synthesized by the reaction : Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide 
(16 g, 0.05 mol) in water (150 mL) was added silver dicyanamide (10.4 g, 0.06 mol) 
whilst stirring. The mixture was refluxed for 12h and the stirred at room temperature 
for 2h. Precipitate produced was filtered and washed with ethyl acetate and ethyl 
ether, then was removed from the supernatant. Therefore, the supernatant was dried 
in vacuum to remove the organic solvents and water. 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium salicylate ([Pr3NC4][Sal]) 
Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium salicylate ([Pr3NC4][Sal]) was synthesized 
by the reaction : Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide (16 g, 0.05 
mol) in water (150 mL) was added silver salicylate (14.7 g, 0.06 mol) whilst stirring. The 
mixture was refluxed for 12h and the stirred at room temperature for 2h. Precipitate 
produced was filtered and washed with ethyl acetate and ethyl ether, then was 
removed from the supernatant. Therefore, the supernatant was dried in vacuum to 
remove the organic solvents and water. 
Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium salicylate ([Pr3NC2][Sal]) 
Triethyl[2-ethoxy-2-oxoethyl]ammonium bromide ([Pr3NC2]Br) was synthesized 
according to previously reported protocols[1]. Triethyl[2-ethoxy-2-
oxoethyl]ammonium salicylate ([Et3NC4][Sal]) was synthesized by the reaction : 
Triethyl[2-ethoxy-2-oxoethyl]ammonium bromide ([Et3NC2]Br) (14.1 g, 0.05 mol) in 
water (150 mL) was added silver salicylate (14.7 g, 0.06 mol) whilst stirring. The 
mixture was refluxed for 12h and the stirred at room temperature for 2h. Precipitate 
produced was filtered and washed with ethyl acetate and ethyl ether, then was 
removed from the supernatant. Therefore, the supernatant was dried in vacuum to 
remove the organic solvents and water. 
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Section E2. Characterization of GB-ILs  
 
n-(1-methylpyrrolidyl-2-butoxy-2-oxoethyl)ammonium bromide ([MePyrNC4][Br]) 
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 1.20 (3 H, t, J=7.1 Hz, H1), 1.91-2.01 (2 H, m, H5), 2.08 (2 
H, s, H11) 2.41 (2 H, t, J=7.2 Hz, H4), 3.27-3.38 (2 H, m, H8, H9), 3.39-3.56 (4 H, m, H6, 
H7, H10) 4.09 (2 H, q, J=7.1 Hz, H2).  
13
C NMR (75,47 MHz, DMSO): δ 11.2 (C1), 14.8 (C8, C9), 19.1 (C5), 21.7 (C4), 23.0 
(C6), 31.3 (C7, C10), 56.9 (C11), 60.5 (C2), 172.5 (C3).  
Elemental Analysis (C11H22BrO2N) 
 
Calculated: C 47.1%, H 7.9%, Br 28.5%, N 5%, O 11.42%. 
 
Experimental: C 44.4%, H 7.8%, N 4.7%. 
 
Molecular Weight: 280.21 
 
Melting Point: 73.24 
 
Temperature of Decomposition: 179.52 
 
Solubility in water (25 ° C): 77.40 g/ 100 ml 
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Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Et3NC4]Br) 
 
 
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 1.19 (12 H, m, H1, H10, H11, H12), 1.77-1.88 (2 H, m, H5), 
2.45 (2 H, t, J=6.9 Hz, H4), 3.09-3.15 (2H, m, H6), 3.24 (6H, q, J=7.7 Hz, H7, H8, H9), 4.08 
(2 H, q, J=7.2 Hz, H2). 
13C NMR (75,47 MHz, DMSO): δ 14.1 (C10, C11, C12), 19.6 (C1), 23.5 (C5), 33.1 (C4), 
56.8 (C6), 58.0 (C7, C8, C9), 60.7 (C6), 62.7 (C2), 139.2 (C3).  
Elemental Analysis (C15H3BrO2N) 
 
Calculated: C 48.6%, H 8.9%, Br 26.9%, N 4.7%, O 10.8%. 
 
Experimental: C 48.0%, H 8.9%, N 4.5%. 
 
Molecular Weight: 296.25 
 
Melting Point: 77.97 
 
Temperature of Decomposition: 187.63 
 
Solubility in water (25 ° C): 72.50 g/ 100 ml 
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Tri(n-propyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Pr3NC4]Br) 
  
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 0.90 (9 H, t, J=7.2 Hz, H13, H14, H15), 1.20 (3 H, t, J=7.1 
Hz, H1), 1.57-1.70 (6 H, m, H10, H11, H12), 1.79-1.81 (2 H, m, H5), 2.43 (2 H, t, J=7.2 
Hz, H4), 3.12-3.20 (8 H, m, H6, H7, H8, H9) 4.08 (2 H, q, J=7.2 Hz, H2). 
13C NMR (75,47 MHz, DMSO): δ 11.1 (C13, C14, C15), 14.4 (C1), 15.2 (C10, C11, C12), 
16.8 (C5), 30.1 (C4), 59.7 (C6, C7, C8, C9), 60.7 (C2), 172.4 (C3).  
Elemental Analysis (C15H32BrO2N) 
 
Calculated: C 53.2%, H 9.5%, Br 23.6%, N 4.1%, O 9.4%. 
 
Experimental: C 51.5%, H 9.6%, N 4.2%. 
 
Molecular Weight: 338.33 
 
Melting Point: 78.18 
 
Temperature of Decomposition: 184.63 
 
Solubility in water (25 ° C): 73.20 g/ 100 ml 
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Tri(n-butyl)[2-butoxy-2-oxoethyl]ammonium bromide ([Bu3NC4]Br) 
  
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 0.94 (9 H, t, J=7.3 Hz, H16, H17, H18), 1.21 (3 H, t, J=7.4 
Hz, H1), 1.25-1.37 (6 H, m, H13, H14, H15), 1.54-1.64 (6 H, m, H10, H11, H12), 1.79-
1.89 (2 H, m, H5), 2.43 (2 H, t, J=6.7 Hz, H4), 3.15-3.21 (8 H, m, H6, H7, H8, H9), 4.09 (2 
H, q, J=7.1 Hz, H2). 
13C NMR (75,47 MHz, DMSO): δ 14.1 (C16, C17, C18), 19.6 (C1), 23.5 (C13, C14, C15), 
33.1 (C5), 56.8 (C10, C11, C12), 58.0 (C4), 60.7 (C6, C7, C8, C9), 62.7 (C2), 139.2 (C3).  
Elemental Analysis (C19H40BrO2N) 
 
Calculated: C 57.8%, H 10.2%, Br 20.2%, N 3.5%, O 8.1%. 
 
Experimental: C 57.1%, H 9.9%, N 3.5%. 
 
Molecular Weight: 394.44 
 
Melting Point: 79.64 
 
Temperature of Decomposition: 153.53 
 
Solubility in water (25 ° C): 79.50 g/ 100 ml 
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Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium saccharinate ([Pr3NC4][Sac]) 
 
1H and 13C NMR  
1H RMN (300 MHz, DMSO): δ 0.89 (9 H, t, J=7.2 Hz, H13, H14, H15), 1.20 (3 H, t, J=7.1 
Hz, H1), 1.56-1.69 (6 H, m, H10, H11, H12), 1.79-1.89 (2 H, m, H5), 2.42 (2 H, t, J=6.8 
Hz, H4), 3.11-3.20 (8 H, m, H6, H7, H8, H9) 4.08 (2 H, q, J=7.1 Hz, H2), 7.61 (2H, m, H2’, 
H5’), 7,68 (2H, m, H3’, H4’).  
13
C NMR (75,47 MHz, DMSO): δ 10.9 (C13, C14, C15), 14.6 (C1), 15.3 (C10, C11, 
C12), 17.2 (C5), 30.2 (C4), 59.8 (C6, C7, C8, C9), 60.6 (C2), 119.6 (C2’), 123.0 (C5’), 
131.6 (C6’), 132.3 (C4’), 135.0 (C3’), 145.6 (C1’), 168.0 (C7’), 172.4 (C3). 
Elemental Analysis (C22H36N2O5S) 
 
Calculated: C 59.9%, H 8.2%, N 6.3%, O 18.1%, S 7.2%. 
 
Experimental: C 56.1, H 8.2%, %, N 6.2%, O 7.0%. 
 
Molecular Weight: 440.60 
 
Melting Point: 98.51 
 
Temperature of Decomposition: 178.81 
 
Solubility in water (25 ° C): 78.02 g/ 100 ml 
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Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium lactate ([Pr3NC4][Lac]) 
 
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 0.90 (9 H, t, J=7.2 Hz, H13, H14, H15), 1.04 (3 H, d, J=7.0 
Hz, H1’), 1.20 (3H, q, J=7.1 Hz, H1), 1.22 (1 H, q, J=7.1 Hz, H2’), 1.57-1.69 (6 H, m, H10, 
H11, H12), 1.79-1.81 (2 H, m, H5), 2.42 (2 H, t, J=6.8 Hz, H4), 3.12-3.20 (8 H, m, H6, H7, 
H8, H9) 4.08 (2 H, q, J=7.1 Hz, H2). 
13
C NMR (75,47 MHz, DMSO): δ 11.1 (C13, C14, C15), 14.4 (C1), 15.2 (C10, C11, 
C12), 22.4 (C1’), 30.4 (C5), 31.2 (C4), 59.6 (C7, C8, C9), 61.1 (C6), 67.6 (C2), 154.1 
(C2’), 172.7 (C3, C3’).  
Elemental Analysis (C18H37NO5) 
 
Calculated: C 62.2%, H 10.7%, N 4.0%, O 23.0%. 
 
Experimental: C 62.8, H 10.0%, %, N 3.7%. 
 
Molecular Weight: 347.50 
 
Melting Point: 33.25 
 
Temperature of Decomposition: 189.64 
 
Solubility in water (25 ° C): 95.90 g/ 100 ml 
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Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium pyruvate ([Pr3NC4][Pyr]) 
 
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 0.90 (9 H, t, J=7.2 Hz, H13, H14, H15), 1.20 (3 H, t, J=7.1 
Hz, H1), 1.57-1.70 (6 H, m, H10, H11, H12), 1.79-1.81 (2 H, m, H5), 2.00 (3H, s, H1’), 
2.42 (2 H, t, J=6.8 Hz, H4), 3.12-3.20 (8 H, m, H6, H7, H8, H9) 4.08 (2 H, q, J=7.1 Hz, H2). 
13
C NMR (75,47 MHz, DMSO): δ 11.1 (C13, C14, C15), 14.4 (C1), 15.2 (C10, C11, 
C12), 17.2 (C5), 28.9 (C1’), 30.2 (C4), 59.7 (C6, C7, C8, C9), 60.7 (C2), 172.4 (C3, 
C3’), 207.6 (C2’).  
Elemental Analysis (C18H35NO5) 
 
Calculated: C 62.5%, H 10.2%, N 4.0%, O 23.1%. 
 
Experimental: C 49.5, H 8.9%, %, N 4.7%. 
 
Molecular Weight: 345.48 
 
Melting Point: 30.58 
 
Temperature of Decomposition: 172.33 
 
Solubility in water (25 ° C): 84.30 g/ 100 ml 
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 215 
Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium dicyanamide ([Pr3NC4][Dca]) 
 
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 0.90 (9 H, t, J=7.2 Hz, H13, H14, H15), 1.20 (3 H, t, J=7.1 
Hz, H1), 1.57-1.70 (6 H, m, H10, H11, H12), 1.79-1.81 (2 H, m, H5), 2.43 (2 H, t, J=7.2 
Hz, H4), 3.12-3.20 (8 H, m, H6, H7, H8, H9) 4.08 (2 H, q, J=7.2 Hz, H2). 
13
C NMR (75,47 MHz, DMSO): δ 11.1 (C13, C14, C15), 14.4 (C1), 15.2 (C10, C11, 
C12), 17.2 (C5), 30.2 (C4), 59.7 (C6, C7, C8, C9), 60.7 (C2), 120.0 (C1’), 172.4 (C3).  
 
Elemental Analysis (C17H32N4O2) 
 
Calculated: C 62.9%, H 9.9%, N 17.2%, O 9.8%. 
 
Experimental: C 60.1, H 9.8%, %, N 16.5%. 
 
Molecular Weight: 324.47 
 
Melting Point: 35.99 
 
Temperature of Decomposition: 156.59 
 
Solubility in water (25 ° C): 74.70 g/ 100 ml 
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Tri(n-ethyl)[2-butoxy-2-oxoethyl]ammonium salicylate ([Pr3NC4][Sal]) 
 
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 0.89 (9 H, t, J=7.2 Hz, H13, H14, H15), 1.20 (3H, t, J=7.1 
Hz, H1), 1.56-1.68 (6 H, m, H10, H11, H12), 1.79-1.89 (2 H, m, H5), 2.40 (2 H, t, J=7.1 
Hz, H4), 3.11-3.20 (8 H, m, H6, H7, H8, H9) 4.08 (2 H, q, J=7.1 Hz, H2), 6.54 (1H, dd, 
J=7.4, 1.2 Hz, H3’), 6.59 (1H, dd, J=8.1, 1.0 Hz, H5’), 7.10 (1H, ddd, J= 8.1, 7.1, 1.9, H4’), 
7.63 (1H, dd, J=7.6, 1.9 Hz, H2’). 
13
C NMR (75,47 MHz, DMSO): δ 11.1 (C13, C14, C15), 14.4 (C1), 15.1 (C10, C11, 
C12), 17.2 (C5), 30.2 (C4), 59.7 (C1’), 60.8 (C5), 116.0 (C5’), 116.2 (C3’), 121.5 (C1’), 
130.2 (C4’), 131.8 (C2’), 163.6 (C6’), 171.6 (C3), 172.7 (C1’’). 
Elemental Analysis (C22H37NO5) 
 
Calculated: C 66.8%, H 9.4%, N 3.5%, O 20.2%. 
 
Experimental: C 61.4, H 9.6%, %, N 3.2%. 
 
Molecular Weight: 395.54 
 
Melting Point: 60.78 
 
Temperature of Decomposition: 151.23 
 
Solubility in water (25 ° C): 77.95 g/ 100 ml 
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Triethyl[2-ethoxy-2-oxoethyl]ammonium salicylate ([Pr3NC2][Sal]) 
 
1H and 13C NMR  
1H NMR (300 MHz, DMSO): δ 0.88 (9 H, t, J=7.2 Hz, H11, H12, H13), 1.24 (3H, t, J=7.1 
Hz, H1), 1.59-1.72 (6 H, m, H8, H9, H10), 3.35-3.40 (6 H, m, H2) 4.23 (2 H, q, J=7.1 Hz, 
H2), 4.36 (2H, s, H4), 6.56 (1H, dd, J=7.4, 1.1 Hz, H3’), 6.60 (1H, dd, J=8.1, 0.8 Hz, H5’), 
7.12 (1H, ddd, J= 8.1, 7.1, 1.9, H4’), 7.64 (1H, dd, J=7.6, 1.7 Hz, H2’). 
13
C NMR (75,47 MHz, DMSO): δ 10.9 (C11, C12, C13), 14.2 (C1), 15.5 (C8, C9, C10), 
61.5 (C4), 62.5 (C2, C5, C6, C7), 116.2 (C5’), 116.3 (C3’), 120.8 (C1’), 130.3 (C2’), 
131.8 (C4’), 163.6 (C6’), 165.2 (C3) 171.6 (C1’’). 
Elemental Analysis (C20H33NO5) 
 
Calculated: C 65.3%, H 9.0%, N 3.8%, O 21.7%. 
 
Experimental: C 62.8, H 8.9%, %, N 3.7%. 
 
Molecular Weight: 367.49 
 
Melting Point: 50.76 
 
Temperature of Decomposition: 176.97 
 
Solubility in water (25 ° C): 94.60 g/ 100 ml 
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Table E1. Experimental weight fraction data for the systems composed of IL (1) + 
K3C6H5O7/C6H8O7 (2) + H2O (3) at 25°C. 
 
[MepyrNC4]Br [Et3NC4]Br [Pr3NC4]Br [Bu3NC4]Br 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 100 w1 100 w2 
62.561 3.612 71.388 0.901 68.296 1.377 71.145 1.942 
59.620 4.436 64.445 3.595 63.890 1.665 64.578 2.334 
54.880 5.301 52.891 5.155 55.345 2.423 56.869 2.569 
52.305 6.323 46.082 7.548 52.219 2.892 54.145 3.178 
50.025 7.159 42.637 9.830 47.855 3.736 51.950 3.614 
47.703 7.952 37.676 12.528 45.762 4.670 49.646 3.983 
45.567 8.885 35.427 12.677 43.724 5.615 47.373 4.398 
42.686 10.595 30.399 16.473 42.033 6.403 46.115 4.870 
39.766 12.436 26.509 19.341 39.542 7.198 44.447 4.606 
37.536 13.565 24.643 20.932 38.013 8.000 43.296 4.981 
35.529 14.797 23.053 22.209 35.076 9.823 42.383 5.378 
33.289 16.292 21.754 23.300 33.984 10.464 41.559 5.766 
30.995 17.916 20.183 24.675 32.727 11.188 40.732 6.046 
29.235 19.081 19.028 25.631 30.069 13.029 39.950 6.116 
27.745 20.241 18.191 26.313 29.272 13.398 39.083 6.293 
26.785 20.833 17.259 27.126 28.238 14.053 37.773 7.046 
24.839 22.314 16.273 28.087 27.166 14.777 37.429 7.390 
23.274 23.476 15.431 28.809 26.297 15.410 36.598 7.742 
22.061 24.379 14.615 29.607 25.398 15.957 35.797 8.012 
20.360 25.770 13.789 30.511 24.681 16.533 35.034 8.246 
19.386 26.518 13.336 30.078 23.923 17.074 34.211 8.612 
18.161 27.604   23.185 17.677 33.303 8.721 
17.002 28.598   22.522 18.066 32.574 9.075 
15.949 29.548   21.806 18.627 31.613 9.241 
14.858 30.626   21.161 19.103 30.930 9.600 
13.905 31.563   20.589 19.520 30.381 9.818 
12.836 32.694   20.115 19.829 29.927 9.911 
11.384 34.382   19.613 20.096 29.341 10.270 
    18.996 20.519 28.828 10.454 
    18.491 20.869 28.257 10.827 
    18.029 21.189 27.653 11.196 
    17.659 21.389 27.310 11.298 
    17.216 21.671 26.758 11.588 
    16.712 22.122 26.308 11.799 
    16.352 22.367 25.941 11.932 
    15.946 22.706 25.656 11.940 
    15.544 22.973 24.834 12.420 
    15.135 23.252 24.484 12.654 
    14.712 23.598 24.222 12.739 
    14.306 23.975 23.864 12.970 
    13.984 24.194 23.521 13.210 
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    13.596 24.492 23.263 13.273 
    13.260 24.819 23.015 13.364 
    12.956 25.094 22.623 13.594 
    12.592 25.420 22.250 13.827 
    12.299 25.659 21.867 13.993 
    11.990 25.911 21.504 14.163 
    11.683 26.191 21.278 14.204 
    11.390 26.468 20.938 14.380 
    11.106 26.737 20.650 14.523 
    10.836 27.020 20.382 14.685 
    10.546 27.368 20.195 14.768 
    10.324 27.580 19.965 14.953 
    10.098 27.798 19.780 14.976 
    9.900 28.045 19.534 15.170 
    9.427 28.522 19.321 15.280 
    9.190 28.799 19.078 15.464 
    8.960 29.082 18.614 15.653 
    8.764 29.300 18.352 15.772 
    8.570 29.514 18.106 15.922 
    8.359 29.796 17.833 15.958 
      17.596 16.108 
      17.391 16.213 
      17.199 16.329 
      16.993 16.470 
      16.665 16.567 
      16.460 16.654 
      16.264 16.747 
      16.038 16.963 
      15.849 17.076 
      15.668 17.179 
      15.486 17.284 
      15.312 17.359 
      15.123 17.453 
      14.946 17.590 
      14.782 17.670 
      14.604 17.759 
      14.445 17.861 
      14.282 17.943 
      14.090 18.085 
      13.905 18.255 
      13.631 18.364 
      13.365 18.473 
      13.155 18.683 
      12.928 18.775 
      12.676 18.947 
      12.469 19.098 
 220 
      12.253 19.270 
      12.037 19.373 
      11.786 19.547 
      11.542 19.758 
      11.233 19.982 
      10.911 20.222 
      10.603 20.482 
      10.292 20.744 
      10.069 20.625 
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Table E2. Experimental weight fraction data for the systems composed of IL (1) + 
K3C6H5O7/C6H8O7 (2) + H2O (3) at 25°C. 
 
[Pr3NC4][Lac] [Pr3NC4][Dca] [Pr3NC4][Pyr] [Pr3NC4][Sac] 
100 w1 100 w1 100 w2 100 w2 100 w1 100 w2 100 w1 100 w2 
54.633 10.399 70.322 0.506 34.046 26.369 58.403 0.516 
50.605 12.069 56.293 1.081 32.658 27.454 51.549 1.328 
47.311 12.874 44.247 1.472 30.827 28.060 45.777 1.808 
44.876 13.864 39.884 1.480 29.131 28.354 40.895 2.288 
42.044 15.416 36.306 1.840 27.785 28.452 37.451 3.156 
38.018 17.146 33.305 2.016 26.921 29.193 34.358 4.869 
35.643 18.465 31.123 2.151 25.800 29.709 27.706 6.334 
33.885 19.373 70.322 0.506 24.628 29.932 25.881 8.066 
31.650 20.522 56.293 1.081 23.850 30.601 23.979 10.197 
28.991 22.111 44.247 1.472 23.330 30.861 22.724 11.416 
26.350 23.847 39.884 1.480 22.868 30.958 21.403 12.846 
24.700 24.817 36.306 1.840 22.301 31.389 20.179 14.017 
22.809 25.548 33.305 2.016 21.759 31.987 19.012 15.148 
21.505 26.388 31.123 2.151 21.266 32.188 17.884 16.364 
20.042 27.355 28.264 2.963 20.678 32.659 16.867 17.551 
18.680 28.287 25.178 3.511 20.086 33.456 16.103 18.282 
17.687 28.977 22.629 3.736 19.504 33.956 15.228 19.188 
16.682 29.690 20.001 4.450 18.955 34.312 14.508 20.063 
15.758 30.305 18.081 4.790 18.456 34.781 13.887 20.782 
14.991 30.874 28.264 2.963 17.780 35.101 13.172 21.600 
14.322 31.366 25.178 3.511 17.380 35.561 12.623 22.187 
13.038 32.332 8.152 9.026 17.022 36.058 12.065 22.785 
12.398 32.853 7.806 9.355 16.420 36.343 11.533 23.406 
11.891 33.245 7.718 9.434 16.176 36.400 11.043 23.993 
11.487 33.537 7.929 9.446 15.958 36.530 10.583 24.544 
10.904 34.037 7.840 9.782 15.659 37.055 10.163 25.095 
10.478 34.391 7.834 9.952 15.344 37.502 9.724 25.738 
9.656 35.147 7.643 10.551 15.095 37.486 9.399 26.131 
8.835 35.916 7.484 10.800 14.801 37.842 9.076 26.522 
  7.376 11.110 14.663 37.932 8.798 26.946 
  7.389 11.297 14.395 38.273 8.163 27.746 
  7.254 12.790 14.221 38.338 7.856 28.190 
  7.110 11.833 13.995 38.692 7.566 28.630 
  6.932 13.348 13.656 38.625 7.324 28.962 
  6.863 13.917 13.479 38.976 7.090 29.282 
  6.869 14.556 13.106 39.668 6.840 29.694 
  6.474 15.091 12.908 39.969   
  6.228 15.583 12.758 39.920   
  5.514 17.046 12.472 40.406   
  5.634 17.902 12.294 40.632   
  4.995 18.918 12.119 40.948   
 222 
    11.684 41.189   
    11.502 41.554   
    11.379 41.508   
    11.236 41.830   
    11.065 42.018   
    10.923 42.209   
    10.775 42.322   
 223 
Table E3. Experimental weight fraction data for the systems composed of IL (1) + 
K3C6H5O7/C6H8O7 (2) + H2O (3) at 25°C. 
 
[Pr3NC4][Sal] [Pr3NC2][Sal] 
100 w1 100 w2 100 w1 100 w2 
68.963 0.961 63.426 3.602 
62.076 1.847 54.584 4.453 
59.345 2.595 47.568 5.162 
55.627 3.192 43.422 5.999 
51.132 3.680 39.607 6.649 
47.180 4.160 37.519 7.355 
44.902 4.566 34.857 7.772 
42.803 5.019 32.916 8.301 
40.931 5.341 31.254 8.788 
39.043 5.699 29.760 9.316 
37.478 6.057 28.023 9.427 
36.139 6.321 26.660 9.955 
34.579 6.599 25.525 10.166 
33.766 6.970 24.644 10.531 
32.589 7.126 23.453 10.853 
31.310 7.316 22.506 11.121 
30.666 7.604 21.627 11.394 
29.628 7.688 20.828 11.582 
28.635 7.860 20.059 11.783 
28.139 8.054 19.361 11.998 
27.219 8.176 18.727 12.197 
26.415 8.312 18.119 12.343 
25.959 8.534 17.556 12.479 
25.169 8.725 17.120 12.674 
24.574 8.884 16.535 12.939 
23.937 9.035 15.788 13.153 
23.392 9.177 15.549 13.349 
22.804 9.256 15.234 13.588 
22.287 9.377 14.827 13.637 
21.779 9.436 14.495 13.785 
21.737 9.738 14.101 13.822 
21.013 9.986 13.723 13.920 
20.435 10.087 13.495 14.044 
20.168 10.165 13.113 14.270 
19.863 10.232 12.776 14.346 
19.600 10.283 12.484 14.422 
19.310 10.408 12.242 14.443 
19.036 10.530 11.948 14.490 
18.771 10.617 11.635 14.795 
18.513 10.663 11.423 14.832 
18.245 10.743 11.258 14.844 
 224 
17.809 10.772 11.055 14.881 
17.587 10.878 10.842 14.935 
17.364 10.994 10.717 15.074 
17.146 11.094 10.542 15.145 
16.935 11.215 10.342 15.180 
16.725 11.311 10.224 15.277 
16.379 11.269 10.075 15.374 
16.218 11.344 9.873 15.496 
16.052 11.397 9.660 15.504 
15.889 11.458 9.583 15.531 
15.745 11.516 9.499 15.657 
15.464 11.488 9.377 15.698 
15.292 11.563 9.262 15.732 
15.144 11.602 9.063 15.959 
14.954 11.766 8.922 15.958 
14.779 11.868 8.734 16.111 
14.629 11.970 8.574 16.185 
14.490 12.031 8.341 16.290 
14.334 12.097 8.140 16.432 
14.117 12.107 7.964 16.575 
13.976 12.178 7.857 16.613 
13.869 12.279 7.694 16.676 
13.672 12.327 7.604 16.711 
13.546 12.413 7.490 16.730 
13.371 12.437 7.418 16.823 
13.182 12.611 7.290 16.920 
13.015 12.606 7.188 17.012 
12.868 12.609 7.079 17.119 
12.757 12.641 6.920 17.349 
12.676 12.693 6.816 17.307 
12.565 12.762 6.745 17.305 
12.476 12.842 6.710 17.328 
12.327 12.868 6.654 17.415 
12.214 12.913 6.576 17.557 
12.115 12.954 6.517 17.518 
12.001 13.008 6.483 17.527 
11.896 13.055 6.441 17.580 
11.805 13.088 6.397 17.641 
11.701 13.145 6.349 17.695 
11.629 13.204 6.283 17.713 
11.475 13.186 6.243 17.757 
11.408 13.237 6.203 17.809 
11.239 13.339 6.148 17.881 
11.084 13.436 6.106 17.941 
10.899 13.507 6.046 17.978 
10.702 13.691 5.993 18.012 
 225 
10.462 13.811 5.884 18.343 
10.262 13.908 63.426 3.602 
10.096 13.962 54.584 4.453 
9.923 14.087 47.568 5.162 
 
Table E6. Recovery yield (RY%PROT) and purification yield (PY%PROT) of MRJP and weight 
fraction compositions of the initial mixtures at 25 °C. 
 
IL 
Weight fraction  
composition / (wt %) DE%HSA ± σ DE%IgG± σ 
IL  K3C6H5O7/C6H8O7 
[MepyrNC4]Br 30.38 ± 0.03 29.17 ± 0.05 100 100 
[Et3NC4]Br 30.02 ± 0.04 29.57 ± 0.02 100 100 
[Pr3NC4]Br 30.22 ± 0.01 29.57 ± 0.08 100 100 
[Bu3NC4]Br 30.22 ± 0.05 29.55 ± 0.02 100 100 
[Pr3NC4][Pyr] 30.26 ± 0.01 30.31 ± 0.07 100 100 
[Pr3NC4][Lac] 29.62 ± 0.11 29.91 ± 0.06 100 100 
[Pr3NC2][Sal] 29.56 ± 0.05 29.61 ± 0.11 100 100 
[Pr3NC4][Sal] 29.52 ± 0.01 29.75 ± 0.09 100 100 
[Pr3NC4][Sac] 29.62 ± 0.04 29.99 ± 0.11 100 100 
[Pr3NC4][Dca] 30.54 ± 0.05 29.17 ± 0.02 100 100 
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Figure E2. IgG calibration curve by SE-HPLC. 
 
 
Figure E3. HSA calibration curve by SE-HPLC. 
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Figure E4. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with [Et3NC4]
+. 
 
Figure E5. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with [Pr3NC4]
+. 
 
Figure E6. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with [Pr3NC2]
+. 
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Figure E7. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with Br-. 
 
Figure E8. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with [Pyr]-. 
 
Figure E9. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with [Sac]-. 
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Figure E10. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with [Sal]-. 
 
Figure E11. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with [Et3NC4]
+. 
 
Figure E12. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with [Pr3NC4]
+. 
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Figure E13. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with [Pr3NC2]
+. 
 
Figure E14. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with Br-. 
 
Figure E15. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with [Pyr]-. 
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Figure E16. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with [Sac]-. 
 
Figure E17. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with [Sal]-. 
 
Figure E18. Docking pose with the lowest absolute value of affinity (kcal/mol) for 
Transferrin with [Et3NC4]
+. 
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Figure E19. Docking pose with the lowest absolute value of affinity (kcal/mol) for 
Transferrin with [Pr3NC4]
+. 
 
Figure E20. Docking pose with the lowest absolute value of affinity (kcal/mol) for 
Transferrin with [Pr3NC2]
+. 
 
Figure E21. Docking pose with the lowest absolute value of affinity (kcal/mol) for 
Transferrin with Br-. 
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Figure E22. Docking pose with the lowest absolute value of affinity (kcal/mol) for 
Transferrin with [Pyr]-. 
 
Figure E23. Docking pose with the lowest absolute value of affinity (kcal/mol) for 
Transferrin with [Sac]-. 
 
Figure E24. Docking pose with the lowest absolute value of affinity (kcal/mol) for 
Transferrin with [Sal]-. 
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Figure E25.Molecular interaction diagrams of [MepyrNC4]
+ and amino acids residues of 
HSA. 
 
Figure E26.Molecular interaction diagrams of [EtNC4]
+ and amino acids residues of 
HSA. 
 
Figure E27.Molecular interaction diagrams of [PrNC4]
+ and amino acids residues of 
HSA. 
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Figure E28.Molecular interaction diagrams of [BuNC4]
+ and amino acids residues of 
HSA. 
 
Figure E29.Molecular interaction diagrams of [Dca]- and amino acids residues of HSA. 
 
Figure E30.Molecular interaction diagrams of [Pyr]- and amino acids residues of HSA. 
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Figure E31.Molecular interaction diagrams of [Sac]- and amino acids residues of HSA. 
 
Figure E32.Molecular interaction diagrams of [Sal]- and amino acids residues of HSA. 
 
Figure E33.Molecular interaction diagrams of [MepyrNC4]
+ and amino acids residues of 
IgG. 
PHE223
ILE290
π-Sulfur
Hydrogen Bond
ALA291
Hydrophobic
ARG222
LEU219
LEU238
TYR411
Hydrophobic
PRO15
Hydrogen Bond
HIS281
 237 
 
Figure E34.Molecular interaction diagrams of [EtNC4]
+ and amino acids residues of IgG. 
 
Figure E35.Molecular interaction diagrams of [PrNC2]
+ and amino acids residues of IgG. 
 
Figure E36.Molecular interaction diagrams of [PrNC4]
+ and amino acids residues of IgG. 
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Figure E37.Molecular interaction diagrams of [BuNC4]
+ and amino acids residues of 
IgG. 
 
Figure E38.Molecular interaction diagrams of [Lac]- and amino acids residues of IgG. 
 
Figure E39.Molecular interaction diagrams of [Dca]- and amino acids residues of IgG. 
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Figure E40.Molecular interaction diagrams of [Pyr]- and amino acids residues of IgG. 
 
Figure E41.Molecular interaction diagrams of [Sac]- and amino acids residues of IgG. 
 
Figure E42.Molecular interaction diagrams of [Sal]- and amino acids residues of IgG. 
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Figure E43.Molecular interaction diagrams of [MepyrNC4]
+ and amino acids residues of 
Transferrin. 
 
Figure E44.Molecular interaction diagrams of [EtNC4]
+ and amino acids residues of 
Transferrin. 
 
Figure E45.Molecular interaction diagrams of [PrNC2]
+ and amino acids residues of 
Transferrin. 
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Figure E46.Molecular interaction diagrams of [PrNC4]
+ and amino acids residues of 
Transferrin. 
 
Figure E47.Molecular interaction diagrams of [BuNC4]
+ and amino acids residues of 
Transferrin. 
 
Figure E48.Molecular interaction diagrams of [Lac]- and amino acids residues of 
Transferrin. 
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Figure E49.Molecular interaction diagrams of [Dca]- and amino acids residues of 
Transferrin. 
 
Figure E50.Molecular interaction diagrams of [Pyr]- and amino acids residues of 
Transferrin. 
 
Figure E51.Molecular interaction diagrams of [Sac]- and amino acids residues of 
Transferrin. 
Hydrogen Bond
TYR188
SER189
Hydrogen Bond
PHE282
HIS289
SER21
PRO288
Hydrogen Bond
GLN184
 243 
 
Figure E52.Molecular interaction diagrams of [Sal]- and amino acids residues of 
Transferrin. 
Hydrogen Bond
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Table E7. Docking affinity energy and interacting amino acid residues predicted by AutoDock vinna for HSA-ILs. 
Compound Affinity (kcal/mol) 
Interacting nucleic acids Type of interaction From To Distance (Å) 
[MepyrNC4]
+ -4.7 TYR161 Hydrogen Bond Tyrosine - OH [MepyrNC4]
+- O 3.16 
[Et3NC4]
+ -4.1 
GLU153 Electrostatic [Et3NC4]
+ - N GlutamicAcid - O 4.40 
ARG257 Hydrogen Bond 
Arginine - N [Et3NC4]
+ - O 2.92 
Arginine - NH2 [Et3NC4]
+ - O 2.80 
HIS242 Hydrophobic [Et3NC4]
+ - C Histidine - H 3.61 
[Pr3NC2]
+ -3.8 - - - - - 
[Pr3NC4]
+ -4.1 THR506 Hydrogen Bond [Pr3NC4]
+ - C Threonine - O 3.39 
[Bu3NC4]
+ -3.9 
SER480 Hydrogen Bond 
[Bu3NC4]
+ - C 
Serine - O 3.55 
LEU347 
Hydrophobic 
Leucine - C 4.84 
LYS351 Lysine - C 3.65 
Br- -1.0 - - - - - 
[Pyr]- -3.5 
SER202 
Hydrogen Bond 
Serine - O [Pyr]- - O 2.99 
LYS199 Lysine - C [Pyr]- - O 3.74 
[Sal]- -5.7 TYR411 Hydrophobic Tyrosine - C [Sal]- - C 3.78 
[Sac]- -5.8 
ARG222 
Hydrogen Bond 
Arginine - N [Sac]- - O 2.80 
ILE290 [Sac]- - N Isoleucine- C 3.04 
PHE223 π-Sulfur [Sac]- - S Phenylalanine- C 5.75 
LEU219 
Hydrophobic 
[Sac]- - C Leucine - C 4.94 
LEU238 [Sac]- - C Leucine - C 5.20 
ALA291 [Sac]- - C Alanine - C 4.68 
[Lac]- -3.5 - - - - - 
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[Dca]- -3.1 
VAL315 
Hydrogen Bond 
Cysteine - N 
[Dca]- - N 
3.06 
CYS316 Valine - N 3.20 
LYS317 Lysine - N 3.29 
TYR370 Tyrosine - OH 2.97 
 
Table E8. Docking affinity energy and interacting amino acid residues predicted by AutoDock vinna for IgG-ILs. 
Compound 
Affinity 
(kcal/mol) 
Interacting nucleic 
acids 
Type of interaction From To Distance (Å) 
[MepyrNC4]
+ -3.6 
HIS281 
Hydrogen Bond [MepyrNC4]
+- C  
Histidine - O 3.37 
PRO15 Proline - O 3.71 
[Et3NC4]
+ -3.2 
TRP290 
Hydrogen Bond 
Tryptophan - N 
[Et3NC4]
+ - O 
3.25 
THR306 Threonine - O 3.23 
SER323 Serine - O 2.92 
[Pr3NC2]
+ -3.3 
TRP103 
Hydrogen Bond 
Tryptophan - N 
[Pr3NC2]
+ - O 
3.14 
VAL102 Valine - C 3.27 
[Pr3NC4]
+ -3.5 
PHE288 
Hydrogen Bond 
Phenylalanine- N 
[Pr3NC4]
+ - O 
2.90 
THR306 Threonine - O 2.89 
PHE288 [Pr3NC4]
+ - C Phenylalanine- O 
3.54 
3.36 
[Bu3NC4]
+ -3.7 
ILE400 Hydrogen Bond 
[Bu3NC4]
+ - C 
Isoleucine - O 3.41 
LYS261 Hydrophobic Lysine - C 4.68 
Br- -0.9 - - - -  
[Pyr]- -3.2 SER280 Hydrogen Bond Serine - O [Pyr]- - O 3.07 
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GLY250 Glycine - C 3.51 
SER280 Serine - C 3.22 
[Sal]- -4.4 
SER473 
Hydrogen Bond 
Serine - O [Sal]- - O 
3.19 
3.14 
SER471 [Sal]- - H Serine - O 2.46 
ARG376 Electrostatic Arginine - NH 
[Sal]- - C 
3.45 
LEU472 
Hydrophobic 
Leucine - C 3.62 
PRO373 [Sal]- - C Proline - O 5.10 
[Sac]- -5.1 
THR97 
Hydrogen Bond 
Threonine - O 
[Sac]- - O 
2.87 
PHE98 Phenylalanine- N 3.02 
THR97 [Sac]- - N Threonine - O 3.15 
[Lac]- -3.3 ASP167 Hydrogen Bond [Lac]- - H  AsparticAcid - O 2.03 
[Dca]- -2.9 
TYR186 
Hydrogen Bond 
Tyrosine - OH 
[Dca]- - N 
3.02 
GLY212 Glycine - N 3.16 
GLU213 GlutamicAcid - N 3.17 
 
Table E9. Docking affinity energy and interacting amino acid residues predicted by AutoDock vinna for Tranferrin-ILs. 
Compound 
Affinity 
(kcal/mol) 
Interacting nucleic 
acids 
Type of interaction From To Distance (Å) 
[MepyrNC4]
+ -3.9 GLN271 Hydrogen Bond [MepyrNC4]
+- C  Glutamine - O 3.78 
[Et3NC4]
+ -3.1 LYS291 Hydrogen Bond Lysine - N [Et3NC4]
+ - O 3.05 
[Pr3NC2]
+ -3.1 GLY34 Hydrogen Bond [Pr3NC2]
+ - C  Glycine - O 3.77 
[Pr3NC4]
+ -3.4 GLY190 Hydrogen Bond Glycine - N [Pr3NC4]
+ - O 3.10 
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SER189 Serine - C 3.32 
[Bu3NC4]
+ -3.3 
ALA322 
Hydrophobic 
Alanine - C [Bu3NC4]
+ - C 3.86 
ILE130 [Bu3NC4]
+ - C Isoleucine - C 4.45 
Br- -0.8 - - - -  
[Pyr]- -3.3 
SER21 
Hydrogen Bond 
Serine - O 
[Pyr]- - O 
3.05 
LYS18 Lysine - C 3.35 
PRO288 Proline - C 3.39 
HIS289 Histidine - C 3.32 
[Sal]- -4.2 ALA322 Hydrogen Bond Alanine - O [Sal]- - O 3.48 
[Sac]- -4.5 GLN184 Hydrogen Bond [Sac]- - O  Glutamine - O 3.28 
[Lac]- -3.4 
ARG124 Electrostatic Arginine - N 
[Lac]- - O 
3.14 
ASP63 
Hydrogen Bond 
AsparticAcid - N 3.02 
HIS249 Histidine - C 3.42 
[Dca]- -3.0 
TYR188 
Hydrogen Bond 
Tyrosine - N 
[Dca]- - N 
3.14 
SER189 Serine - N 3.09 
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Section F5. Synthesis and characterization of the Good’s buffers ionic liquids 
[P4444][MES]: From the MES buffer (48.5 mmol), this compound was obtained as a 
white solid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 3.63 (t, 4H), 2.99 
(t, 2H), , 2.72 (t, 2H), 2.50 (t, 4H), 2.02 (m, 8H), 1.27-1.42 (m, 16H), 0.78 (t,12H,). 13C 
NMR (75.47 MHz, D2O/TSP): 68.80, 55.44, 55.11, 50.02, 26.28, 20.80, 20.16, 15.44.  
[P4444][TES]: From the TES buffer (45.1 mmol), this compound was obtained as a 
transparent viscous liquid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 
3.31 (s, 6H), 2.82 (s, 2H), 2.57 (t, 2H), 2.10 (m, 8H), 1.29-1.49 (m,16H), 0.79 (t, 12H). 
13C NMR (75.47 MHz, D2O/TSP): 60.65, 57.63, 51.58, 37.69, 26.28, 20.83, 20.17, 
15.46.  
[P4444][CHES]: From the CHES buffer (47.2 mmol), this compound was obtained as a 
transparent viscous liquid. Water content <0.05 wt%. 1H NMR (300 MHz, D2O/TSP); 1H 
NMR (300 MHz, D2O/TSP); 2.95 (m, 2H), 2.38-2.47 (m, 1H), 2.02 (m, 8H), 1.28-1.45 (m, 
16H,), 0.94 (m, 10H), 0.78 (t, 12H). 13C NMR (75.47 MHz, D2O/TSP): 63.37, 63.09, 
53.42, 39.56, 26.28, 26.08, 25.60, 20.30, 20.15, 15.43.  
[P4444][HEPES]: From the HEPES buffer (44.3 mmol), this compound was obtained as a 
yellowish white solid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 3.59 
(t,4H), 2.97 (t, 2H), 2.94 (t, 2H), 2.67 (t, 2H), 2.46 (t, 8H), 2.03 (m, 8H), 1.28-1.45 (m, 
16H), 0.79 (t, 12H). 13C NMR (75.47 MHz, D2O/TSP): 61.59, 60.87, 55.02, 54.78, 54.19, 
50.39, 26.29, 20.80, 20.16, 15.44.  
[P4444][Tricine]: From the Tricine buffer (50.3 mmol), this compound was obtained as 
white solid. Water content < 0.05 wt%. 1H NMR (300 MHz, D2O/TSP): 3.37 (s, 6H), 3.12 
(s, 2H), 2.00 (m, 8H), 1.27-1.44 (m, 16H), 0.77 (t. 12H). 13C NMR (75.47 MHz, 
D2O/TSP): 182.71, 63.12, 62.97, 47.68, 26.28, 20.79, 20.15, 15.42. 
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Figure F1. Experimental data for CF of the systems composed of [P4444][MES] + 
K3C6H5O7 + H2O at (25 ± 1) °C. 
 
Figure F2. Experimental data for CF of the systems composed of [P4444][HEPES] + 
K3C6H5O7 + H2O at (25 ± 1) °C. 
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Figure F3. Experimental data for CF of the systems composed of [P4444][Tricine] + 
K3C6H5O7 + H2O at (25 ± 1) °C. 
 
Figure F4. Experimental data for CF of the systems composed of [P4444][TES] + 
K3C6H5O7 + H2O at (25 ± 1) °C. 
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Figure F5. BLItz calibration curve for PSA in aqueous solution. 
 
Figure F6. SE-HPLC profile of pure PSA in aqueous solution, human urine (from a 
female donor and from a healthy male donor) and in the top and bottom phases of an 
ABS composed of [P4444][CHES] + salt + human urine: (a) PSA in aqueous solution 
(150 mg/ml); (b) Female urine sample; (c) IL rich-phase (female pure urine); (d) Salt 
rich-phase (female pure urine).  
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Figure F7. The PSA docking pose with the lowest absolute value of affinity (kcal/mol) 
for PSA with [HEPES]
-
. 
 
Figure F8. The PSA docking pose with the lowest absolute value of affinity (kcal/mol) 
for PSA with [TES]
-
. 
 
Figure F9. The PSA docking pose with the lowest absolute value of affinity (kcal/mol) 
for PSA with [Tricine]
-
. 
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Figure F10: Molecular interaction diagrams of [CHES]
-
 and amino acids residues of 
PSA. 
 
Figure F11: Molecular interaction diagrams of [MES]
-
 and amino acids residues of 
PSA. 
 
Figure F12: Molecular interaction diagrams of [HEPES]
-
 and amino acids residues of 
PSA. 
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Figure F13: Molecular interaction diagrams of [TES]
-
 and amino acids residues of 
PSA. 
 
 
Figure F14: Molecular interaction diagrams of [Tricine]
-
 and amino acids residues of 
PSA. 
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Table F1. Experimental weight fraction data for the system composed of IL (1) + 
K3C6H5O7 (2) + H2O (3) at 25 °C and atmospheric pressure. 
[P4444][TES] [P4444][MES] [P4444][HEPES] 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
76.71 0.96 62.37 1.95 79.05 1.21 
70.87 1.36 55.07 3.07 57.38 3.82 
68.27 2.17 46.15 5.21 54.39 4.36 
65.19 2.44 38.99 7.55 52.99 4.88 
61.73 2.92 35.53 9.45 51.00 5.21 
59.35 3.82 32.17 10.43 49.78 5.79 
57.40 4.38 29.24 12.18 48.55 6.45 
55.12 4.67 25.01 14.22 46.85 6.80 
51.18 5.62 24.37 14.94 45.84 7.21 
48.08 6.76 23.45 15.59 44.92 7.54 
45.45 7.58 22.73 15.99 43.94 8.03 
44.36 8.01 22.10 16.27 43.08 8.33 
43.30 8.31 21.05 17.21 42.24 8.63 
41.47 9.27 20.19 17.49 41.06 9.46 
39.38 10.12 19.88 17.71 40.29 9.76 
37.71 10.70 19.30 18.08 39.61 9.99 
36.76 11.09 18.82 18.32 38.78 10.41 
35.71 11.69 18.48 18.78 38.09 10.79 
34.46 12.49 17.96 19.05 37.15 11.51 
33.18 12.85 17.56 19.34 36.51 11.87 
32.30 13.27 17.16 19.51 35.92 12.10 
31.34 13.85 16.73 19.90 35.09 12.68 
30.81 13.98 16.30 20.01 34.58 12.88 
29.88 14.51 15.93 20.21 33.99 13.09 
29.46 14.56 15.77 20.58 33.20 13.63 
28.66 14.96 15.05 21.16 32.72 13.81 
27.96 15.39 14.78 21.34 31.98 14.39 
27.22 15.82 14.47 21.49 31.54 14.60 
26.42 15.92 14.02 21.86 31.09 14.79 
 259 
25.57 16.33 13.60 22.21 30.50 15.29 
24.21 16.84 13.35 22.44 30.07 15.47 
23.85 16.93 13.12 22.55 29.44 15.97 
23.30 17.33 12.86 22.75 29.03 16.18 
22.99 17.35 12.62 22.89 28.48 16.60 
22.38 17.80 12.33 23.10 28.11 16.77 
21.60 18.21 12.13 23.25 27.54 17.25 
21.33 18.26 11.94 23.41 27.16 17.43 
20.90 18.58 11.64 23.79 26.77 17.63 
20.47 18.89 11.41 23.87 26.26 18.10 
20.22 18.89 11.19 24.14 25.91 18.23 
19.77 19.19 10.81 24.41 25.55 18.44 
19.25 19.37 10.64 24.57 25.09 18.84 
18.93 19.56 10.26 25.32 24.76 19.04 
18.65 19.78 10.05 25.33 24.43 19.19 
18.28 20.02 9.90 25.44 24.13 19.35 
17.65 20.34 9.76 25.58 23.85 19.47 
17.44 20.36 9.49 25.92 23.56 19.66 
17.12 20.62 9.35 26.10 23.14 20.09 
16.97 20.76   22.88 20.22 
16.55 21.14   22.60 20.41 
16.16 21.25   22.37 20.51 
15.95 21.33   22.09 20.67 
15.78 21.37   21.74 21.01 
15.56 21.32   21.49 21.16 
15.14 21.59   21.23 21.33 
14.97 21.66   20.99 21.51 
14.68 21.95   20.76 21.65 
14.35 22.09   20.50 21.80 
14.21 22.12   20.17 22.17 
14.06 22.17   19.95 22.32 
13.81 22.43   19.74 22.44 
13.46 22.70   19.53 22.58 
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13.30 22.75   19.33 22.70 
13.00 23.11   19.13 22.81 
12.87 23.18   18.93 22.94 
12.66 23.37   18.74 23.05 
12.36 23.56   18.56 23.13 
12.12 23.69   18.37 23.28 
11.86 23.81   18.18 23.40 
11.66 23.92   17.99 23.56 
11.44 24.04   17.80 23.71 
11.15 24.30   17.64 23.81 
10.94 24.38   17.47 23.90 
10.68 24.58   17.31 23.99 
10.50 24.64   17.06 24.27 
10.28 24.80   16.91 24.34 
9.98 25.04   16.76 24.43 
    16.62 24.49 
    16.46 24.55 
    16.31 24.67 
    16.16 24.83 
    16.01 24.98 
    15.89 25.08 
    15.75 25.17 
    15.61 25.27 
    15.44 25.35 
    15.25 25.43 
    14.96 25.57 
    14.78 25.57 
    14.66 25.64 
    14.54 25.73 
    14.43 25.80 
    14.33 25.87 
    14.22 25.96 
    14.11 26.08 
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    14.01 26.14 
    13.90 26.24 
    13.68 26.44 
    13.44 26.52 
    13.33 26.61 
    13.12 26.95 
    13.02 27.04 
    12.93 27.10 
    12.82 27.18 
    12.73 27.26 
    12.64 27.31 
    12.56 27.38 
    12.45 27.48 
    12.35 27.56 
    12.26 27.64 
    12.18 27.71 
    12.04 27.55 
    11.91 27.53 
    11.83 27.64 
    11.74 27.74 
    11.66 27.79 
    11.57 27.79 
    11.44 28.00 
    11.36 28.06 
    11.21 28.19 
    11.13 28.24 
    11.06 28.32 
    10.98 28.36 
    10.90 28.43 
    10.82 28.50 
    10.75 28.55 
    10.69 28.59 
    10.56 28.68 
 262 
    10.45 28.84 
    10.39 28.88 
    10.31 28.92 
    10.17 29.06 
    10.10 29.11 
    10.00 29.20 
    9.93 29.24 
    9.87 29.29 
    9.77 29.42 
    9.71 29.47 
    9.65 29.52 
    9.60 29.55 
    9.51 29.73 
    9.39 29.79 
    9.29 29.88 
    9.13 29.82 
    9.01 29.84 
    9.08 30.39 
    8.39 31.06 
    7.78 31.65 
    7.40 31.77 
    7.01 31.97 
    6.68 32.26 
    6.31 32.71 
    5.94 33.24 
    5.73 33.55 
    5.43 34.05 
    5.19 34.18 
    4.90 34.49 
    4.65 34.80 
    4.42 35.07 
    4.20 35.30 
    3.96 35.32 
 263 
    3.90 35.14 
    3.47 35.48 
    3.24 35.97 
    3.03 36.46 
    2.84 36.98 
    2.67 37.33 
    2.53 37.67 
    2.36 38.17 
    2.18 38.61 
    2.03 39.14 
    1.87 39.49 
    1.71 39.92 
    1.55 40.36 
    1.39 40.79 
    1.23 41.22 
    1.07 41.65 
    0.90 42.08 
    0.74 42.51 
    0.58 42.94 
    0.42 43.38 
    0.26 43.81 
    0.10 44.24 
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Table F2. Experimental weight fraction data for the system composed of IL (1) + 
K3C6H5O7 (2) + H2O (3) at 35 °C and atmospheric pressure. 
[P4444][CHES] [P4444][Tricine] 
100 w1 100 w2 100 w1 100 w2 
44.76 3.92 77.51 1.40 
41.71 4.74 69.04 3.28 
39.33 5.34 60.39 4.60 
37.55 5.83 45.31 10.91 
36.22 6.34 43.30 12.04 
34.48 6.67 41.79 12.71 
33.48 7.04 40.77 13.40 
32.32 7.47 39.41 13.86 
30.98 7.83 38.48 14.52 
29.73 8.17 37.52 15.07 
28.73 8.39 36.64 15.63 
27.94 8.79 35.83 16.16 
27.39 9.18 35.08 16.64 
26.69 9.53 34.32 17.15 
25.86 9.67 33.65 17.61 
25.25 10.02 32.93 18.09 
24.53 10.24 32.27 18.52 
23.96 10.60 31.59 18.97 
23.32 10.72 30.98 19.39 
22.79 10.83 30.45 19.68 
22.46 11.16 29.86 20.06 
21.96 11.28 29.33 20.41 
21.47 11.46 28.80 20.78 
21.06 11.73 27.97 21.61 
20.53 11.92 27.50 21.99 
20.03 12.05 27.05 22.29 
19.69 12.25 26.61 22.58 
19.27 12.36 26.18 22.80 
18.95 12.57 25.52 23.47 
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18.58 12.67 25.11 23.75 
18.27 12.86 24.71 23.98 
17.91 12.90 24.29 24.15 
17.61 13.14 23.95 24.37 
17.24 13.19 23.41 24.94 
16.95 13.38 23.08 25.13 
16.60 13.53 22.78 25.31 
16.27 13.70 21.98 25.95 
15.94 13.83 21.69 26.17 
15.64 13.97 21.24 26.63 
15.35 14.12 20.99 26.78 
15.08 14.19 20.71 26.95 
14.87 14.13 20.26 27.41 
14.62 14.20 20.04 27.47 
14.36 14.23 19.66 27.85 
14.17 14.41 19.44 28.02 
13.93 14.57 19.21 28.17 
13.71 14.61 18.90 28.45 
13.49 14.73 18.61 28.74 
13.32 14.86 18.30 29.02 
13.10 14.96 18.11 29.14 
12.89 15.07 17.78 29.48 
12.69 15.11 17.58 29.57 
12.53 15.23 17.41 29.75 
12.36 15.28 17.19 29.88 
12.18 15.41 16.93 30.15 
11.96 15.35 16.67 30.38 
11.87 15.52 16.51 30.52 
11.73 15.61 16.25 30.77 
11.61 15.71 16.09 30.87 
11.47 15.78 15.86 31.06 
11.33 15.81 15.61 31.28 
11.22 15.89 15.36 31.53 
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11.11 15.94 15.22 31.58 
11.01 16.05 14.99 31.80 
10.89 16.07 14.77 32.00 
10.78 16.18 14.54 32.24 
10.59 16.16 14.27 32.41 
10.50 16.22 14.09 32.60 
10.40 16.32 13.97 32.64 
10.30 16.38 13.78 32.85 
10.18 16.43 13.64 32.97 
10.05 16.65 13.47 33.15 
9.90 16.63 13.27 33.23 
9.81 16.70 13.10 33.42 
9.73 16.76 12.88 33.71 
9.65 16.83 12.77 33.76 
9.55 16.88 12.49 33.98 
9.46 16.96 12.03 34.02 
9.37 16.94 11.87 34.18 
9.28 17.00 11.71 34.36 
9.17 17.17 11.58 34.49 
9.04 17.35 11.43 34.66 
8.88 17.45 11.31 34.79 
7.88 19.13 11.16 34.83 
7.59 19.32 11.03 35.00 
7.24 19.86 10.89 35.17 
6.97 19.88 10.81 35.17 
6.67 20.18 10.70 35.31 
6.39 20.24 10.46 35.57 
6.16 20.70 10.62 35.21 
5.89 20.61 10.23 35.74 
5.59 21.35 9.84 36.26 
5.27 21.22 9.45 36.79 
5.05 21.46 9.06 37.32 
4.85 21.89 8.68 37.85 
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4.64 22.17 8.29 38.37 
4.44 22.21 7.90 38.91 
4.28 22.48 7.51 39.43 
4.15 22.83 7.12 39.95 
3.98 23.02 6.72 40.44 
3.80 23.28 6.36 41.05 
3.67 23.42 5.95 41.44 
3.52 23.64 5.55 42.03 
3.42 23.80 5.36 42.28 
3.30 23.90 5.07 42.55 
3.22 24.19 4.87 42.87 
3.11 24.21 4.75 42.71 
3.00 24.53 4.50 43.09 
2.90 25.13 4.30 43.28 
2.79 25.33 4.08 43.58 
2.71 25.53 3.86 43.86 
2.62 25.68 3.73 43.88 
2.62 24.71 3.61 43.81 
2.45 24.16 3.42 44.21 
2.38 24.30 3.28 44.45 
2.31 24.53 3.13 44.73 
2.25 24.62 2.98 45.05 
2.16 24.77 2.86 45.34 
2.08 25.04 2.74 45.59 
2.00 25.34 2.59 45.88 
1.91 25.76 2.48 46.17 
1.83 25.92 2.33 46.53 
1.75 26.28 2.23 46.67 
1.67 26.45 2.13 46.91 
1.60 26.74 1.99 47.40 
1.52 26.98 1.89 47.13 
1.46 27.28 1.74 47.23 
1.39 27.59   
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1.31 27.82   
1.23 28.19   
1.17 28.53   
1.10 28.85   
1.04 29.09   
0.99 29.39   
 
 
Table F3. Experimental data for the CF of the systems composed of [P4444][GB] + 
K3C6H5O7 + water at (25 ± 1) °C. 
[P4444][MES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1538 0.8746 0.9034 0.4669 0.608 0.3206 0.2578 
w Salt/ g 0.4907 11.1844 28.8004 29.0330 58.2693 40.8537 40.8927 
w H2O/ g 0.3556 7.9404 20.3765 20.5313 41.1231 28.8267 28.8521 
w Top/ g 0.0783 0.4023 0.4108 0.2064 0.2603 0.1476 0.1166 
w Bottom/ g 0.8099 18.7884 48.9843 46.2209 98.9366 69.2375 69.1359 
Real CF 4.54 19.74 49.60 99.47 157.98 195.30 247.45 
 
[P4444][CHES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1546 0.8718 0.896 0.4543 0.3079 0.317 0.2541 
w Salt/ g 0.4918 11.2273 28.8647 29.1384 29.2327 40.9848 41.0242 
w H2O/ g 0.3553 7.9012 20.2728 20.4156 20.4793 28.7043 28.7221 
w Top/ g 0.0855 0.4322 0.3842 0.2101 0.1319 0.1406 0.1174 
w Bottom/ g 0.8246 17.8944 48.8542 49.2884 49.1391 68.4552 69.6864 
Real CF 4.16 18.28 52.77 97.17 155.26 204.16 244.65 
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[P4444][HEPES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 5  20  50  100  150  200  250  
w Salt/ g 0.1590  0.8554  0.8861  0.4548  0.6189  0.3307  0.2691  
w H2O/ g 0.4999  11.3395  29.164  29.4442  57.0792  41.4222  41.4620  
w Top/ g 0.3530  7.8059  19.95  20.1002  40.3018  28.2491  28.273  
w Bottom/ g 0.0730  0.4038  0.3922  0.2042  0.264  0.142  0.1119  
Real CF 0.7998  18.8912  48.7235  49.3160  98.9670  68.8742  69.4209  
 
[P4444][TES] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1565  0.6673  0.9148  0.4615  0.3091  0.3267  0.2603  
w Salt/ g 0.4839  8.2646  28.3289  28.6225  28.7143  40.266  40.3037  
w H2O/ g 0.3588  6.0672  20.7886  20.9159  20.9797  29.413  29.4364  
w Top/ g 0.0801  0.3159  0.4201  0.2118  0.1394  0.1438  0.115  
w Bottom/ g 0.7982  14.2206  48.4881  49.3160  49.1121  67.8044  69.5518  
Real CF 4.48  19.21  49.48  98.75  150.50  204.54  255.97  
 
[P4444][Tricine] 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL / g 0.1582  0.9758  1.1577  0.7204  0.5731  0.1582  0.9758  
w Salt/ g 0.4862  11.1054  28.575  28.8193  28.0000  0.4862  11.1054  
w H2O/ g 0.3542  7.931  20.3498  20.4447  20.5376  0.3542  7.931  
w Top/ g 0.0800  0.4147  0.4138  0.2111  0.1426  0.0800  0.4147  
w Bottom/ g 0.7948  19.4130  49.1102  49.3373  49.3575  0.7948  19.4130  
Real CF 4.43  19.12  49.18  96.85  144.02  4.43  19.12  
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Table F4. Docking affinity energy and interacting amino acid residues predicted by AutoDock vinna for PSA-GB-ILs. 
Compound  Affinity (kcal/mol) 
Interacting nucleic acids Type of interaction From To Distance (Å) 
[P4444]
+
 -2.6 - - - - - 
[CHES]
-
 -3.4 
PHE95 Hydrophobic Phenylalanine - C [CHES]
- 
- C 5.46 
SER192 
Hydrogen Bond 
Serine - O [CHES]
- 
- O 2.91 
Serine - O [CHES]
- 
- O 2.83 
GLY193 Glycine - N [CHES]
- 
- O 3.15 
[MES]
-
. -3.7 SER195 Hydrogen Bond 
Serine - O [MES]
- 
- O 2.93 
Serine - O [MES]
- 
- O 3.21 
[HEPES]
-
. -3.2 
THR125 
Hydrogen Bond 
Threonine - N [HEPES]
-
. - O 3.14 
GLN128 
Glutamine - N [HEPES]
-
. - O 2.80 
Glutamine - N [HEPES]
-
. - O 3.30 
GLU129 GlutamicAcid - N [HEPES]
-
. - O 2.95 
GLN210 
Glutamine - N [HEPES]
-
. - O 2.97 
Glutamine - N [HEPES]
-
. - O 2.96 
VAL208 Hydrophobic - C [HEPES]
-
. - C 5.18 
[TES]
-
. -3.8 
THR125 
Hydrogen Bond 
Threonine - N [TES]
-
.- O 2.94 
GLN128 Glutamine - N [TES]
-
.- O 3.14 
GLU129 GlutamicAcid - N [TES]
-
.- O 2.97 
GLN210 Glutamine - N [TES]
-
.- O 3.21 
ASN202 
[TES]
-
.- H Asparagine - O 2.06 
[TES]
-
.- C Asparagine - O 3.59 
[Tricine]
-
 -3.1 HIS233 Hydrogen Bond [Tricine]
-
 -H Histidine - O 2.13 
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ARG235 Arginine - N [Tricine]
-
 - O 2.91 
LYS236 Lysine -N [Tricine]
-
 - O 2.91 
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Table G1. Depletion efficiency of IgG and HSA (DE%PROT) and extraction efficiency of 
LDH (EE%LDH) and weight fraction compositions of the initial mixtures at 25 °C. 
 
IL 
Weight fraction  
composition / (wt %) DE%Prot ± σ EE%LDH± σ 
IL  K3C6H5O7/C6H8O7 
[P4444]Cl 30.21 ± 0.03 30.08 ± 0.01 19.31 100 
[P4444]Br 
30.01 ± 0.01 29.97 ± 0.05 100 100 
30.11 ± 0.03 10.28 ± 0.01 100 100 
30.02 ± 0.01 20.31 ± 0.03 100 100 
15.30 ± 0.05 20.16 ± 0.03 100 100 
29.89 ± 0.01 20.09 ± 0.02 100 100 
30.04 ± 0.04 20.05 ± 0.06 100 100 
 
 
 
Figure G1. IgG calibration curve by SE-HPLC. 
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Figure G2. HSA calibration curve by SE-HPLC. 
 
 
Figure G3. LDH calibration curve by SE-HPLC. 
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Figure G4. Docking pose with the lowest absolute value of affinity (kcal/mol) for HSA 
with [P4444]
+. 
 
Figure G5. Docking pose with the lowest absolute value of affinity (kcal/mol) for IgG 
with [P4444]
+. 
 
Figure G6. Docking pose with the lowest absolute value of affinity (kcal/mol) for LDH 
with [P4444]
+. 
HIS281
PHE118
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Figure G7.Molecular interaction diagrams of [P4444]
+.and amino acids residues of IgG. 
 
Figure G8.Molecular interaction diagrams of [P4444]
+.and amino acids residues of LDH. 
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Table G2. Docking affinity energy and interacting amino acid residues predicted by 
AutoDock vinna for HSA-ILs. 
Compound 
Affinity 
(kcal/mol) 
Interacting 
nucleic acids 
Type of 
interaction 
From To Distance (Å) 
[P4444]
+
 -3.6 - - - - - 
Br
-
 -1.0 - - - - - 
Cl
-
 -1.0 - - - - - 
 
Table G3. Docking affinity energy and interacting amino acid residues predicted by 
AutoDock vinna for IgG-ILs. 
Compound 
Affinity 
(kcal/mol) 
Interacting 
nucleic acids 
Type of 
interaction 
From To 
Distance 
(Å) 
[P4444]
+
 -2.8 HIS281 Hydrophobic [P4444]
+
- C  Histidine - H 3.95 
Br
-
 -0.8 - - - - - 
Cl
-
 -0.9 - - - - - 
 
Table G4. Docking affinity energy and interacting amino acid residues predicted by 
AutoDock vinna for LDH-ILs. 
Compound 
Affinity 
(kcal/mol) 
Interacting 
nucleic acids 
Type of 
interaction 
From To 
Distance 
(Å) 
[P4444]
+
 -3.2 PHE118 Hydrophobic [P4444]
+
- C  
Phenylalanine - 
H 
3.96 
Br
-
 -0.9 - - - - - 
Cl
-
 -0.9 - - - - - 
 
 
 
